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Abstract
Strategy of endovascular versus open repair for patients
with clinical diagnosis of ruptured abdominal aortic
aneurysm: the IMPROVE RCT
Pinar Ulug,1 Robert J Hinchliffe,2 Michael J Sweeting,3
Manuel Gomes,4 Matthew T Thompson,5 Simon G Thompson,3
Richard J Grieve,4 Raymond Ashleigh,6 Roger M Greenhalgh1 and
Janet T Powell1* on behalf of the IMPROVE trial investigators
1Vascular Surgery Research Group, Imperial College London, London, UK
2Bristol Centre for Surgical Research, Department of Surgical Sciences, University of Bristol,
Bristol, UK
3Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
4Department of Health Services Research and Policy, London School of Hygiene & Tropical
Medicine, London, UK
5Vascular Surgery, St George’s Hospital, London, UK
6Department of Radiology, Wythenshawe Hospital, Manchester University NHS Foundation Trust,
Manchester, UK
*Corresponding author j.powell@imperial.ac.uk
Background: Ruptured abdominal aortic aneurysm (AAA) is a common vascular emergency. The mortality
from emergency endovascular repair may be much lower than the 40–50% reported for open surgery.
Objective: To assess whether or not a strategy of endovascular repair compared with open repair reduces
30-day and mid-term mortality (including costs and cost-effectiveness) among patients with a suspected
ruptured AAA.
Design: Randomised controlled trial, with computer-generated telephone randomisation of participants in
a 1 : 1 ratio, using variable block size, stratified by centre and without blinding.
Setting: Vascular centres in the UK (n = 29) and Canada (n = 1) between 2009 and 2013.
Participants: A total of 613 eligible participants (480 men) with a ruptured aneurysm, clinically diagnosed
at the trial centre.
Interventions: A total of 316 participants were randomised to the endovascular strategy group (immediate
computerised tomography followed by endovascular repair if anatomically suitable or, if not suitable, open
repair) and 297 were randomised to the open repair group (computerised tomography optional).
Main outcome measures: The primary outcome measure was 30-day mortality, with 30-day
reinterventions, costs and disposal as early secondary outcome measures. Later outcome measures
included 1- and 3-year mortality, reinterventions, quality of life (QoL) and cost-effectiveness.
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Results: The 30-day mortality was 35.4% in the endovascular strategy group and 37.4% in the open
repair group [odds ratio (OR) 0.92, 95% confidence interval (CI) 0.66 to 1.28; p = 0.62, and, after
adjustment for age, sex and Hardman index, OR 0.94, 95% CI 0.67 to 1.33]. The endovascular strategy
appeared to be more effective in women than in men (interaction test p = 0.02). More discharges in the
endovascular strategy group (94%) than in the open repair group (77%) were directly to home (p < 0.001).
Average 30-day costs were similar between groups, with the mean difference in costs being –£1186 (95% CI
–£2997 to £625), favouring the endovascular strategy group. After 1 year, survival and reintervention rates
were similar in the two groups, QoL (at both 3 and 12 months) was higher in the endovascular strategy
group and the mean cost difference was –£2329 (95% CI –£5489 to £922). At 3 years, mortality was 48%
and 56% in the endovascular strategy group and open repair group, respectively (OR 0.73, 95% CI 0.53 to
1.00; p = 0.053), with a stronger benefit for the endovascular strategy in the subgroup of 502 participants
in whom repair was started for a proven rupture (OR 0.62, 95% CI 0.43 to 0.89; p = 0.009), whereas
aneurysm-related reintervention rates were non-significantly higher in this group. At 3 years, considering all
participants, there was a mean difference of 0.174 quality-adjusted life-years (QALYs) (95% CI 0.002 to
0.353 QALYs) and, among the endovascular strategy group, a cost difference of –£2605 (95% CI –£5966
to £702), leading to 88% of estimates in the cost-effectiveness plane being in the quadrant showing the
endovascular strategy to be ‘dominant’.
Limitations: Because of the pragmatic design of this trial, 33 participants in the endovascular strategy
group and 26 in the open repair group breached randomisation allocation.
Conclusions: The endovascular strategy was not associated with a significant reduction in either 30-day
mortality or cost but was associated with faster participant recovery. By 3 years, the endovascular strategy
showed a survival and QALY gain and was highly likely to be cost-effective. Future research could include
improving resuscitation for older persons with circulatory collapse, the impact of local anaesthesia and
emergency consent procedures.
Trial registration: Current Controlled Trials ISRCTN48334791 and NCT00746122.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 31.
See the NIHR Journals Library website for further project information.
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Plain English summary
Rupture of a swelling of the aorta (abdominal aortic aneurysm), the main blood vessel in the body,causes massive bleeding and leads to the death of about 6000 people annually in the UK. Many of
these people do not reach hospital. The only hope is an emergency operation to repair the aorta and, even
then, < 60% of people survive. The Immediate Management of the Patient with Rupture: Open Versus
Endovascular repair (IMPROVE) trial compared two different methods for repairing the aorta, endovascular
repair (the newer keyhole approach via a small cut in the groin, if the aorta is the right shape for this) and
open repair (via a big cut in the belly).
A total of 613 participants (nearly one-quarter of them women) with a diagnosis of ruptured abdominal
aortic aneurysm were randomised, half to an endovascular strategy and half to open repair, and followed
for survival, further operations, recovery and quality of life, and treatment costs.
At 30 days after rupture (standard surgical reporting), almost two-thirds of each group were still alive,
but those in the endovascular strategy group recovered quicker and went home sooner. The endovascular
strategy appeared to be slightly more effective in saving lives in women than in men.
By 1 year after rupture, just over half of both the endovascular strategy group and the open repair group
were alive, with no difference between the groups in the number of further operations needed. However,
quality of life was better in the endovascular strategy group at both 3 and 12 months.
By 3 years after rupture, slightly more participants in the endovascular strategy group (54%) were alive
than in the open repair group (46%); quality of life was good for both groups and the number of further
operations was small.
At all time points, the endovascular strategy had non-significantly lower health-care costs.
Overall, the endovascular strategy was likely to be more cost-effective than open repair, with benefits
observed for participants and health-care providers.
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Scientific summary
Background
Ruptured abdominal aortic aneurysm (AAA) remains a common vascular emergency in the older population,
causing ≈6000 deaths each year in the UK. Without repair of the burst aorta, death is almost inevitable.
More than half of people with ruptured aneurysms die before reaching hospital, and not all patients who
reach hospital are offered a life-saving repair. Until the early part of this century, the only type of repair
available was open surgical repair, which carried a very high mortality of ≈50%. The first published case
showing the feasibility of using the less invasive endovascular repair was from Nottingham in 1994 (Yusuf SW,
Whitaker SC, Chuter TA, Wenham PW, Hopkinson BR. Emergency endovascular repair of leaking aortic
aneurysm. Lancet 1994;344:1645). By 2007, systematic reviews had been published to suggest that
endovascular aneurysm repair (EVAR) could halve the operative mortality for ruptured aneurysms. By then,
the number of centres in the UK that were experienced in using EVAR in the elective situation was
sufficient to consider a randomised trial of emergency EVAR compared with open repair for ruptures.
Design
Because the applicability of EVAR is restricted by the morphology of the aorta, a trial of an endovascular
strategy (EVAR if morphologically feasible, default open repair) compared with open repair was designed.
Therefore, randomisation was carried out at the point of in-trial hospital diagnosis by a senior clinician,
before a computerised tomography, which might delay transfer to theatre for emergency repair. To be able
to join the trial, a centre had to have carried out at least five emergency EVARs with acceptable results. The
sample size calculations indicated that a total of 300 participants in each group would be needed to have
90% power to show a significant reduction in 30-day operative mortality (the primary outcome measure)
from 44.7% for open repair to 30.4% for the endovascular strategy group. It was also planned to follow up
the participants for 12 months to allow us to carry out a cost-effectiveness evaluation.
Results
Between September 2009 and July 2013, 613 eligible participants with an in-hospital diagnosis of ruptured
aneurysm were randomised: 316 to the endovascular strategy group and 297 to the open repair group.
These 613 participants were derived from a total cohort of 1275 patients who were admitted with a
clinical diagnosis of ruptured aneurysm at the 30 trial centres during the same period.
The 613 participants had a mean age of 77 years and a mean aortic diameter of 8.3 cm and included
133 women (22%). The diagnosis of rupture was later confirmed, using a core laboratory, in 536 out
of 613 participants (87%; of these, 60% were morphologically suitable for EVAR); 22 participants had an
acute symptomatic aneurysm, 46 participants had an asymptomatic aneurysm or other acute diagnosis,
and only nine participants had no aortic aneurysm.
Overall 30-day mortality was 35.4% in the endovascular strategy group and 37.4% in the open repair
group [unadjusted odds ratio (OR) 0.92, 95% confidence interval (CI) 0.66 to 1.28; p = 0.62], with similar
results after adjustment for age, sex and Hardman index (an established morbidity score for ruptured
aneurysms). There was weak evidence that the endovascular strategy was more effective in women than in
men (interaction p = 0.02). Most participants (555/613; 91%) adhered to the trial protocol. Among the
502 participants with a proven rupture and for whom repair commenced, the 30-day mortality was 32%
(84/259 participants) in the endovascular strategy group and 36% (87/243 participants) in the open repair
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group (OR 0.86, 95% CI 0.59 to 1.24). The average hospital costs, including reinterventions, within the
first 30 days of randomisation were similar between the randomised groups: mean £13,433 [standard
deviation (SD) £10,354] and mean £14,619 (SD £12,353) for the endovascular strategy group and open
repair group, respectively. At 30 days, some participants remained in hospital (28 in the endovascular
strategy group, compared with 47 in the open repair group), but 94% of discharges in the endovascular
strategy group were directly to home compared with 77% in the open repair group.
The recruited participants were also used in a large cohort analysis to identify factors, other than type of
repair, that might be associated with postoperative survival (30-day mortality). The cohort analyses showed
that shorter aneurysm neck length, admission at weekends and out of hours, and very low admission
systolic blood pressures were all associated with higher operative mortality. In contrast, the use of EVAR
under local, rather than general, anaesthesia was associated with much lower operative mortality (adjusted
OR 0.27, 95% CI 0.10 to 0.70). An additional important factor that influenced 30-day mortality was the
morphological parameter of aneurysm neck length. Operative mortality was much lower in the group of
participants with aneurysm neck lengths of > 15 mm than in the group of participants with aneurysm neck
lengths of < 15 mm, irrespective of whether endovascular or open repair was used. This is likely to be an
important finding, which partly explains why observation series report much lower operative mortality for
EVAR than for open repair: participants with long aneurysm necks are the most morphologically suitable
for, and most likely to receive, EVAR.
At 1 year after randomisation, two participants in the open repair group had emigrated and had been lost
to follow-up for mortality. All-cause mortality was 41.1% for the endovascular strategy group and 45.1%
for the open repair group (OR 0.85, 95% CI 0.62 to 1.17; p = 0.325), with similar reintervention rates in each
group (between 31 days and 1 year, there were 12 procedures involving 11 participants and 13 procedures
involving nine participants in the endovascular and open repair groups, respectively). The average total
hospital stay was 17 days in the endovascular strategy group and 26 days in the open repair group
(p < 0.001). Among participants surviving rupture, the average utility score on the EuroQol-5 Dimensions,
three-level version (EQ-5D-3L), was higher in the endovascular strategy group than in the open repair group
[mean differences of 0.087 (95% CI 0.017 to 0.158) and 0.068 (95% CI –0.004 to 0.140) at 3 months and
12 months, respectively]. There were indications that quality-adjusted life-years (QALYs) were higher and
costs were lower for the endovascular strategy, combining to give an incremental net monetary benefit of
£3877 (95% CI £253 to £7408) or €4356 (95% CI €284 to €8323) at a willingness-to-pay threshold of
£30,000 per QALY.
Soon after completion of randomisation, it was estimated that ≈50% of participants would remain alive
at 3 years, and an application was made to extend participant follow-up for clinical effectiveness and
cost-effectiveness evaluations to 3 years and to conduct individual patient data meta-analyses across the
three recent European trials for the repair of ruptured aneurysm [Immediate Management of the Patient
with Rupture: Open Versus Endovascular repair (IMPROVE), Amsterdam Acute Aneurysm trial (AJAX)
(the Netherlands) and Endovasculaire versus Chirurgie dans les Anévrysmes Rompus (ECAR) (France)] to
1 year. These meta-analyses all supported the main findings of the IMPROVE trial: no difference in mortality
between the randomised groups at 1 year but more rapid participant recovery in the endovascular groups
and the important effect of aneurysm neck length on 30-day mortality. IMPROVE was the only trial with full
reporting to 3 years.
By 3 years after randomisation, a further two participants had emigrated and were lost to follow-up, this
time in the endovascular strategy group. The mean participant follow-up was 4.9 years. Overall, there
were 179 deaths (22.0 per 100 person-years) in the endovascular strategy group and 183 deaths (25.2 per
100 person-years) in the open repair group [hazard ratio (HR) 0.92, 95% CI 0.75 to 1.13; p = 0.41].
However, at 3 years, the survival curves had their widest separation, before converging again by 6 years, and
for the prespecified mid-term period (3 months to 3 years) results favoured the endovascular strategy group
(HR 0.57, 95% CI 0.36 to 0.90). At 3 years, mortality was 48% and 56% in the endovascular strategy group
and the open repair group, respectively (OR 0.73, 95% CI 0.53 to 1.00; p = 0.053), with a more pronounced
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effect for the endovascular strategy in the subgroup of 502 participants in whom repair was started for a
proven rupture, in which the mortality rate was 42% and 54%, respectively (OR 0.62, 95% CI 0.43 to 0.89;
p = 0.009). There was also weak evidence that the endovascular strategy was more effective in women than
in men, but no such finding was observed for any other subgroup. In both randomised groups, there were
continuing aneurysm-related reinterventions, the rate being non-significantly higher in the endovascular
strategy group but the reinterventions being more severe in the open repair group. At 3 and 12 months,
quality of life (QoL) was better in the endovascular strategy group but, by 3 years, there was no difference;
mean EQ-5D-3L scores were 0.74 and 0.73 in the endovascular strategy group and open repair group,
respectively. This was similar to the age- and sex-matched population. At 3 years, the endovascular strategy
group had gained a mean of 0.166 QALYs (95% CI 0.002 to 0.311 QALYs; p = 0.045), the largest gains
being for women and those with an admission Hardman index score of ≥ 2. By 3 years, the average number
of days in hospital for aneurysm-related care was 14.4 days and 20.5 days in the endovascular strategy
group and open repair group, respectively, with a mean incremental cost of –£2607 (95% CI –£5949 to
£735). The higher costs of open repair in primary admission had not been eroded by any excess of later
aneurysm-related reinterventions in the endovascular strategy group. With survival, QoL and costs all
favouring the endovascular strategy group at 3 years, there was an incremental net monetary benefit (INMB)
of £7833 (95% CI £1655 to £14,011) for the endovascular strategy group, for a QALY valued at £30,000.
The probability that the endovascular strategy is more cost-effective was > 90% at all realistic thresholds of
willingness to pay for a QALY gain. Therefore, at 3 years, the endovascular strategy appeared to be both
clinically effective and cost-effective.
The overall survival curves for patients admitted to hospitals with a diagnosis of ruptured aneurysm show a
very steep attrition rate during the first 48 hours. However, all current risk scores, which may be used to
select patients for surgery, are based on 30-day survival, a time period during which intensive care and
several specialties other than vascular surgery contribute to patient care. Additionally, none of the available
risk scores uses morphological data such as neck length. Additional funding was awarded to develop a
risk score for 48-hour mortality in patients presenting with a ruptured aneurysm and to validate the score
using external trials and observational cohorts. The developed model included the predictors of age, sex,
haemoglobin, creatinine, systolic blood pressure, aneurysm neck length, neck angle and acute cardiac
ischaemia. A simplified model that could be used at the bedside was also developed. The calibration slope
was estimated as 1.08 (95% CI 0.81 to 1.35; p = 0.54) for the bedside score derived in the IMPROVE trial,
indicating that both low and high predictions are well calibrated. The ability of the IMPROVE trial score to
discriminate between patients who would and would not survive for 48 hours was reasonable, but not
exceptional, with an area under receiver operating characteristic curve of 0.720 [standard error 0.025].
An external validation revealed that the score performed adequately in the ECAR trial and the Amsterdam
cohort and did not perform well in AJAX or the Stockholm area cohort. Similarly, none of the previously
published risk scores performed well in all of the different cohorts. The inability of risk scores to predict
outcomes following emergency surgical repair with sufficient accuracy indicates that any risk score should
be used only for either comparing different populations or adjusting population data, as the Hardman
index was used in the IMPROVE trial. If the mortality risk of ruptured AAA repair cannot be predicted with
sufficient accuracy, we suggest that the focus should shift to offering emergency repair to more patients
and reducing the non-intervention rate.
Collaborative projects
The trial has also formed the basis for several collaborative projects. First was a Delphi consensus approach
(vascular surgeons and emergency medicine physicians) to develop guidelines for the equitable and rapid
transfer of patients with a clinical diagnosis of a ruptured AAA from district general hospitals to vascular
centres, which resulted in the Royal College of Emergency Medicine Best Practice Guidelines. Second
was a project to investigate whether or not missing QoL data were really missing at random. A third study
compares the morphology of intact and ruptured AAAs to try and identify morphological features, other
than maximum aortic diameter, which may be helpful in predicting aneurysms at the highest risk of rupture.
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Fourth is a study of common iliac aneurysms, which may have an undilated contralateral iliac artery,
to assess computational flow dynamic characteristics associated with the natural history of these
little-studied aneurysms. The last two of these collaborative projects are still in progress and the transfer
guidelines will be updated as part of the ongoing National Institute for Health and Care Excellence
AAA review.
Conclusions
The primary outcome measure of the IMPROVE trial was mortality. Despite the lack of any significant
difference in mortality (the primary outcome measure) between the randomised groups at 30 days and
1 year, by 3 years the story had changed. At 3 years, there was an interim mid-term survival benefit for the
endovascular strategy, without an excess of aneurysm-related reinterventions. The more rapid recovery of
the participants in the endovascular strategy group led to early gains in QoL. Together, these have led to
an increase in QALYs for the endovascular strategy group, without additional costs compared with the
open repair group. All of the outcomes favour the endovascular strategy, leading to it being highly likely
that the endovascular strategy was cost-effective after 3 years.
The trial has also been the springboard for other important scientific projects including best practice
guidelines for the transfer of patients with a suspected ruptured aneurysm into a vascular centre.
Therefore, the results of this project should continue to influence the improvement of care for patients
with a ruptured AAA.
Trial registration
This trial is registered as ISRCTN48334791 and NCT00746122.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Abdominal aortic aneurysm (AAA) is a common degenerative disease, with a current prevalence of≈2% in men aged 65 years; the prevalence increases with age. AAA is about fourfold less common in
women. Small AAAs are rarely associated with symptoms but their natural history is progressive enlargement
until rupture occurs. Following several randomised trials, a screening programme for 65-year-old men was
rolled out, between 2009 and 2013, to cover the UK. Elective aneurysm repair is recommended when the
diameter is > 5.5 cm (about three times the normal aortic diameter); the operative mortality for elective
procedures for screen-detected aneurysms is low.1–3 Without intervention, a ruptured AAA is fatal and the
overall mortality is > 80%. About half of patients with ruptured aneurysms die in the community. More
than one-third of patients who arrive in accident and emergency departments do not reach the operating
theatre alive. Among the patients who reach the operating theatre (for open surgical repair under general
anaesthesia), only half will leave hospital alive. These stark figures changed little over the 50 years between
1960 and 2010.4 Ruptured aneurysm is a common vascular emergency, involving various symptoms that
are not specific to AAA rupture, usually back or abdominal pain and collapse. It tends to occur in elderly
patients who often have comorbidities that may preclude a successful repair, especially if the diagnosis is not
made promptly.
Ruptured aortic aneurysms are a common cause of death in the UK and, in the last century, infrarenal
AAAs caused ≈8000 deaths per annum in England and Wales. The incidence of both AAAs and ruptured
AAAs continued to increase year on year until about 2000 in both men and women.5,6 More recently,
the number of deaths from ruptured AAAs has declined rapidly because of the reducing prevalence of
smoking in the population and the increasing number of elective aneurysm repairs in the population
aged > 75 years, using the minimally invasive endovascular repair.7 Nevertheless, when this trial started in
2009, there were still 2581 deaths from AAA ruptures (285 of these in women) in England and Wales.
Until about 2004, routine practice was to direct patients with a suspected ruptured AAA directly to the
operating theatre for open repair, without preoperative computerised tomography (CT). In England, there
were about 1300 open surgical repairs for ruptured aneurysms each year, with 30-day and in-hospital
mortality being similar at 47–48%.4,8,9
For open AAA repair, the aneurysm is usually approached by a midline laparotomy, carefully moving aside
the colonic viscera and cross-clamping the aorta, below the renal arteries wherever possible, and inserting
a prosthetic inlay graft, using a tube configuration with sutured anastomoses to the aorta both proximally
and distally to exclude the aneurysm wherever possible (Figure 1). When the aneurysm extends beyond the
aorta into the common iliac arteries, the use of a bifurcated graft becomes necessary. These procedures
FIGURE 1 Schematics of aneurysm repair, showing (left) open repair, (centre) endograft insertion for endovascular
repair and (right) endovascular repair in progress.
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are conducted under general anaesthesia and the patients require a critical care bed postoperatively.
The in-hospital care of those patients undergoing open surgical repair of a ruptured aneurysm is costly, as
many days are spent in the intensive care unit (a mean of 3.5 days for uncomplicated cases and 9.5 days
for complicated cases) and the average hospital stay is long. Recuperation after discharge following open
surgery for a ruptured aneurysm can take up to 6 months, having a further impact on the resources of the
family, social care and general practice. Although the recovery may be slow, the evidence shows that the
results of elective open repair are durable and there is no need for longer-term follow-up. Interestingly,
the operative mortality of open surgery appears to be independent of hospital volume, although this may
be influenced by case selection.10
Urgent CT angiography is necessary to confirm the diagnosis of ruptured aneurysm and plan the feasibility
of endovascular repair. In general, aneurysm neck diameter, length and angulation should be ≤ 3.4 cm,
≥ 10 mm and < 60°, respectively. Catheters are used to deliver the endograft through the femoral arteries,
so that tortuous, very narrow or calcified femoral arteries are additional contraindications to endovascular
repair. The femoral arteries are accessed via small incisions in the groin and, under imaging control, the
endograft is delivered, positioned and secured in place (see Figure 1). This procedure requires specialist imaging
equipment and the presence of a CT radiographer as part of the endovascular team. The configuration of
the endograft is either bifurcated or aorto-uni-iliac. When the latter endografts are used, the contralateral
iliac artery is occluded and a femoro-femoral crossover graft is used to supply blood to the contralateral limb.
Endovascular repair can be conducted under local or regional anaesthesia, although general anaesthesia
often is used and becomes necessary for most femoro-femoral crossover grafts. Some patients may not need
to be transferred to a critical care bed and, in general, recovery is faster after endovascular repair than after
open surgical repair. However, in contrast with open repair, continued surveillance of the endograft is
necessary and reinterventions for endoleaks and other problems are not uncommon. This is likely to require
at least two additional CT scans in the year following endovascular repair.
When this trial was first discussed, observational studies (synthesised in systematic reviews11–14) were
reporting much lower 30-day mortality for endovascular repair of ruptured AAAs and some such studies11
have suggested that this should become the new gold standard treatment of ruptured aneurysms without
the need for a randomised trial. In addition, the in-hospital and 1-year costs of treating ruptured aneurysms
by endovascular repair may be up to 40% lower than for treatment by open repair.15 However, a single
centre pilot randomised trial16 with 32 participants, carried out in Nottingham, UK, showed a 30-day
mortality of > 50% for participants treated with either endovascular aneurysm repair (EVAR) or open repair.
By 2004, randomised trials had shown the advantage of EVAR for elective repairs through reducing
30-day operative mortality threefold compared with open repair,3,17 and endovascular technology, no
longer confined to academic centres, was widely available and preferred by patients. It remained an open
question whether or not endovascular repair would have the same impact on reducing mortality from
ruptured AAAs. Importantly, it was considered that only ≈55% of patients with a ruptured AAA would be
anatomically suitable for endovascular repair, so that, for many patients, endovascular repair would not be
an option.14
Therefore, the design of any randomised trials was a question of considerable debate. In the Netherlands,
a small randomised trial18 in the Amsterdam region started in 2007. This trial considered only patients with
a ruptured AAA of relative haemodynamic stability after CT had demonstrated the anatomical feasibility
of EVAR and then randomised these participants to either EVAR or open repair.18 The primary outcome
measure of this trial was combined mortality and morbidity at 30 days and, with optimistic power
calculations, it was planned to randomise just 80 participants. Later, in 2010, the trial was extended to
include 120 participants; the results were finally reported in late 2013.19 A trial20 with a similar design
started in France in 2008, with the aim of recruiting 160 participants, but it used the rather weak
methodology of randomising participants by week of the year. The French trial recruited 107 participants
and reported the early outcomes in late 2014. Both the Dutch trial and the French trial had a selective
recruitment policy. In contrast, the Immediate Management of the Patient with Rupture: Open Versus
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Endovascular repair (IMPROVE) trial,21 the last European trial to start, larger than all of the other trials
combined, had a non-selective recruitment policy for participants with the clinical diagnosis of ruptured
aneurysm, so that health policy implications could be addressed.
Objectives of the IMPROVE trial
In participants with a clinical diagnosis of ruptured AAA who were randomised to either a strategy of
endovascular repair (if feasible, with open repair when not feasible) or to a strategy of open repair:
1. Assess whether or not the endovascular strategy was associated with a lower 30-day and mid-term
mortality (the primary outcome measure).
2. Determine the proportion of participants in each group who were discharged directly to home (disposal).
3. Assess whether or not the endovascular strategy was associated with lower 30-day costs.
4. Determine the proportion of participants who were suitable for endovascular repair and operational
barriers to endovascular repair.
5. Assess whether or not an endovascular strategy was associated with improved 1-year survival and
quality of life (QoL) and was cost-effective.
6. Identify subgroups of participants who derived greater benefit from endovascular repair.
The trial was initially funded by a Health Technology Assessment Emergency and Trauma Care initiative.
As the trial progressed, it was extended to include three further objectives:
7. Assess whether or not an endovascular strategy was associated with improved 3-year survival and QoL
and was cost-effective.
8. Conduct an individual patient meta-analysis of participants randomised in all of the European
randomised trials [Amsterdam Acute Aneurysm trial (AJAX),19 Endovasculaire versus Chirurgie dans les
Anévrysmes Rompus (ECAR)22 and IMPROVE23], with respect to common 30-day and 1-year outcomes.
9. Develop a risk score for 48-hour mortality for patients with a ruptured AAA.
In addition, the resources and information gathered during the trial have stimulated associated projects
including the development of best practice guidelines24 for the transfer of patients and the influence of
aortic morphology on mortality and reinterventions, as well as several collaborative projects.
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Chapter 2 Methods
The methods for the IMPROVE trial, given in this chapter, are reproduced, in part, from publishedwork.23 © The Author 2015. Published by Oxford University Press on behalf of the European Society of
Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution
Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial
re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For
commercial re-use, please contact journals.permissions@oup.com.
Trial design
The IMPROVE trial was a multicentre randomised trial that randomised patients with a clinical diagnosis of
ruptured AAA to either an endovascular strategy of immediate CT and emergency EVAR, with open repair
for those who were anatomically unsuitable for EVAR (endovascular strategy group), or to the standard
treatment of emergency open repair (open repair group). This trial was conducted in 30 eligible centres
(29 in the UK and one in Canada). The eligibility of each centre to participate in the trial was determined
by its clinical credentials, including audited volumes of elective EVAR of > 20 cases per year out of
≥ 50 cases of aortic surgery, evidence of good interdisciplinary teamworking, team availability for ≥ 66%
of the week, rapid access to emergency CT (target of 20 minutes) and audited experience of emergency
EVAR (five or more cases). The trial protocol and the guidelines for fluid management, anaesthesia and
management of abdominal compartment syndrome as well as statistical analysis plans are available at
www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/ (accessed 16 November 2017).
All patients aged > 50 years with a clinical diagnosis of ruptured AAA or ruptured aortoiliac aneurysm,
diagnosed by a senior trial hospital clinician (either in emergency medicine or vascular surgery), were
recorded and were eligible for inclusion. The first brief consent process could be written, verbal or from a
relative and, if necessary, in England only, from a non-treating physician, using the Mental Capacity Act
2005.25 Participants were re-consented for continued participation in the trial during the recovery period.
Patients were excluded if they had had a previous aneurysm repair or a current rupture of an isolated internal
iliac aneurysm, aorto-caval or aorto-enteric fistulae, a recent anatomical assessment of the aorta (e.g. awaiting
elective EVAR), a connective tissue disorder or if intervention was considered futile (patient moribund).
Randomisation
An independent contractor (Sealed Envelope Ltd, London, UK) provided telephone randomisation, with
computer-generated assignation of participants in a 1 : 1 ratio, using variable block size and stratified by
centre. The date and time of randomisation, together with type of initial consent (written/verbal/other),
were recorded automatically. The randomisation was communicated by e-mail to the trial manager, site
principal investigator and trial co-ordinator. Participants were randomised either to an endovascular
strategy (immediate CT followed by EVAR if locally determined as anatomically suitable and open repair
when not suitable) or to immediate open repair, with CT being optional. Because this was a surgical trial,
neither investigators nor participants could be masked to the treatment allocation. Adherence to the
allocated treatment group, wherever possible, was reinforced by on-site training and newsletters.
Recruitment and progress
The first participant was randomised into the trial in September 2009; recruitment was initially slow
because of the regulatory difficulties in opening centres. By the end of the recruitment phase, 29 centres
had been opened in the UK and one had been opened in Canada, but some of the UK sites were
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subsequently closed by mergers and the creation of larger vascular centres. Recruitment closed in July 2013
after 613 eligible participants had been randomised, 316 to the endovascular strategy and 297 to open
repair. Full details of the progress of the trial are given in Appendix 1.
Data verification, role of the computerised tomography core laboratory
in the diagnosis of aneurysm rupture, symptomatic unruptured
aneurysm or other cause of admission
All consent forms were audited, and source data for a minimum of 15% of participants at each centre
were verified. Admission CT scans were sent for analysis in the trial core laboratory (St George’s Hospital,
London) and were subject to expert review for the presence of rupture. Aneurysm rupture was defined
in accordance with the protocol. Briefly, evidence on CT scans of the presence of blood or haematoma
outside the aneurysm wall (abdominal aorta and/or common iliac artery) constituted a diagnosis of
aneurysm rupture. If no CT scan was available, the diagnosis of rupture was made intraoperatively. In
those participants who had not undergone CT or laparotomy, diagnosis was deduced from the underlying
cause of death. All participants who were randomised in the UK were registered to obtain automatic
reporting of the date and cause of death from the Office for National Statistics (via NHS Digital).
Participants who were admitted with symptoms attributable to an AAA but in whom there was no robust
evidence of aortoiliac rupture (core laboratory diagnosis or laparotomy findings), and who underwent
repair semielectively during the same admission, were categorised as having ‘symptomatic, non-ruptured
aneurysm’. Other participants had primary hospital discharge diagnoses that were unrelated to AAAs.
The core laboratory also measured detailed aneurysm morphology in accordance with the method
previously described.26 The repeatability of the key variables of maximum aortic diameter, neck diameter,
neck length, neck conicality, proximal and distal neck angles and maximum common iliac diameter was
assessed using Bland–Altman methods.27
Participant follow-up
Participants were followed up closely through their primary hospital admission, and the following were reported: stays
in intensive therapy units and other high-dependency units and readmissions to theatre with types of complications
and adverse events. Participants also were followed up at 3, 12 and 36 months with questionnaires for QoL
[EuroQol-5 Dimensions (EQ-5D)] and use of health resources, in addition to clinical follow-up for aneurysm-related
complications and reinterventions. Between the primary hospital discharge and 3 years, participants were followed
up for aneurysm-related reinterventions both prospectively and by annual audit of hospital notes, with a final QoL
questionnaire on trial exit at 36 months. Mortality reporting, including the cause, for all UK participants was from the
Office for National Statistics (via NHS Digital) and was from local state sources for Canadian participants. All of the
case report forms (CRFs) are provided at www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/, accessed
16 November 2017. In addition, because > 90% of participants were recruited from England, Hospital Episode
Statistics (HES) data were used to cross-check reinterventions and identify those taking place at non-trial centres for
the 12- and 36-month analyses.
The IMPROVE trial approvals
Ethics approval for the participation of patients in England and Wales was from the South Central Berkshire
Research Ethics Committee (08/H0505/173), in Scotland from the Scotland A Research Ethics Committee
08/MRE00/90 and in Canada from the University of Western Ontario Health Sciences Research Ethics Board
(17698). Approval for the use of routine NHS data for participants lost to follow-up in England and Wales
was obtained from the National Information Governance Board [Ethics and Confidentiality Committee
(ECC) 4-03 (f) 2012].
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
Trial outcomes
The primary outcome measure was survival at 30 days after randomisation. The trial, comparing the groups
as randomised, had 94% power to detect (as significant at 5%) a difference in 30-day mortality of 14%
with 600 participants enrolled. This was based on estimated 30-day mortalities of 47% and 21% for
participants receiving open repair and EVAR, respectively,4,14 an estimate of 55% of participants being
anatomically suitable for EVAR after CT and an estimate that 5% of both randomised groups would not
have a proven diagnosis of ruptured AAA and no 30-day mortality.16 Hence, the estimated 30-day
mortality was 44.7% in the open repair group [(0.95 × 47) + (0.05 × 0)] and 30.4% in the endovascular
strategy group [(0.55 × 21) + (0.4 × 47) + (0.05 × 0)].
Early secondary outcome measures included 24-hour mortality, in-hospital mortality, costs of primary
admission, number of reinterventions, time of discharge and the place to which the participant was
discharged from the trial hospital after the primary admission. Details of specialist care bed-days, organ
support and reinterventions were recorded primarily to inform costs. In the first 30 days, reinterventions
were categorised as rebleeding, limb ischaemia, mesenteric ischaemia, abdominal compartment syndrome
or other, with details of others being provided as free text. Complications such as strokes or myocardial
infarction were not recorded separately from the need for specialist stroke or coronary care unit bed-days.
The unit costs of the stents and consumables used for rupture repair were taken from manufacturers’ list
prices and published sources (see Appendix 2, Table 28). Salary costs for rupture repair were calculated by
combining staffing levels reported from a survey of 10 IMPROVE trial centres (see Appendix 2, Table 29)
with published staffing costs. The costs per critical care bed-day by Healthcare Resource Group were taken
from the Payment by Results database.28 Unit costs for outpatient visits and community service use were
obtained from a recommended source for health and social care costs.29
In addition, the impact of aortic morphology on reinterventions and mortality has been assessed. To
optimise generalisability, most of these listed outcomes have also been assessed in an individual patient
data meta-analysis that was conducted across all three recent European trials (see Individual patient data
meta-analysis of three European ruptured aneurysm trials).
Longer-term outcomes measures (at 1 and 3 years) took a health economic perspective, in addition to
measuring mortality and reinterventions. QoL, using the EQ-5D, was reported at 3, 12 and 36 months
after randomisation, and the costs of aneurysm-related care were evaluated to 3 years. This enabled
cost-effectiveness evaluations at 1 and 3 years. The detailed methods for the health economic and other
analyses are encompassed within their statistical analysis plans (www.journalslibrary.nihr.ac.uk/
programmes/hta/073764/#/; accessed 16 November 2017) and are detailed in Chapter 5.
Oversight of the trial
The Trial Steering Committee, chaired by Professor Ian Roberts (members listed in Appendix 1), was
responsible for ensuring that adequate recruitment strategies were in place and that the ethics framework
for conducting this emergency surgery trial was adhered to.
An independent Data Monitoring Committee, chaired by Professor Charles Warlow (members listed in
Appendix 1), reviewed the data, with interim analyses carried out after the enrolment of 50, 200 and
400 participants, and agreed that it was safe to continue the trial. The statistician on this committee was
the responsible statistician for the Dutch ruptured aneurysm trial (AJAX).19
The Trial Management Committee, chaired by Professor Janet T Powell (members listed in Appendix 1),
took responsibility for the day-to-day running and timely reporting of the trial. The progress of the trial and
recruitment information are detailed in Appendix 1.
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Patient and public involvement in the trial
Before the trial was designed, a group of seven patients was consulted. Their viewpoints were incorporated
into the trial design (e.g. place of discharge from primary admission) and can be found in the published
supplement to the 1-year outcomes paper.23
The Trial Steering Committee included Anne Cheetham, the wife of a patient who survived an open repair
of a ruptured AAA after a stormy course. She also is active in the Circulation Foundation (a peripheral
arterial disease charity).
At the end of the trial, a small group of patients and members of the public (associated with the Circulation
Foundation) were consulted about their views on the seriousness and fear of reinterventions that may
become necessary after the original aneurysm repair. Their view of the severity of reinterventions (detailed at
www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/; accessed 16 November 2017) was different
from that of clinicians. These views of the patients and members of the public have been incorporated into
the 3-year analysis results, in which reinterventions are also reported according to the views about the most
severe reinterventions. Further research on the development and use of metrics that are important to
patients is suggested in Chapter 9.
A patient focus group (run by Professor Matt Bown in Leicester) and Anne Cheetham provided input for
the plain English summary of the trial.
Timelines for reporting of IMPROVE trial outcomes
The reporting of IMPROVE trial outcomes took place in three phases: (1) 30-day outcomes, (2) 1-year
outcomes and (3) 3-year outcomes. The 3-year outcomes analysis was delayed by 4/5 months because of
changes in application procedures at NHS Digital (the provider of both mortality reporting and HES data).
Prespecified statistical analysis plans
For each analysis conducted, a prespecified analysis plan was prepared and approved by the Trial Management
Committee and by the Data Monitoring and Ethics Committee for the main 30-day, 1- and 3-year analyses.
The analysis plans were then placed on the trial websites (www.Improvetrial.org and www.imperial.ac.uk/
medicine/improvetrial). These analysis plans, together with full details of the different analyses, are provided at
www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/ (accessed 16 November 2017).
All analyses, except the causal analyses, were intention-to-treat analyses. The primary outcome measures
assessed the proportion of participants surviving for 30 days in each of the randomised groups, following
an intention-to-treat policy using a Pearson’s chi-squared test without continuity correction. The primary
outcome measure was then adjusted for age, sex and Hardman index using logistic regression (with the
age and Hardman index considered as continuous), providing an adjusted odds ratio (OR) (Hardman index
is a validated risk scoring system for ruptured aneurysms).30,31 Missing baseline data were multiply imputed
using chained equations to increase the precision of the estimates:32 the variables used for imputation
are provided at www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/ (accessed 16 November 2017).
Sensitivity analyses were undertaken: (1) including centre as a random effect in a generalised linear mixed
model and (2) restricting analysis to participants with a confirmed diagnosis of rupture only. A complier
average causal effects model was also fitted to obtain an unbiased estimate of the potential policy effect
if participants had adhered to trial allocation.33 Specifically, participants who were randomised to the
endovascular strategy but who were subsequently found to be not anatomically suitable and thus were
treated by open repair were considered to have adhered to trial allocation. Otherwise, reasons for
crossover were classified as non-adherence (see www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/,
accessed 16 November 2017, for further details). Prespecified subgroup analyses were conducted for all
outcomes (age, sex and Hardman index).
METHODS
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Secondary end-point analyses were undertaken to assess time to in-hospital mortality and time to
discharge using competing risks methodology, with in-hospital mortality and discharge as the two
competing risks. Gray’s non-parametric test was used to compare cumulative incidence curves.34 Hospital
costs were also evaluated, with full details of the methods provided at www.journalslibrary.nihr.ac.uk/
programmes/hta/073764/#/ (accessed 16 November 2017).
A causal analysis in the ruptured AAA population only was conducted to determine the effect of an
endovascular strategy compared with open repair in this population if all participants had adhered to the
IMPROVE trial policy design (i.e. a CT scan plus EVAR if found anatomically suitable compared with open repair).
The causal analysis estimates the effect of the interventions in participants, as randomised, on the primary
outcome (30-day mortality) in a complier population.33 This provides an unbiased estimate of the true treatment
effect, subject to certain modelling assumptions,35 which would not be possible with a per-protocol analysis.
For the causal analyses, participants who were randomised to the endovascular strategy who were
found to be not anatomically suitable and underwent open repair were classified as having adhered
to randomisation. Failure to receive the allocated treatment for any other reason was classified as
non-adherence. Participants who had no operation (died before repair) were excluded from the analysis
under the assumption that their outcome would be the same no matter what group they were randomised
to. Participants who had a converted operation (EVAR converted to open repair) in the group randomised
to the endovascular strategy, and who were anatomically suitable, were considered to have adhered to
randomisation. Participants who had a converted operation after randomisation to open repair were
classified as non-adherent.
Subsequent analyses of mortality and reinterventions at 1 and 3 years followed a similar pattern but
included analysis of AAA-related mortality, reporting of other causes of death and full health economic
evaluations. The reinterventions at these later time points were categorised as arterial, laparotomy related
or other and according to their severity as perceived by (1) clinicians and (2) patients and members of
the public (details of the coding of 30-day reinterventions and later reinterventions are provided at
www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/; accessed 16 November 2017).
The cost analysis took a UK NHS and Personal Social Services perspective36 and included costs up to 1 or
3 years after randomisation, for all randomised participants. Resource use measures were taken from the
IMPROVE trial CRFs for the initial hospital admission, readmissions and outpatient visits to the study hospitals
that were related to ruptured AAAs. Other outpatient visits and community service use (visits to the family
doctor and home nursing) were taken from responses to a health services questionnaire administered to
surviving ruptured AAA participants at 3 and 12 months after randomisation. The specific resource use
categories included were (1) medical devices and consumables for each intervention (see Appendix 2,
Table 28), (2) length of hospital stay during the primary admission, including critical and specialist unit
bed-days and extent of organ support, (3) all reinterventions during the primary admission, whether or not
directly associated with the ruptured aneurysm (including time in the operating theatre or endovascular
suite), and use of devices and consumables, (4) readmissions related to the ruptured aneurysm (a sensitivity
analysis was undertaken including all readmissions) and (5) outpatient and community services whether their
use was related to the ruptured aneurysm or other conditions. The unit costs of the stents and consumables
used for rupture repair were taken from manufacturers’ list prices and published sources (see Appendix 2,
Table 28). Salary costs for rupture repair were calculated by combining staffing levels reported from a survey
of 10 IMPROVE trial centres (see Appendix 2, Table 29) with published staffing costs.
Health-related QoL (HRQoL) was measured using a generic measure, the EuroQol-5 Dimensions, three-level
version (EQ-5D-3L), which requires patients to describe their health on five dimensions: mobility, self-care,
usual activities, pain/discomfort and anxiety/depression. Each dimension requires patients to state whether
they have ‘no problems’ ‘some problems’ or ‘severe problems’. A participant’s described health at each
time point was valued in accordance with health state preferences from the general population to
calculate EQ-5D-3L utility scores, which are anchored on a scale from 0 (death) to 1 (perfect health).37
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Quality-adjusted life-years (QALYs) were assessed at 3 months, 1 year and 3 years. For survivors at
3 months, QALYs were calculated using the EQ-5D-3L scores at 3 months, assuming a EQ-5D score of 0 at
randomisation and a linear interpolation between randomisation and 3 months. This implies that, at day 30,
the EQ-5D utility score is approximately one-third of that at 3 months. For decedents between randomisation
and 3 months, we assumed zero QALYs. For those surviving up to 12 months, we assumed a linear
interpolation, using the EQ-5D-3L scores at 3 months and 12 months. For decedents between 3 months
and 12 months for which a EQ-5D-3L score at 3 months was available, a linear interpolation was applied
between EQ-5D-3L at 3 months and the date of death, at which point a EQ-5D-3L score of 0 was applied.
A similar approach was used for decedents between 1 and 3 years.
The mean differences in 1- or 3-year QALYs and costs [measured in Great British pounds (GBP) and
converted into US dollars (USD)]38 between the endovascular strategy and the open repair strategy were
reported. The differences in mean costs and QALYs were plotted on the cost-effectiveness plane and
were used to calculate incremental net benefits (INBs) by valuing the incremental (difference in mean)
QALYs at recommended thresholds of willingness to pay for a QALY gain36 and subtracting from this the
incremental costs.
Cost-effectiveness results were also reported for the prespecified subgroups (according to age, sex and
Hardman index). Missing data on baseline covariates (Hardman index), QoL and costs were addressed with
multiple imputation, using the same variables as the clinical analyses32 (full details at www.journalslibrary.
nihr.ac.uk/programmes/hta/073764/#/; accessed 16 November 2017). Sensitivity analyses were undertaken
to assess whether or not the cost-effectiveness results were robust to alternative assumptions (rationale
and details in Chapter 5). Additional work concerning methods and assumptions for missing QoL data is
discussed in Chapter 8.
Total costs at 1 year and 3 years were calculated by combining the resource use with unit costs at 2012
and 2016 prices, respectively (in GBP), and then converting them to USD.38 This conversion rate was
based on purchasing power parities, which avoided the impact of short-term currency fluctuations, and
recognised the relative purchasing power of the USA compared with the UK in 2012 and 2016. In the
base case, incremental costs were reported as unadjusted mean differences between randomised groups,
together with 95% confidence intervals (CIs).
The differences in average costs and QALYs between the randomised groups were used to calculate the
incremental net monetary benefits (INMBs). We valued the incremental QALYs according to threshold of
willingness to pay for a QALY gain recommended by the National Institute for Health and Care Excellence
(NICE) (between £20,000 and £30,000 per QALY),36 and subtracted from this the incremental cost. INBs
were reported overall, and for the same prespecified subgroups as for the clinical end points.
The uncertainty around the differences in average costs and QALYs between the randomised groups
is illustrated in the cost-effectiveness plane. We estimated the incremental costs and QALYs with a
seemingly unrelated regression model.39 To express the uncertainty in the estimation of the incremental
costs and QALYs, we used the estimates of the means, variances and the covariance from the regression
model to generate 500 estimates of incremental costs and QALYs from the joint distribution of these
end points, assuming asymptotic normality. We then plotted these incremental costs and QALYs in the
cost-effectiveness plane. We also reported cost-effectiveness acceptability curves, by calculating the
probability that, compared with open repair, the endovascular strategy is cost-effective at alternative levels of
willingness to pay for a QALY gain. Sensitivity analyses were conducted, varying the base-case assumptions,
including costs of the devices, use of additional theatre staff, for participants with a proven ruptured AAA
only and including hospital readmissions for all causes taken from the Health Resources Questionnaire
(available at www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/; accessed 16 November 2017).
The rationale for the sensitivity analyses and details of resource use, multiple imputation and handling of
missing data are described in Chapter 5.
METHODS
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Individual patient data meta-analysis of three European ruptured aneurysm trials
The three recent European trials20,40,41 for the management of ruptured AAAs have published their methods
and results. AJAX19 included only participants in whom CT revealed both probable rupture and aortic
anatomy suitable for endovascular repair using aorto-uni-iliac stent grafts and all participants had to be
eligible for both open and endovascular repair. AJAX randomised 116 participants in three centres between
2004 and 2011, using sealed envelopes for randomisation to either open or endovascular repair. The ECAR
trial22 had a similar selection methodology and design but used the additional criterion for haemodynamic
stability of a systolic blood pressure of > 80 mmHg and used both aorto-uni-iliac and bifurcated stent grafts.
The ECAR trial randomised 107 participants, with treatment allocation by weekly rotation to either open or
endovascular repair, in 14 centres between 2008 and 2012. In contrast, the IMPROVE trial randomised
participants with an in-hospital clinical diagnosis of ruptured aneurysm, before CT, either to an endovascular
strategy (with open repair if endovascular repair was not anatomically feasible) or to open repair. The
IMPROVE trial randomised 613 participants in 30 centres between 2009 and 2013.
The three data sets were merged, based on the largest trial (IMPROVE), enabling estimation of Hardman
index scores for all participants.
Statistical analysis
The primary analyses considered mortality according to the groups, as randomised, within each trial,
irrespective of the different trial designs. The timing of death was assessed from randomisation (for the
IMPROVE trial) and from hospital admission (for the AJAX19 and ECAR22 trials). Logistic regression analysis
was used to estimate the OR of both 30- and 90-day mortality for endovascular repair (or endovascular
strategy) compared with open repair, adjusting for trial to obtain a one-stage fixed-effect pooled estimate.
Further analysis was conducted by estimating the OR separately for each trial and then pooling using
random-effects meta-analysis, estimating between-study heterogeneity using a method of moments.42 The
proportion of between-trial variability beyond that expected by chance was quantified using the I2 statistic.43
Analyses were then adjusted for age, sex and Hardman index score.30,31 Multiple imputation using chained
equations was used to account for missing baseline covariates in adjusted analyses.32
Secondary analyses were conducted on a restricted subgroup of more homogeneous participants from the
three trials. The restrictions imposed were (1) a confirmed diagnosis of rupture and (2) anatomical suitability
for EVAR. EVAR suitability was an entry criterion for inclusion in both the AJAX19 and ECAR22 trials. For the
IMPROVE trial, suitability for EVAR was defined as local CT assessment of suitability; if not assessed locally,
a ‘within liberal instructions for use’ definition from a core laboratory CT analysis was used.
Kaplan–Meier survival plots and cumulative incidence of time to primary hospital discharge, by randomised
group, were produced within each trial separately and were accompanied by a log-rank test. A Cox
proportional hazards model was used to assess whether or not the randomised groups differed in terms of
the cause-specific hazard of primary hospital discharge (competing in-hospital mortality notwithstanding).
The age, sex and Hardman index scores of the subgroups were assessed for differences in the effect of the
endovascular and open strategies by including an interaction term between the subgroup and randomised
group in a logistic regression model.
The reporting of reinterventions was very different across the three trials; all trials reported on the use of
occlusion balloons and the incidence of the abdominal hypoperfusion syndromes (abdominal compartment
syndrome and mesenteric and colonic ischaemia),44 although the abdominal compartment syndrome data
for AJAX were collected retrospectively. The largest trial, IMPROVE, did not report complications such as
myocardial infarction, whereas complications were reported for both the AJAX and ECAR trials.
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In addition, AAA diameter, aortic neck diameter, aortic neck length and proximal neck α angulation
(aortic morphology) were assessed within each trial for their effect on 30-day mortality. These analyses are
not a comparison between randomised groups and, therefore, were adjusted for the following potential
confounding factors: age, sex (the AJAX and IMPROVE trials), Hardman index, admission systolic blood
pressure, mean arterial pressure, treatment commenced and randomised group (the IMPROVE trial only).
Each of the other four morphological variables was analysed, both adjusted and unadjusted for the other
three variables.
Development of a new risk score
The purpose of this work was to develop a novel, point-of-care, risk score based on both physiological
and imaging data that are immediately available in the emergency department to identify patients with
ruptured AAAs in whom aneurysm repair or transfer to a specialist centre for repair is futile. The definition
of futile is death within 48 hours of presentation, either with or without aneurysm repair.
The principal outcome measure is mortality within 48 hours of randomisation. The secondary outcome
measure is death within 30 days of randomisation.
Participants from the IMPROVE trial were used to develop the score, excluding participants with a final
diagnosis other than ruptured AAA (incidental or symptomatic AAA) but including participants with
aortoiliac ruptures. All participants with ruptured AAA or aortoiliac rupture were considered in the risk
score regardless of whether or not an operation was carried out. These criteria resulted in 536 participants,
before the exclusion of those with missing risk factor data (e.g. CT results were not available).
External validation of the risk score will be conducted in participants from the AJAX19 and ECAR22
randomised controlled trials (RCTs), the wider Amsterdam cohort for AJAX, which included those
unsuitable for randomisation in AJAX, and data from Stockholm. There also will be internal validation of
derived risk scores using 10-fold cross-validation.
Full details of the statistical analysis are provided at www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/
(accessed 16 November 2017).
Other risk scores for ruptured AAAs have been proposed. From the available information in the IMPROVE,
AJAX and ECAR trials, it may be possible to calculate these other risk scores. We will compare the
discrimination (c-statistic) of the published risk scores, calculated in the IMPROVE, AJAX and ECAR trials,
with the derived risk score. This will initially be done using 48-hour mortality as the outcome measure.
However, as the published risk scores were derived from longer-term (in-hospital or 30-day) mortality, we
will also compare the discrimination of these risk scores against our derived risk score using 30-day
mortality as the outcome measure.
METHODS
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Chapter 3 Mortality and other 30-day outcomes
in the IMPROVE trial and the other ruptured
aneurysm trials
The first pilot randomised trial of endovascular repair compared with open repair of ruptured AAAswas conducted in Nottingham and randomised 32 unselected patients between September 2002 and
December 2004.45 The 30-day mortality was 53% in each group. This contrasted with results from
observational studies, which indicated that the 30-day mortality following emergency EVAR for ruptured
AAAs was much lower, at about 25%.46,47 Since the time of this initial trial, experience with EVAR, devices
and imaging have all improved. Moreover, observational studies continued to report similarly low 30-day
mortality for EVAR and reported a 30-day mortality of closer to 50% for open repair.14,48 Therefore, there
was a clear need for larger multicentre randomised trials.
Design of the recent randomised trials
The first of the later randomised trials (AJAX)19 started in the Netherlands in 2004 and had a selective
recruitment design. Participants with a suspected rupture underwent CT. Next, if rupture was observed and
the aortic morphology was suitable for EVAR, relatively haemodynamically stable patients were approached
for consent for randomisation (using sealed envelopes) to either EVAR or open repair. Just 116 out of a target
of 120 participants were randomised between 2004 and 2011 at three centres. A French trial (ECAR)22 started
in 2008, with even more selective patient recruitment: only haemodynamically stable patients (systolic blood
pressure of > 80 mmHg) with aortic morphology suitable for EVAR were included and the randomisation
was based on a weekly rotation of treatment (EVAR one week, open repair the next). This trial recruited
107 participants at 14 centres between 2008 and 2012. The IMPROVE trial was much larger, with a total
target recruitment of 600 unselected patients (all-comers), randomised at the point of in-hospital clinical
diagnosis, before CT, to confirm either the diagnosis or morphological suitability for EVAR. This trial
randomised 613 participants between 2009 and 2013. The different trial designs are shown in Figure 2.
Clinical diagnosis of ruptured AAA
CT scan Brief consent (patient, relative or non-treating
clinician before suitability for EVAR is assessed)
•  Rupture observed
•  Anatomy suitable for EVAR Randomisation
The AJAX and ECAR trials The IMPROVE trial
The AJAX trial:
consent
The ECAR trial:
weekly rotation
Randomisation
EVAR Open repair
•  CT scan
•  EVAR if anatomy suitable
•  Open repair default
•  CT scan optional
•  Open repair 
•  Other
    diagnosis
•  Open repair
FIGURE 2 Comparison of designs for three European trials comparing endovascular and open repair for a
ruptured AAA.
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The first results of 30-day mortality came from the Dutch trial (AJAX) in August 2013,14,19 after recruitment
to the IMPROVE trial had closed on 21 July 2013. AJAX reported a low 30-day mortality for both randomised
groups (21% for the EVAR group and 25% for the open repair group; p = 0.66); however, this was a
secondary outcome measure. The primary outcome measure was 30-day mortality and major complications,
which also did not differ significantly between the randomised groups.19
The IMPROVE trial
The 30-day outcomes for the IMPROVE trial were first presented at the Annual Scientific Meeting of the
Vascular Society of Great Britain and Ireland at the end of November 2013, followed by publication by the
IMPROVE trial investigators.21 in January 2014. Between September 2009 and July 2013, 613 participants
with an in-hospital diagnosis of ruptured AAA, made by a senior hospital clinician, were randomised either
to EVAR (with the default of open repair when EVAR was not anatomically feasible; n = 316) or to open
repair (n = 297). Randomisation, which was computer based, was carried out by an independent contractor
with the assignation of participants in a 1 : 1 ratio using variable block sizes. These 613 participants
constitute 48% of 1275 patients admitted at the trial hospitals with a diagnosis of ruptured AAA during the
trial recruitment period. The recruitment rate and list of participating centres are shown in Appendix 1 and
at www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/, accessed 16 November 2017, respectively.
A Consolidated Standards of Reporting Trials (CONSORT) diagram and the baseline characteristics of the
randomised participants are given in Figure 3 and Table 1, respectively.
The diagnosis of ruptured aneurysm was confirmed either by CT or in surgery in 275 out of 316 participants
(87%) in the endovascular strategy group and in 261 out of 297 participants (88%) in the open repair
group. In the endovascular strategy group, 64% of participants (174/272) were considered suitable for EVAR
after CT. A further eight participants (3%) in the endovascular strategy group and 14 participants (5%) in the
open repair group had a repair of a symptomatic intact aneurysm in the same admission. The 55 participants
(33 in the endovascular strategy group and 22 in the open repair group) with a final diagnosis unrelated to
an AAA had a wide range of other primary diagnoses, varying from ruptured thoracic aortic aneurysm to
urinary tract infection, but 45 of these participants (82%) had an asymptomatic AAA. One further participant
had a thoracoabdominal aneurysm, and only 9 out of 613 participants (1.5%) did not have an aortic aneurysm.
The primary outcome measure was 30-day mortality. The overall 30-day mortality was 35.4% (112/316
participants) in the endovascular strategy group and 37.4% (111/297 participants) in the open repair
group (OR 0.92, 95% CI 0.66 to 1.28; p = 0.62). However, in each group, some participants died before
aneurysm repair or breached the randomisation allocation. In the endovascular repair group, 28 participants
who were morphologically suitable for EVAR (26 with rupture and 2 without rupture) received emergency
open repair for operational reasons (e.g. staff or endovascular suite not available or not yet available when
the patient was deteriorating). In the open repair group, 33 participants with a rupture had emergency
EVAR, mainly because the anaesthetist deemed them unsuitable for general anaesthesia, and a further three
participants had delayed elective repair with EVAR. The detailed results are presented in Figure 3. Overall,
548 out of 613 participants (89%) adhered to the trial protocol. Among 502 participants with a ruptured
aneurysm who received repair, the 30-day mortality was 32% (84/259 participants) in the endovascular
strategy group and 36% (87/242 participants) in the open repair group (OR 0.86, 95% CI 0.59 to 1.24).
Limited subgroup analyses (age, sex and Hardman index) were also conducted for the primary outcome
measure (30-day mortality by randomised group). There were no clear differences between the
randomised groups according to age (above or below 77 years) or Hardman index (0, 1 or ≥ 2). However,
there was weak evidence that the endovascular strategy was more effective in women than in men
(p = 0.02). Among women, 30-day mortality was 37% (26/70 participants) in the endovascular strategy
group and 57% (36/63 participants) in the open repair group, compared with 35% (86/246 participants)
and 32% (75/234 participants), respectively, among men.
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Other
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FIGURE 3 A CONSORT diagram showing the flow of participants through the trial, with 30-day mortality for each group. Details of the post-randomisation exclusions (n= 10)
are given in Appendix 1.
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The secondary outcome measures at 30 days included 24-hour mortality, in-hospital mortality (Table 2),
number of reinterventions, time and place of discharge, and costs. The first three of these outcomes were
similar between the randomised groups and are reported in full by Powell et al.21 In the endovascular
strategy group, nearly all of the patients discharged (94%) within 30 days were discharged home,
compared with only 77% in the open repair group (p < 0.001) (see Table 2). The mean resource use
costs to 30 days was £13,433 [standard deviation (SD) £10,354] in the endovascular strategy group and
£14,619 (SD £12,353) in the open repair group (mean difference –£1186, 95% CI –£2997 to £625)
(see Appendix 2, Table 30).
The mean use of critical care was 4.5 bed-days (SD 5.9 bed-days) in the endovascular strategy group,
compared with 6.3 bed-days (SD 7.7 bed-days) in the open repair group. Postoperatively, renal replacement
therapy was used in 78 participants: 32 in the endovascular strategy group and 46 in the open repair group,
but only one participant, in the open repair group, was discharged on dialysis. Specialist coronary care was
used in 11 participants (total of 38 bed-days), nine in the endovascular strategy group and two in the open
repair group (total of 4 bed-days) within 30 days of randomisation; there was no additional coronary care
TABLE 1 Baseline characteristics of IMPROVE trial participants, by randomised group
Variable
Missing
data (n)
Trial group
Endovascular strategy
(N= 316)
Open repair
(N= 297)
Age (years), mean (SD) 0 76.7 (7.4) 76.7 (7.8)
Male sex, n/N (%) 0 246/316 (78) 234/297 (79)
Admission blood pressure (mmHg), mean (SD) 12 N= 306 N= 295
Systolic 110.3 (32.9) 110.4 (31.2)
Diastolic 65.3 (21.4) 66.8 (22.5)
Admission haemoglobin (g/dl), mean (SD) 6 11.2 (2.5); N= 312 11.1 (2.3); N = 295
Admission creatinine (µmol/l), median (IQR) 13 117 (94–152); N= 312 115 (93–151); N= 288
Acute myocardial ischaemia ECG, n/N (%) 52 22/291 (8) 23/270 (8)
Loss of consciousness, n/N (%) 27 29/305 (10) 21/281 (7)
Hardman index score,a n (%) 74 N= 282 N= 257
0 93 (33) 69 (27)
1 130 (46) 126 (49)
2 46 (16) 48 (19)
3 11 (4) 12 (5)
4 2 (1) 2 (1)
5 0 (0) 0 (0)
CT carried out, n/N (%) 0 305/316 (97) 266/297 (90)
Maximum aortic diameter (mm), mean (SD) 86 84 (19); N= 263 81 (18); N = 264
Time from randomisation to theatre admission
Ruptures (minutes), median (IQR) 6 47 (28–73) 37 (22–62)
Symptomatic aneurysms (hours), median (IQR) 2 3.6 (3.1–15.6) 3.0 (1.5–17.6)
ECG, electrocardiogram; IQR, interquartile range; SD, standard deviation.
a Scores 1 point each for age > 76 years, acute myocardial ischaemia on ECG, haemoglobin < 9.0 g/dl, creatinine
> 190 µmol/l and loss of consciousness after admission.
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between 30 and 90 days. A total of 28 participants in the endovascular strategy group and 47 participants
in the open repair group were still in hospital 30 days after randomisation.
Individual patient meta-analysis of the three recent European trials
By 2015, four European trials had reported results, and searching the published literature and clinical
trial databases did not reveal any further trials. The ECAR trial22 was presented to the European Society
for Vascular Surgery in September 2014 and published results in 2015, with 30-day mortality rates
(the primary outcome measure) similar to those reported in AJAX:19 19% for the EVAR trial group and
24% for the open repair group. Unfortunately, half of the data for the Nottingham trial16 had been lost,
but the other three trials agreed to pool their data for an individual patient meta-analysis.
The baseline descriptions of the participants in the three trials are compared in Table 3. The IMPROVE trial
had recruited older patients, less haemodynamically stable patients (lower admission blood pressure) and a
higher proportion of women than the other two trials. There were other important differences too, with
the AJAX and ECAR trials using predominantly aorto-uni-iliac configurations of endografts so that the
procedure could not be completed under local anaesthesia, and the ECAR trial aggressively monitoring for
abdominal hypoperfusion syndromes postoperatively (abdominal compartment syndrome and colonic and
mesenteric ischaemia).
Survival to 30 days by trial and by randomised group is shown in Figure 4. Additionally, the Kaplan–Meier
curves for restricted IMPROVE trial participants who were morphologically suitable for endovascular repair
(and more similar to the participants in the AJAX and ECAR trials) are shown in Appendix 2, Figure 24.
Mortality was higher for both randomised groups in the IMPROVE trial than in either the AJAX or ECAR trials.
However, restricting the IMPROVE trial population to those patients who were morphologically suitable
for EVAR reduced the mortality in both groups. When the results from the three trials were pooled in a
TABLE 2 Place of discharge of IMPROVE trial participants, by randomised group and in-hospital mortality
Discharge status
Trial group, n (%)
Endovascular strategy (N= 316) Open repair (N= 297)
Discharged alive from trial hospital
Yes 201 (64) 183 (62)
No 115 (36) 114 (38)
Place of discharge
Home 189 (94) 141 (77)
Another hospital: routine bed 7 (3) 28 (15)
Another hospital: intensive care 0 (0) 1 (1)
Nursing home 0 (0) 3 (2)
Residential home 1 (1) 3 (2)
Sheltered accommodation 1 (1) 0 (0)
Other 3 (1) 7 (4)
Note
Reprinted with permission from the British Medical Journal 2014;348:f7661.21 Copyright © 2014, British Medical Journal
Publishing Group. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non
Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
See: http://creativecommons.org/licenses/by-nc/3.0/.
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meta-analysis, there was no evidence of heterogeneity (pooled OR 0.88, 95% CI 0.66 to 1.18) (Figure 5).
When only patients with a ruptured aneurysm who were eligible for both EVAR and open repair were
included (AJAX, n = 113; ECAR, n = 104; and IMPROVE, n = 310), the pooled OR reduced slightly (OR 0.80)
but the CI widened (95% CI 0.54 to 1.17) (see Figure 5).
There was little evidence of treatment effect changing according to age or Hardman index. There were no
early deaths among women who had EVAR in the ECAR trial. However, in the pooled analyses, women
benefited more than men from an endovascular strategy (OR 0.47, 95% CI 0.23 to 0.97). For abdominal
compartment syndrome, the highest rate was reported from the ECAR trial. Over the three trials, there was
no significant difference in the incidence of abdominal compartment syndrome between the randomised
groups, although the AJAX team is currently conducting per-protocol analyses. However, there was an
indication that the incidence of colonic and mesenteric ischaemia was lower after EVAR or an endovascular
strategy than after open repair (pooled ORs 0.57, 95% CI 0.32 to 1.01) (Table 4). A higher rate of
TABLE 3 Descriptive statistics for the three recent European ruptured AAA trials
Numbers, clinical details and baseline variables
Trial
AJAX (N= 116) ECAR (N= 107) IMPROVE (N= 613)
Randomised group, n (%)
EVAR/endovascular strategy 57 (49.1) 56 (52.3) 316 (51.5)
Open repair 59 (50.9) 51 (47.7) 297 (48.5)
Ruptured AAA suitable for EVAR,a n (%) N = 113 N= 104 N= 310
EVAR/endovascular strategy 57 (50.4) 54 (51.9) 168 (54.2)
Open repair 56 (49.6) 50 (48.1) 142 (45.8)
Procedure started, n (%)
EVAR 57 (49.1) 56 (52.3) 192 (31.3)
Aorto-uni-iliac 49 (86) 43 (77) 39 (20)
Open repair 59 (50.9) 50 (46.7) 331 (54.0)
Tube 50 (88) 26 (54) 268 (81)
No aneurysm repair 0 (0) 1 (0.9) 90 (14.7)
Age (years), mean (SD) 74.2 (9.4) 74.4 (10.6) 76.7 (7.6)
Male sex, n (%) 99 (85) 97 (91) 480 (78)
Maximum AAA diameter (cm), mean (SD) 7.6 (1.6) 7.7 (2.0) 8.4 (1.9)
Aneurysm neck length (mm), median (IQR) 25 (19–34) 22 (16–32) 22 (10–34)
Admission blood pressure (mmHg),b mean (SD) 87 (27); N= 113 108 (30); N = 104 81 (24); N= 601
Hardman index score, n (%) N = 61 N= 105 N= 539
0 26 (43) 41 (39.0) 164 (30.4)
1 19 (31) 44 (41.9) 254 (47.1)
2 12 (20) 11 (10.5) 94 (17.4)
≥ 3 4 (7) 9 (8.6) 27 (5.0)
IQR, interquartile range.
a Suitability for EVAR in the IMPROVE trial was defined by a local assessment of suitability, if available; otherwise, a core
laboratory assessment of ‘within liberal instructions for use’ was used to define suitability. Suitability was not assessed in
46 ruptured AAAs in the IMPROVE trial and one in the ECAR trial.
b Mean arterial blood pressure recorded only in the ECAR trial; for AJAX and IMPROVE, it was approximated by two-thirds
diastolic + one-third systolic blood pressure.
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FIGURE 5 The 30-day mortality by randomised group. (a) Restricted to 527 participants with a ruptured AAA who
were eligible for both EVAR and open repair; and (b) 834 participants (two ECAR trial participants lost to
follow-up before 30 days).
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FIGURE 4 The 30-day mortality by randomised group across the three recent European ruptured aneurysm trials.
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ischaemic colitis after open repair than after endovascular repair has recently been reported in the analysis
of a large US database.49
The three trials were set in different health-care systems, leading to differences in discharge policies,
including the use of ‘step-down’ care. For instance, many of the French ECAR trial participants were
discharged to other facilities for convalescent care, whereas more participants in the IMPROVE trial were
discharged directly to home. Over the three trials, for those participants discharged alive from the main
trial hospital, the primary hospital stay was shorter for participants in the EVAR or endovascular strategy
groups [pooled hazard ratio (HR) for discharge 1.24, 95% CI 1.04 to 1.47] (see Appendix 2, Figure 22).
The individual patient data meta-analyses have been reported with 90-day mortality50 as the primary
outcome measure;51 again, there was no difference in mortality between the randomised groups, but
EVAR appeared to be more effective in women than in men.
Discussion
The best evidence comes from the synthesis of evidence from randomised trials, and 30-day mortality is
the standard surgical outcome measure. This best evidence, from the 836 participants from the three
recent trials, shows that there is no significant difference in 30-day mortality between EVAR or an
endovascular strategy and open repair (pooled OR 0.88, 95% CI 0.66 to 1.18), with no evidence of
heterogeneity. The absolute differences between the trials, lowest mortality in the ECAR trial and highest
mortality in the IMPROVE trial, probably relate to the selection criteria for participants in the three trials,
AJAX and ECAR being highly selective and IMPROVE being unselective and ‘real world’. The influence of
some of these selection criteria on 30-day mortality is explored and discussed in Chapter 4. The flexibility
of individual patient meta-analysis also allowed only specific participant subsets to be included in the
analysis. All trials included some participants in whom rupture was not confirmed, at laparotomy in the
AJAX and ECAR trial and either at CT scan or at laparotomy in the IMPROVE trials. At 30 days, there was
no evidence that EVAR offered a survival advantage in participants with a confirmed rupture who were
eligible for both endovascular and open repair, although the pooled OR had reduced to 0.80.
TABLE 4 Reported incidence of abdominal compartment syndrome and other mesenteric hypoperfusion
syndromes, colonic ischaemia and mesenteric ischaemia, by randomised group across three randomised trials
Trial
Trial group, n/N (%)
EVAR/endovascular strategy Open repair
AJAX
ACS 5/57 (9) 2/59 (3)
CMI 2/57 (4) 5/59 (8)
ECAR
ACS 8/56 (14) 1/51 (2)
CMI 4/56 (7) 8/51 (16)
IMPROVEa
ACS 14/259 (5.4) 13/243 (5.3)
CMI 14/259 (5.4) 19/243 (7.8)
ACS, abdominal compartment syndrome; CMI, chronic mesenteric ischaemia.
a The denominator is the number of ruptured aneurysms repaired.
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One of the surprising findings from the IMPROVE trial was that there was weak evidence that an
endovascular strategy was more effective in women than in men, partly attributable to the very high
mortality after open repair in women. Despite the scant number of women in the other two trials, this
finding was maintained on meta-analysis. This could suggest that EVAR should be a more common
treatment option for women, although further research is needed. There was no clear effect of age.
These main findings from the trials have not been universally welcomed. The AJAX and ECAR trials have
been dismissed as being too small and criticised for their use of aorto-uni-iliac endografts; certainly both
trials took a long time to recruit not very many patients. The IMPROVE trial was more ‘real world’ but has
been criticised for including participants who did not have a ruptured aneurysm or who died before repair
could be accomplished. This serves to highlight the difference in time taken to start definitive repair with
either EVAR or open repair. In each trial, the time taken to bring a participant to endovascular repair was
significantly longer than for a participant to have open repair started; this difference was 0.48 hours,
1.6 hours and 0.16 hours for the AJAX, ECAR and IMPROVE trials, respectively. There is weak evidence
showing that time to treatment influences survival adversely.52,53 This might be have been a contributor to
mortality in the EVAR groups of the AJAX and ECAR trials but, for the IMPROVE trial, the time difference
was much shorter. Misdiagnosis might also contribute to the mortality rate in the EVAR group because
diagnosis, even after CT, can be in doubt.27 In both the AJAX and IMPROVE trials, other bleeding
diagnoses were shown to be the cause of admission in a few participants at laparotomy, whereas, at
endovascular repair, such diagnoses would have been missed. Since the inception of the trials and since
publication of the trial results, there have been several observational studies to show how team training
and protocols can enhance performance and reduce mortality.54,55 This could include improved reading of
CT scans and a reduction in the time to start EVAR. Team training could also limit misjudgement about
attempting EVAR because, in the randomised trials, conversion to open repair was associated with
100% mortality. However, part of the reported reduction in mortality from team training might also
have been achieved by different selection of patients for repair; few other studies report the number of
untreated patients.
The appropriate time to subject new technologies to a randomised trial is controversial. The IDEAL (Idea,
Development, Exploration, Assessment and Long-term follow-up) recommendations56 suggest that a trial
should be considered when an intervention is sufficiently well evolved to warrant evaluation, but without
the expectation that the intervention will continue to develop. Before the start of the IMPROVE trial, the
uptake of EVAR for ruptured aneurysms was low and patchy and NICE recommended emergency EVAR for
evaluation purposes only.57 Therefore, the IMPROVE trial might have started when experience and team
training for emergency EVAR was rather limited in some centres. However, with its widespread coverage of
experienced EVAR centres that participated across the UK, the trial has acted as stimulus to evaluate the
new technology. Data taken from HES for 2014/15 show that, in England, 36.4% of emergency aneurysm
repairs in men and 31.7% in women were conducted using EVAR (Professor Jonathon Michaels, University
of Sheffield, 2016, personal communication).
Other criticisms of the IMPROVE trial include the fact that we did not highlight the relatively low mortality
in the participants who actually received EVAR58 and that, partly because of the improvements in intensive
care medicine, there may be many ‘long-stayers’ and, therefore, 90-day outcome measures are more
relevant than 30-day outcome measures.59 Even after 90 days, there was no difference in mortality
between the randomised groups in any of the three trials considered.51 Surprisingly, few sources in the
literature have highlighted another important outcome measure for patients: time to discharge and place
of discharge. Regarding this outcome, there is a clear benefit from the EVAR/endovascular strategy, with
times to discharge being much shorter than after open repair, which was observed in all three trials. These
trials were set in different health-care systems and only the IMPROVE trial specifically reported discharge to
home, which was much more common after the endovascular strategy (94%) than after open repair (77%).
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Summary
Neither IMPROVE, the largest of the three recent trials, nor pooled data from the three trials identified that
an endovascular strategy or EVAR led to lower 30-day mortality. At the time of rupture, the main clinical
concern is to stop the bleeding and it is recognised that the initial repair, either endovascular or open, may
need to be supported by further reinterventions beyond 30 days. For these reasons, longer-term follow-up
is needed for all principal outcome measures, as well as patient QoL and cost-effectiveness, which were
not assessed at 30 days, and to advise whether or not the benefits of an endovascular strategy for
subgroups or secondary outcomes, observed in IMPROVE and the other trials, are maintained in the
longer term.
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Chapter 4 Factors other than the type of repair
that influence 30-day survival of patients with a
ruptured abdominal aortic aneurysm
The type of aneurysm repair, endovascular or open surgery, is not the only factor that influences theoutcome for patients with a ruptured AAA. First, the patient may present at the emergency department
of a hospital that does not offer emergency vascular surgery and a decision will be made as to whether or
not the patient should be transferred to a specialist vascular centre. Then, the time taken for patients to be
transferred to a vascular centre could be influential.53,60 Next, there is evidence that operative mortality after
rupture is lower in the larger-volume vascular centres10 and that, at least in England, operative mortality for
all types of emergency surgery is lower if patients present within working hours.61 Even larger-volume
centres cannot usually offer sufficiently sized prospective case series in which to investigate other hospital,
patient and clinical factors that may be associated with better or worse patient outcomes. To date, the
largest patient series focused on endovascular repair reported on 473 patients who were treated between
1998 and 2011 from centres in two countries.10 The IMPROVE trial recruited 613 eligible patients with a
clinical diagnosis of abdominal aortic rupture between late 2009 and the summer of 2013. Some 536
participants had a confirmed aneurysm rupture, together with 22 urgent symptomatic aneurysms, making
this the largest contemporary prospective cohort in which to investigate both the factors used for primary
adjustment of 30-day mortality results (age, sex, Hardman index) and the role of factors, such as hospital
presentation, time to surgery, fluid replacement therapy, aortic morphology and type of anaesthesia, on
the outcomes of emergency surgery. As expected, Hardman index score was highly predictive of 30-day
mortality, but mortality also increased with age; for each 5-year increase in age, the OR was 1.37
(95% CI 1.21 to 1.56) (Table 5).
Transfer guidelines
At the beginning of the IMPROVE trial, we conducted a survey of the participating centres about the type
of patient with a ruptured AAA who would accept for transfer from another hospital that did not offer
emergency vascular surgery. It was clear that there was a wide disparity of opinion about suitable patients
for transfer. This stimulated a Delphi consensus approach, working with the vascular surgeons, emergency
TABLE 5 Adjusted effect of main variables (age, sex, Hardman index and randomised group) on 30-day mortality in
558 participants (complete-case analysis)
Variable OR 95% CI p-value (z-test)
Age (per 5-year increase)a 1.20 1.04 to 1.38 0.015
Sex
Female 1.00 0.45 to 1.14 0.162
Male 0.72
Hardman index score (per 1-unit increase) 1.62 1.26 to 2.08 < 0.001
Randomised group
Open repair 1.00 0.62 to 1.28 0.535
Endovascular strategy 0.89
a Not full effect of age because of dichotomised age being included in Hardman index. OR of age (per 5-year increase)
excluding Hardman index from adjustment list is 1.37 (95% CI 1.21 to 1.56; p< 0.001).
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medicine physicians and anaesthetists from the IMPROVE trial centres, as well as emergency medicine
physicians and senior trainees across the NHS Wessex Clinical Strategic Network. Eventually, this generated
best practice guidelines,24 endorsed by the Royal College of Emergency Medicine, the Vascular Society of
Great Britain and Ireland and the Royal College of Radiologists.62 These guidelines emphasise that there is
no upper age limit for transferring patients and that all patients aged < 85 years, alert or with fluctuating
consciousness, with moderate or minimal systemic disease and who need no or some help with daily living
should be transferred, whereas those with cardiac arrest in current episode should not. Speed is accepted
as important, and specialty trainees should be allowed to arrange transfer (target of ≤ 20 minutes of
clinical diagnosis) if consultants are not on-site. CT confirmation of diagnosis is not necessary before
transfer (although ultrasound assessment is desirable) and transfers should not be delayed by waiting for
specific tests. A systolic blood pressure of ≥ 70 mmHg is sufficient for transfer without the need for
intravenous fluids, unless deterioration occurs, in which case any fluids should be administered in small
boluses only.
Use of the IMPROVE trial as a large observational series of patients with
abdominal aortic aneurysm rupture
Before the IMPROVE trial had closed to randomisation, the possibility of using the patient series to
investigate a number of hypotheses relating to other factors that might influence 30-day survival had been
discussed and analysis plans had been formulated to address the following hypotheses:
1. Thirty-day mortality is lower in patients randomised during routine working hours than at other times.
2. Patients transferred from other hospitals to trial centres have lower Hardman index scores and better
outcomes than those arriving primarily at the trial centre.
3. Lowest blood pressure is not associated with 30-day survival because overadministration of fluid and/or
blood products is associated with higher mortality.
4. General anaesthesia for endovascular repair is associated with higher operative mortality than
local anaesthesia.
5. Aortic morphology, particularly increasing aneurysm diameter and hostile aneurysm necks, is associated
with high 30-day mortality.
All of these analyses focused on the 558 participants who had a confirmed diagnosis of either ruptured
AAA or acute symptomatic AAA.
Time of presentation
Those participants who were randomised out of hours had higher 30-day mortality (144/362) than those
randomised within routine working hours (65/196) (primary adjusted OR 1.47, 95% CI 1.00 to 2.17;
p = 0.048).63 However, there was little evidence that the efficacy of the endovascular strategy compared
with open repair in those participants who were randomised out of hours was different from that in those
randomised during routine working hours (test of interaction p = 0.100). This suggestion that mortality is
higher among patients who are admitted out of hours is supported by data from the National Inpatient
Sample in the USA. Among 5800 ruptured AAA participants, the in-hospital mortality was significantly
higher among those participants admitted at weekends than among those admitted during the week
(OR 1.32, 95% CI 1.13 to 1.55; p = 0.0004), and only 77% of those admitted at weekends underwent
same-day repair, compared with 80% admitted during the week (p = 0.004).52 Given the large sample size,
Groves et al.52 tried to identify factors contributing to the increased (32% higher) mortality at the weekend.
It was not related to differential use of EVAR but, at weekends, participants received blood transfusion
more often than during the week. Higher mortality among patients admitted at weekends may be a
widespread phenomenon – it also has been reported in Italy64 and in Canada,65 where in-hospital mortality
was 42% at weekends compared with 36% during the week – and might be attributable to the lower
availability of specialised teams for treating patients or to staffing levels more generally.
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Patient transfers: primary presentation compared with secondary presentation
The characteristics of participants with direct and secondary presentation to trial centres, including
Hardman index scores, were similar, although a higher proportion of secondary presentation patients
(221/335, 70%) were randomised out of hours. After adjustment for this, there was no difference in the
30-day mortality of those participants who were admitted directly to the trial centre and those (233 out of
335) transferred from other hospitals (adjusted OR 0.76, 95% CI 0.52 to 1.12). There are several potential
explanations for this result, including the possibility that only lower-risk patients were transferred or that
the highest-risk patients died during transfer. One recent study from the USA has suggested that 17% of
patients die during transfer.60
Preoperative variables: fluid administration and blood pressure
There was no evidence from IMPROVE trial participants that the volume of fluids administered before
arrival in the operating theatre had a significant effect on postoperative mortality in a multivariable model.
However, the volume of fluids given was recorded in only 302 participants. In contrast, there was a strong
inverse association between the lowest in-hospital preoperative measured systolic blood pressure and
mortality, with no significant association between this blood pressure measurement and the fluid volume
administered. The association between the lowest systolic blood pressure and 30-day mortality showed no
evidence of non-linearity [adjusted OR per 10-mmHg increase in blood pressure of 0.88 (95% CI 0.82 to 0.94)]
(see Appendix 2, Figure 23). The 30-day mortality among participants whose blood pressure was above and
below the threshold value of 70 mmHg was 34% and 51%, respectively.
General anaesthesia compared with local anaesthesia
Overall, among participants undergoing EVAR (n = 186), the 30-day mortality associated with procedures
conducted under local anaesthesia only appeared to be substantially lower. After adjustment for age, sex,
Hardman index, lowest systolic blood pressure and randomised group, local anaesthesia was associated
with a fourfold reduction in 30-day mortality (adjusted OR 0.27, 95% CI 0.10 to 0.70; p = 0.007). Local
anaesthesia was more commonly used with bifurcated graft configurations whereas general anaesthesia
was more commonly used with aorto-uni-iliac configurations because of the requirement for a femoro-
femoral crossover graft, which causes considerable ischaemic leg pain that cannot be tolerated under local
anaesthesia. Even after adjustment for graft configuration, the benefits of local anaesthesia remained
highly significant. By 2016, there was increasing recognition that endovascular repair of ruptured AAA
should be conducted under local anaesthesia whenever possible.63,66,67
Aortic morphology and the hostile aneurysm neck
Nearly all patients presenting with a clinical diagnosis of ruptured AAA undergo CT, so that rupture can be
confirmed and aortic morphology can be assessed rapidly to determine whether or not the patient is a
suitable candidate for EVAR. One liberal definition of suitability for endovascular repair that has been used
by laboratories for centralised assessment of CT scans includes an aneurysm neck length of ≥ 10 mm, a
neck diameter of < 32 mm and a neck angle of < 60°.68 A retrospective Swiss study69 found that the
30-day mortality for open repair among patients whose aneurysm falls outside this definition was eight to
nine times higher than in those whose aneurysm complied with this definition, whereas a Dutch study70
found no difference. Others have suggested that mortality following rupture in patients with very large
aneurysms is worse than mortality in patients with smaller aneurysms,71 but good-quality data to support
such suggestions are scant.
The IMPROVE trial core laboratory held good-quality CT scans for 458 participants with confirmed AAA
rupture. First, working to a predefined analysis plan, the main morphological features (Figure 6)72 were
compared in participants in whom treatment was initiated with either EVAR or open repair (Table 6). It is
immediately evident that the main difference between the EVAR participants and the open repair participants
is in the aneurysm neck length. Overall, if the aortic morphology was within the liberal instructions for use
(IFU) defined in the previous paragraph, 30-day mortality was marginally lower than for participants with
aortic morphology outside the liberal IFU (adjusted OR 0.64, 95% CI 0.41 to 1.01; p = 0.054), with the
association being stronger for those in whom open repair had started. There was a stronger and linear
DOI: 10.3310/hta22310 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 31
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Ulug et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
25
inverse association of 30-day mortality with neck length (adjusted OR 0.72, 95% CI 0.57 to 0.92), again
with the association being stronger for those in whom open repair had started; both ORs were adjusted for
age, sex, Hardman index, lowest recorded systolic blood pressure and randomised group. The relationship
between aneurysm neck length and mortality is shown in Figure 7, with data on neck length category and
treatment started given in Table 7.
These results suggest that a single morphological parameter, aneurysm neck length, appears to have a
significant influence on operative mortality following surgery for a ruptured AAA, independent of known
confounders. As the aneurysm neck shortens, conventional EVAR either becomes impossible or, if
attempted, carries a very high mortality rate. This relationship has also been suggested to hold for open
repair.69 We also observed a strong relationship between short aneurysm neck length and high mortality
after open repair, which explains why mortality after open repair remains high; many of these patients
have juxtarenal aneurysms. Open juxtarenal aneurysm repair requires cross-clamping of the aorta above
A    maximum aortic diameter
B     neck diameter
C     neck length
D     maximum common iliac diameter
E     proximal neck angle
B
C
A
E
D
FIGURE 6 Primary morphological variables for analysis.
TABLE 6 Baseline morphological criteria according to treatment started for 458 participants with rupture and
CT scans assessed in the core laboratory
Morphological criteria N
Trial commenced, mean (SD)
p-valuea
Total, mean
(SD) (N= 458)
EVAR commenced
(N= 177)
Open repair
(N= 281)
Within liberal IFU 389 108 (71.5) 119 (50.0) < 0.001 227 (58.4)
Maximum aneurysm diameter (mm) 427 85.6 (18.2) 86.3 (17.0) 0.59 86.0 (17.4)
Aortic neck diameter at distal renal
artery (mm)
374 25.1 (3.8) 25.9 (4.7) 0.21 25.6 (4.4)
Neck length (mm) 409 29.2 (14.8) 19.5 (15.8) < 0.001 23.3 (16.1)
Conicality (% change per 1-mm length) 361 0.46 (0.89) 0.93 (1.99) 0.030 0.73 (1.63)
Proximal neck angle (degrees) 406 31.0 (19.0) 33.9 (20.9) 0.17 32.7 (20.2)
Maximum common iliac diameter (mm) 404 21.5 (8.1) 20.6 (9.3) 0.040 21.0 (8.8)
IFU, instructions for use.
a Wilcoxon rank-sum test for continuous variables and Pearson χ2 test for binary variables.
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the renal arteries, with inevitable compromise of the visceral circulation, especially in shocked patients.
In contrast, for longer aneurysm necks (≥ 18 mm when infrarenal aortic clamps for open repair can readily
be deployed), the operative mortality rates for open repair and EVAR are closely similar (≈25%). Perhaps
surprisingly, we did not identify any association between maximum aortic diameter (or any other
morphological variable assessed) and mortality following repair of a ruptured AAA. Our findings may also
help to explain why population-level observational studies and meta-analyses of observational studies report
that, for ruptured aneurysms, operative mortality for EVAR is about half of that for open repair (the patients
with long aneurysm necks have EVAR and those with short aneurysm necks have open repair), as well as
why the mortality following the repair of a ruptured AAA is much higher in women than in men (in women,
the AAA has a much shorter proximal neck).
These findings of the association between aneurysm neck length and mortality need to be verified in an
independent cohort, but there are few large unselective cohorts available with detailed morphology of
both endovascular and open repairs. However, we have shown, in an individual patient data meta-analysis,
that the association for open repair was also observed for patients randomised in the AJAX19 and ECAR22
trials (in which all participants were morphologically eligible for EVAR).51 There is support for such findings
from Baderkhan et al.,73 who reported, based on 112 participants undergoing EVAR, that both the number
of reinterventions and 3-year mortality were significantly higher for those repaired within the IFU than for
those repaired outside the IFU. However, others may hold different opinions: van Beek et al.70 studied 279
consecutive participants undergoing open repair and concluded that participants with ‘hostile’ and
‘friendly’ aortic necks had similar 30-day mortality.70
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FIGURE 7 Association between neck length and proximal aortic neck length. Univariate effect of quintiles of neck
length on 30-day mortality (complete case analysis with 409 participants), after adjustment for age, sex, Hardman
index, lowest recorded systolic blood pressure, randomised group and treatment commenced.
TABLE 7 The 30-day mortality by categories of neck length according to treatment started for rupture (complete
case analysis with 409 participants)
Treatment commenced
Neck length (mm), % (n/N)
Total, % (n/N)0–4 5–9 10–14 15–29 ≥ 30
Overall 50 (30/60) 49 (17/35) 43 (17/40) 29 (40/139) 24 (33/135) 34 (137/409)
EVAR 33 (2/6) 63 (5/8) 20 (2/10) 27 (18/66) 24 (17/71) 27 (44/161)
Open repair 52 (28/54) 44 (12/27) 50 (15/30) 30 (22/73) 25 (16/64) 38 (93/248)
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For our work on risk scoring (see Chapter 8), we are using data from 192 unselected patients in the
Stockholm area,74 and the association will be tested in this cohort in the future. This future work will add
depth to the current debate regarding whether or not aortic neck pathology influences survival following
repair of ruptured aneurysms.
Summary
To ensure that patients across the UK who present with a clinical diagnosis of ruptured AAA have similar
access to transfer to specialist vascular centres, multidisciplinary best practice clinical guidelines for the
transfer of patients with a clinical diagnosis of ruptured AAA have been developed. Using the participants
from the IMPROVE trial as an observational cohort of participants with ruptured AAAs, we have been
able to identify several important factors, other than the type of aneurysm repair (endovascular or open),
that influence the outcome of this deadly disorder. Some of these findings suggest ways to improve the
outcomes of patients with ruptured AAAs, particularly through the use of local anaesthesia for emergency
EVAR. Other findings, such as the higher mortality for participants admitted out of hours or at weekends,
are observed throughout surgery and have been noted in other large series. The guidelines for hypotensive
haemostasis75–77 have been developed in trauma patients aged < 55 years; in a much older population, we
have shown the adverse effect of blood pressures of < 70 mmHg on mortality and this is just one piece of
evidence that contributes to the debate about the definitions of hypotensive haemostasis in the elderly
population.75–78 The inverse association between proximal aneurysm neck length and 30-day mortality is
probably crucial to understanding why observational series always report a much more favourable outcome
for emergency EVAR than for emergency open repair; these observational series do not compare like with
like, as patients with long aneurysm necks receive EVAR whereas those with short and challenging aortic
necks receive open repair.
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Chapter 5 One-year outcomes, survival,
reinterventions and health economics
Some of the material in this chapter has been reproduced in part from published work.23 © The Authors2015. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an
Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial
License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution,
and reproduction in any medium, provided the original work is properly cited. For commercial re-use,
please contact journals.permissions@oup.com.
Overview
A ruptured AAA is an acute event and the success of aneurysm repair is assessed predominantly by 30-day
mortality. Although there are many reports of 30-day mortality (see Chapter 3), there are far fewer reports of
outcomes at ≥ 1 year. The largest series reporting on the comparative effectiveness of endovascular repair and
open repair in the longer term comes from the Medicare data set in the USA.47 In propensity-matched cohorts,
Edwards et al.47 observed a relative survival advantage at 1 year for patients of all ages who had undergone
EVAR rather than open repair, and this advantage persisted for 4 years, before being dissipated. Rather similar,
more recent, results have come from the Vascular Study Group of New England.79 Such studies, from large
registries, focus on mortality and reinterventions only and provide no data concerning patient QoL, costs or
cost-effectiveness. All previous studies of QoL come from the period when only open surgery was used for
repair and use data from repairs that were conducted before 2000. There are a few reports of the relative
cost-effectiveness of endovascular repair compared with open repair for ruptured aneurysms. One report
comes from AJAX,80 in which cost-effectiveness was reported as incremental cost-effectiveness per death
prevented to 6 months. They found that, at 6 months, EVAR was not cost-effective. Another report, with the
opposite conclusion, comes from a retrospective analysis of participants at a single UK centre but without QoL
having been measured.81 The French randomised trial, ECAR,22 did not attempt to assess cost-effectiveness.
Therefore, the IMPROVE trial23 is the first study to assess the full cost-effectiveness of an endovascular strategy
compared with open repair for ruptured aneurysms.
Additional methods for cost-effectiveness analyses: categories of
resource use, handling of missing data and rationale for assumptions for
the base-case and sensitivity analyses
The specific resource use categories included in the cost-effectiveness analysis were (1) medical devices and
consumables for each intervention (see Appendix 2, Table 28); (2) length of hospital stay during the
primary admission, including critical and specialist unit bed-days and extent of organ support; (3) all
reinterventions during the primary admission, whether or not directly associated with the ruptured
aneurysm, including time in the operating theatre or endovascular suite, devices and consumables;
(4) readmissions related to the ruptured aneurysm and a sensitivity analysis including all readmissions; and
(5) outpatient and community service costs whether related to the ruptured aneurysm or other conditions.
Missing data on baseline covariates, resource use and QoL variables were handled with multiple imputation
using chained equations. Under this approach, each variable was imputed, conditional on fully observed
baseline variables, such as age and sex, and all other imputed variables, with the same variables being used
for the clinical and health economic analyses. All the variables considered for multiple imputation and, for
each variable, the number of missing values and the imputation model chosen are reported in Appendix 2,
Table 31.
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The major incomplete resource use components, such as time in the operating theatre, length of stay
in critical care or on routine wards (within either primary admission or readmission) and the use of
community care, were addressed with multiple imputation. For those participants with ruptured AAA for
whom aneurysm repair was commenced, missing resource use components were imputed from those
participants with ruptured AAA with observed resource use data. Participants who did not have a ruptured
AAA, and had no information recorded on being in critical care, were assumed to stay on a routine ward
for their entire hospital stay.
In the case of participants with a proven ruptured AAA who failed to return the QoL questionnaire that
was administered at 3 or 12 months, their EQ-5D scores were imputed from those of other ruptured AAA
survivors. For example, of the participants with ruptured AAA for whom repair had commenced and who
were eligible for the 3-month follow-up, 66 did not complete the EQ-5D questionnaire. For these 66
participants with missing EQ-5D scores at 3 months, EQ-5D scores were imputed using EQ-5D data from
those 252 participants with ruptured AAA who fully completed the EQ-5D questionnaire at 3 months (see
Appendix 2, Table 32). Hence, these imputations did not use information from those participants who had
died prior to either time point (who were assigned a EQ-5D score of 0), participants with a ruptured AAA in
whom repair had not commenced or participants who had a symptomatic AAA. In the case of participants
who were alive but otherwise ineligible for follow-up, we assumed that the EQ-5D score at either time point
was the average of the EQ-5D scores at baseline for participants with ruptured AAA presenting for elective
repair,41 in that their EQ-5D scores were 0.75, 0.75 and 0.74 at baseline (preoperatively) and at 3 and
12 months postoperatively, respectively.
The main assumptions made in the base-case scenario, and how each was relaxed in sensitivity analyses,
are shown in Appendix 2, Figure 26. The results of the sensitivity analysis were reported as the mean INB
with corresponding 95% CIs. These assumptions, which were relaxed in the sensitivity analyses, included:
1. Covariate adjustment. The base case reported unadjusted mean differences of both incremental costs
and QALYs, assuming randomisation had ensured that there were no imbalances in key prognostic
factors such as age, sex and Hardman index. In the sensitivity analysis, we adjusted for any chance
imbalances in age, sex and Hardman index using seemingly unrelated regression.
2. Distributional assumptions on costs and QALYs. The base case assumed that costs and QALYs were normally
distributed when reporting the 95% CIs around incremental costs and QALYs. In sensitivity analyses, we
assessed the robustness of the cost-effectiveness results to alternative distributional assumptions about both
outcomes. The sensitivity analysis considered a gamma distribution for costs as they had a right-skewed
distribution. For QALYs, the sensitivity analysis also considered a gamma distribution because a large
proportion of decedents had 0 QALYs and the remainder of the distribution was, again, right-skewed.
3. Staffing levels in the operating theatre. In the base case, we assumed the minimum number of staff
required in the operating theatre to undertake either type of repair. In sensitivity analyses, we allow for
additional staff used in some IMPROVE trial centres according to the results of the staffing survey.
4. Prices of devices for the endovascular procedure (stent grafts). In the base case, unit costs for the
devices and consumables of endovascular intervention were taken from manufacturing list prices,
assuming all hospitals would pay the same for these items, irrespective of the number of cases. In
sensitivity analysis, we considered a cost per case for the device of £4000–10,000, which may reflect,
for example, differential prices according to the number of cases, because the pricing of endovascular
stent grafts varied remarkably across different English hospitals because of different discounts.
5. Participants without proven rupture. For participants without a proven ruptured AAA, resource use
beyond the primary admission and QoL data were not collected because postoperative participant
consent was not required. In the base case, assumptions were made about EQ-5D-3L score based on
participants from an elective surgery trial; participants who did not have an aneurysm repair were
assumed to stay on a routine hospital ward for the primary admission and subsequently assumed
to have no reinterventions or readmissions and one outpatient visit. To assess whether or not the
overall cost-effectiveness results were sensitive to the inclusion of these participants and the requisite
assumptions, we ran a sensitivity analysis in which we excluded them from the sample.
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6. Readmissions. The base case only included costs from ruptured AAA-related readmissions to study
centres that were recorded in the CRFs. Sensitivity analysis allowed for other readmissions, by using
information collected in the health services questionnaire, although it was not always clear which of
these admissions were aneurysm-related. For these readmissions, we assumed the average readmission
cost from those readmissions recorded in the CRFs.
Results
Mortality
Between 3 months and 1 year after randomisation, two participants in the open repair group were lost
to follow-up (leaving 295 participants in this group available for 1-year analysis). By 1 year, 98 participants
in the endovascular strategy group and 103 participants in the open repair group had died (the flow of
participants through the IMPROVE trial to 3 years is shown in Figure 8). At 1 year, mortality was 41.1% for the
endovascular strategy group compared with 45.1% for the open repair group (OR 0.85, 95% CI 0.62 to 1.17).
Details and causes of death are given in Table 8. As at 30 days, the endovascular strategy was more effective in
women than men (interaction p= 0.034). Again, we conducted an individual patient meta-analysis of mortality
across the three recent European randomised trials, which included both participants as randomised and the
308 IMPROVE trial participants with a proven diagnosis of rupture only who were suitable for endovascular
repair.82 The survival curves to 1 year for each trial and for the restricted IMPROVE trial population are shown in
Appendix 2, Figure 24a. By 1 year, the ECAR trial suffered from almost 20% of participants being lost to
follow-up, so that the apparent separation of the survival curves was not significant. There was no significant
difference in mortality between the randomised groups for any trial, with the pooled OR being 0.84 (95% CI
0.63 to 1.11), with no significant heterogeneity (see Appendix 2, Figure 24b). Even if only the restricted
population from the IMPROVE trial was included in the meta-analysis, the pooled OR only reduced to 0.80
(95% CI 0.56 to 1.16); data are not shown. However, it is interesting to note the better survival of the
participants from the IMPROVE trial who were anatomically suitable for endovascular repair (compare parts a
and b in Appendix 2, Figure 24a), in keeping with our earlier findings that overall 30-day mortality was lower
(irrespective of type of repair) in participants with long aneurysm necks.83
If the overall benefit of an endovascular strategy confers only a relative 15% lower mortality at 1 year, we
would have needed to randomise almost 5000 participants to show a significant difference in 1-year mortality.
Reinterventions
By 1 year, the number of reinterventions per person was very similar in the endovascular strategy group
and the open repair group of the IMPROVE trial, with 78% of participants needing no reintervention in the
endovascular strategy group compared with 77% in the open repair group and, overall, the reintervention
rate of participants following hospital discharge was rather low. The very different reporting of complications
and reinterventions across the IMPROVE,23 AJAX80 and ECAR22 trials meant that a full meta-analysis was not
feasible. In the IMPROVE trial, complications were not captured and reinterventions were reported mainly
from a health economic perspective. However, a meta-analysis has been conducted for some of the rarer
events, particularly amputation. In the IMPROVE trial, there were a total of nine amputations above the knee
and more proximally, eight of which occurred within 1 year of randomisation. Within 1 year, five amputations
were in the endovascular strategy group and three in the open repair group. However, seven out of eight of
these amputations were in participants who received open repair. In a meta-analysis with AJAX (three
amputations in the open repair group) and the ECAR trial (two amputations in the open repair group), the risk
of amputation was much lower after EVAR (OR 0.20, 95% CI 0.05 to 0.88), with no evidence of heterogeneity.
Resource use
The data came from CRFs and questionnaires from the 502 participants in whom repair of a rupture had
started. Data completeness at 12 months in the endovascular strategy group was 89% for CRFs and 79% for
questionnaires. Data completeness at 12 months in the open repair group was 91% for CRFs and 79% for
questionnaires. The imputation of missing data, including for participants without a final diagnosis of ruptured
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Died within 90 days
(n = 91)
• Non-AAA admission, n = 22
• Symptomatic AAA, n = 14
• Died by 3 years, n = 16/36a
• Non-AAA admission, n = 33
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• Died by 3 years, n = 26/41a
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Open repair
(n = 297)
Died from 91 days to
1 year
(n = 7)
Died within 90 days
(n = 93)
Died between 1 and
3 years
(n = 28)
Died from 91 days to
1 year
(n = 10)
Ruptured AAA
and died
before repair
(n = 16)
Ruptured AAA
and operation
commenced
(n = 243c)
Ruptured AAA
and died
before repair
(n = 18)
FIGURE 8 A CONSORT diagram showing participant flow and follow-up to 3 years. a, Number of deads/(alive + died); b, with 26 participants who had open repairs in breach of
protocol; c, with 33 participants who had EVARs in breach of protocol; and d, participants withdrew consent to be contacted about completing EQ-5D questionnaires, but
allowed their other data to be used (five participants per randomised group). Completion rates reported indicate fully completed questionnaires.
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AAA, has been discussed in Additional methods for cost-effectiveness analyses: categories of resource use,
handling of missing data and rationale for assumptions for the base-case and sensitivity analyses.
Table 9 summarises the resource use up to 1 year after randomisation, related to primary admission,
readmissions and community care. Operation time was lower for participants who were randomised to an
endovascular strategy than for those randomised to the open repair procedure (see Table 9); mean time in
theatre was 157 minutes (SD 100 minutes) and 180 minutes (SD 108 minutes) for endovascular strategy and
open repair procedure, respectively. The endovascular strategy had, on average, a higher cost of medical
devices (including the stent graft) and consumables compared with the open repair procedure (see Table 9).
Participants in the endovascular group had a relatively lower mean cost in critical care compared with the
open repair group (£6300 vs. £9280, respectively). Theatre and general medical costs were relatively similar
between groups. Participants in the endovascular strategy stayed, on average, for fewer days in hospital
compared with participants in the open repair group; mean time in hospital was 14 days (SD 21.6 days)
compared with 20.1 days (SD 31.6 days), respectively. Participants in the endovascular strategy group were
discharged earlier from critical care units (mean 5.1 days compared with 7.4 days in the open repair group)
and fewer participants were transferred to other (secondary) hospitals than in the open repair group:
10 (3%) compared with 36 (12%), respectively. One participant in each randomised group was discharged
on haemodialysis. The costs related to stay in secondary hospitals were lower for the endovascular strategy
TABLE 8 Mortality for the 613 randomised participants and numbers of reinterventions in the 502 participants with
ruptured AAA who had aneurysm repair started
Variable Missing data (n)
Trial group, n (%)
Endovascular strategy Open repair
Deaths N = 316 N = 297
Within 30 days 0 112 (35.4) 111 (37.4)
Before primary hospital discharge 0 115 (36.4) 114 (38.4)
Before overall hospital discharge 0 115 (36.4) 116 (39.1)
Within 1 year 2 130 (41.1) 133 (45.1)
Cause of death 2
AAA 107 (33.9) 116 (39.3)
Myocardial disease 4 (1.3) 0 (0.0)
Pulmonary disease 6 (1.9) 4 (1.4)
Cancer 4 (1.3) 2 (0.7)
Stroke and other vascular 7 (2.2) 8 (2.7)
Other 2 (0.6) 3 (1.0)
Participants with reinterventionsa N = 259 N = 243
AAA-related reintervention 0 55 (21.2) 49 (20.2)
Non-AAA-related reintervention 0 6 (2.3) 11 (4.5)
Number of reinterventions per persona
0 0 201 (77.6) 187 (77.0)
1 0 42 (16.2) 38 (15.6)
2 0 11 (4.3) 13 (5.4)
≥ 3 0 5 (1.9) 5 (2.1)
a Among 502 participants with ruptured AAA who had aneurysm repair started.
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TABLE 9 Resource use and costs (GBP) up to 1 year, reported across all randomised participants
Component
Resource use Cost (£)
Endovascular
strategy (N= 316)
Open repair
(N= 297)
Endovascular
strategy (N= 316)
Open repair
(N= 297)
Primary admission
Time in emergency room (minutes),
mean (SD)a
93 (370) 73 (157) 135 (138) 118 (50)
Devices and consumables,
mean (SD)
4337 (2913) 2540 (2053)
Time in theatre (minutes),
mean (SD)b
157 (100) 180 (108) 2057 (1299) 2110 (1276)
Days in critical care, mean (SD) 5.1 (10.6) 7.4 (11.1) 6300 (16,289) 9280 (15,003)
Days on routine ward, mean (SD)c 7.3 (12.2) 7.5 (12.5) 1973 (3213) 2044 (3406)
Participants with at least one
reintervention, n (%)d
58 (18) 56 (19)
Number of reinterventions,
mean (SD)
0.26 (0.6) 0.32 (1.0) 545 (1388) 642 (1765)
Transfer to secondary hospital,
n (%)e
10 (3) 36 (12)
Number of days in secondary
hospital, mean (SD)
0.7 (4.5) 4.7 (21.0) 174 (1158) 1208 (5452)
Readmissions
Number of readmissions, n (%) 26 (8) 12 (4)
Number of readmissions, mean (SD) 0.1 (0.5) 0.05 (0.2) 284 (1805) 119 (863)
Total days in hospital, mean (SD) 14.0 (21.6) 20.1 (31.6)
Total hospital cost, mean (SD) 15,804 (19,318) 18,062 (20,296)
Outpatient and community care, mean (SD)
Outpatient visits 3.2 (5.7) 2.9 (8.5) 397 (718) 292 (483)
Days in nursing home 0 (0) 1.8 (22.0) 0 (0) 192 (2309)
Family doctor visits 2.8 (3.9) 2.5 (3.8) 153 (216) 139 (209)
Community nurse visits 2.2 (6.7) 2.1 (7.4) 40 (120) 38 (134)
Outpatient and community care
total costs
590 (902) 661 (1468)
Total cost, mean (SD) 16,394 (19,543) 18,723 (20,599)
Incremental cost (95% CI) –2329 (–5489 to 922)
a Includes costs of CT scan and contrast agent.
b The unit costs of the theatre time were £885 per hour for those who actually received an endovascular procedure and
£675 per hour for those who actually received open repair (for further details, see www.journalslibrary.nihr.ac.uk/
programmes/hta/073764/#/; accessed 16 November 2017).
c Participants who did not undergo aneurysm repair (8.9%) were assumed to stay on a routine ward throughout the
hospitalisation (details of sensitivity analyses are available in Appendix 2, Figure 26).
d Although the proportion of participants with reinterventions was not significantly different between groups, participants
undergoing open repair had, on average, a higher number of reinterventions per participant.
e Includes those discharged to ‘other’ facilities, mainly rehabilitation facilities.
Notes
Results are reported after multiple imputation.
Unit costs are reported in Appendix 2, Table 28.
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group than for the open repair group. The costs of outpatient visits and community care were comparable
between randomised groups. The number of hospital readmissions up to 1 year after randomisation was
higher for the endovascular group than for the open repair group: 26 readmissions (8%) and 12 readmissions
(4%), respectively. Participants across the randomised groups had similar service use after hospital discharge,
including outpatient, general practitioner and nurse visits (see Table 9).
The net effect of the higher intervention cost, but lower critical care and secondary hospital care costs, was
that the mean total cost per participant was lower for the endovascular strategy group (£16,394) than that
for the open repair group (£18,723); the mean cost difference at 1 year was –£2329 (95% CI –£5489
to £922).
Health-related quality of life
At 3 months after randomisation, a higher proportion of participants in the endovascular strategy group
than in the open repair group reported ‘no problems’ on the physical health dimensions (mobility, self-care
and pain) of the EQ-5D-3L questionnaire (see Appendix 2, Table 32). For example, 74 participants (54%)
in the endovascular group reported ‘no problems’ in mobility compared with 51 participants (45%) in the
open repair group. At 12 months after randomisation, the distribution of the health status profiles was
more similar between randomised groups, but a higher proportion of the open repair participants reported
‘severe problems’ with self-care, usual activities and pain. For example, seven participants (7%) randomised
to the open repair group reported extreme pain at 12 months, compared with only one participant (1%) in
the endovascular group (see Appendix 2, Table 32).
The mean EQ-5D-3L utility scores were higher in the endovascular strategy group compared with the
open repair group (Table 10); the mean differences in the EQ-5D-3L score (among ruptured AAA survivors)
were 0.087 (95% CI 0.017 to 0.158; p = 0.015) and 0.068 (95% CI –0.004 to 0.140; p = 0.063) at 3 and
12 months post randomisation, respectively. The QoL (using the EQ-5D-3L) reported at 1 year following
emergency repair is very similar to that reported by participants undergoing elective repair.41 This is an
interesting finding given that participants enrolled in the randomised trial of elective EVAR compared with
open repair were, on average, 3 years younger than those in the IMPROVE trial.
TABLE 10 Quality of life, total costs (GBP) and cost-effectiveness outcomes up to 1 year
Outcome measure
Trial group, n (%)
Mean difference (95% CI)
Endovascular strategy Open repair
n Mean (SD) n Mean (SD)
EQ-5D-3La,b at 3 months for ruptured
AAA survivors
168 0.76 (0.24) 150 0.67 (0.32) 0.087 (0.017 to 0.158)
EQ-5D-3La,b at 12 months for
ruptured AAA survivors
161 0.77 (0.20) 140 0.71 (0.35) 0.068 (–0.004 to 0.140)
QALYsb,c for all randomised
participants
316 0.40 (0.35) 297 0.35 (0.35) 0.052 (–0.005 to 0.108)
Total costb (£) 316 16,394 (19,543) 297 18,723 (20,599) –2329 (–5489 to 922)
INMBb,d (£) (95% CI) 3877 (253 to 7408)
a The EQ-5D-3L is a QoL measure anchored on a scale that includes 0 (death) and 1 (perfect health).
b The EQ-5D-3L, QALY, cost and INB results are reported after multiple imputation to address missing values. The
complete case results are shown in Appendix 2, Table 32.
c The QALY estimation for all randomised participants assumes that, for participants without a proven rupture, the QoL
was the same as at baseline for participants included in the EVAR 1 trial41 (see www.journalslibrary.nihr.ac.uk/
programmes/hta/073764#, accessed 16 November 2017, for further details).
d The INB for the endovascular strategy compared with open repair is calculated by multiplying the difference in mean
QALYs by the NICE-recommended threshold of willingness to pay for the UK (£30,000 per QALY)36 and subtracting from
this the incremental cost.
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The relative gains in both QoL and mortality led to a higher mean QALY value at 12 months for participants
in the endovascular strategy (0.36 QALYs) compared with that in the open repair group (0.30 QALYs);
incremental QALY gain was 0.052 (95% CI –0.005 to 0.108; p = 0.072).
Cost-effectiveness
At 12 months post randomisation, the QALY gain coupled with a lower mean total cost led to a positive
INMB (assuming a threshold of £30,000 per QALY gain) for the endovascular strategy compared with the
open repair randomised group: £3877 (95% CI £253 to £7408) (see Table 10). The uncertainty in the
mean cost, mean QALYs and their joint (normal) distribution is represented on the cost-effectiveness plane
(see Appendix 2, Figure 25). The majority of the points are in the quadrant that shows that the endovascular
strategy has a lower mean cost and higher mean QALYs, suggesting that this intervention is likely to be
cost-effective. The probability that the endovascular strategy compared with open repair is cost-effective is
> 0.9, irrespective of how much the decision-maker or society is willing to pay for a QALY gain.
The cost-effectiveness of endovascular repair compared with open repair does not differ by participant
subgroup (Table 11). Female participants appeared to benefit relatively more from the endovascular strategy –
incremental QALY gain was 0.133 (95% CI 0.02 to 0.247) – but they also had higher costs, mostly associated
with longer stays in critical care. The subgroup of participants with worse preoperative Hardman index scores
(of ≥ 2) had similar results. The 95% CIs of the INB included zero for all subgroups, except for men (£37 to
£8012). The results of the sensitivity analysis suggest that the relative cost-effectiveness of the endovascular
strategy compared with open repair is robust to departures from the different base-case assumptions
(see Appendix 2, Figure 26). For example, when we considered a higher cost (£10,000) for the endovascular
stent, the INB remained positive, although the 95% CI included zero. Similarly, restricting the analysis to the
participants with a proven ruptured aneurysm led to a similar 95% CI (£143 to £8467) of the INB compared
with the base case.
Main findings of the IMPROVE trial at 12 months
The IMPROVE trial showed no significant survival benefit at any time point for an endovascular strategy
(using a standard endovascular device whenever anatomically and operationally possible, with open repair
as a default option) compared with open repair during the first 12 months after randomisation, although,
again, women benefited more than men from the endovascular strategy. There was no evidence of a
TABLE 11 Incremental net monetary benefit (95% CI) (GBP) within the first year of randomisation, by subgroup,
at the recommended willingness-to-pay threshold stipulated by NICE (£30,000 per QALY)36
Subgroup
Incremental
INB (95% CI)a, £ p-valueCost (95% CI), £ QALYs (95% CI), £
Age (years)
≤ 77 –2032 (–6579 to 2514) 0.025 (–0.050 to 0.101) 2797 (–2252 to 7846) 0.719
> 77 –2560 (–7005 to 1885) 0.064 (–0.012 to 0.140) 4483 (–501 to 9467)
Sex
Male –3264 (–6831 to 302) 0.025 (–0.035 to 0.086) 4025 (37 to 8012) 0.661
Female 1882 (–4861 to 8626) 0.133 (0.020 to 0.247) 2112 (–5421 to 9646)
Hardman index score
0 –2513 (–8383 to 3357) 0.034 (–0.064 to 0.131) 3525 (–3064 to 10,114) 0.631
1 –2561 (–7277 to 2155) 0.020 (–0.061 to 0.101) 3161 (–2115 to 8437)
≥ 2 –863 (–7350 to 5623) 0.114 (0.004 to 0.224) 4290 (–2898 to 11,478)
a Results are following multiple imputation. Estimates were obtained from a regression model that included a randomised-
group-by-subgroup interaction term. p-values were reported for this interaction coefficient.
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difference in the number or rate of reinterventions (including those for endoleaks) at any time during the
first year, with no significant interaction on the basis of age, sex or preoperative Hardman index. In
contrast, there were gains for the endovascular strategy group compared with the open repair group
with respect to patient-preferred outcomes of faster discharge, more home discharges and better HRQoL
(using EQ-5D-3L) and, overall, the endovascular strategy was cost-effective. The cost-effectiveness results
were robust to alternative departures from base-case assumptions, including prices for stent grafts,
specification of the regression model and AAA type (ruptured, incidental or symptomatic).
Interpretation
There are some potential reasons for why there was no difference in survival between the randomised
groups. First, shock with systemic organ damage might lead to very high early mortality after ruptured
AAA repair, irrespective of the type of repair. Second, the operative mortality from open repair was lower
than was anticipated. Third, we now know that aortic anatomy, particularly aneurysm neck length, has an
important influence on mortality. In particular, the group of patients who are not candidates for standard
endovascular repair (≈40%) has the highest operative mortality, especially for open repair, and the group
of patients who are anatomically suitable for the endovascular procedure has a much lower mortality after
either EVAR or open repair.83 Fourth, the trial was designed to be inclusive and consider whether or not
the availability of an endovascular service would improve the outcome of all patients with a rupture,
not just those anatomically suitable for EVAR. So, inevitably, the endovascular strategy group included a
significant proportion of participants who had to be treated with open repair. Moreover, if the overall
benefit of an endovascular strategy confers only a relative 15% lower mortality at 1 year, we would have
needed to randomise almost 5000 participants to show a significant difference in 1-year mortality.
Among survivors, however, the findings suggesting faster recovery in the endovascular group are notable.
These were (1) a shorter average hospital stay, (2) a greater probability of being discharged to home
and (3) better HRQoL than the open repair group. The between-group mean differences in QoL, 0.087
(3 months) and 0.068 (1 year), exceed the minimum clinically important difference of 0.03,84 although the
mean difference was no longer statistically significant 1 year after randomisation. The average EQ-5D-3L
utility scores of the endovascular strategy group at 3 and 12 months (0.76 and 0.78, respectively) were
slightly higher than the scores for those undergoing elective EVAR in the EVAR 1 trial41 (0.71 and 0.74,
respectively), whereas the EQ-5D-3L scores of the open repair group at 3 and 12 months (0.69 and 0.74,
respectively) were similar to the scores for those undergoing elective open repair (0.67 and 0.75, respectively).
In addition, the risk of reintervention for endoleak up to 1 year post operation in the endovascular group
(8%) was not significantly different to that in the open repair group, and seems generally lower than the
10–23% range suggested in previous reports.85,86
Participants were discharged home earlier and returned to ‘normal’ HRQoL quicker in the endovascular
strategy group than in the open repair group, which translated into lower health-care costs. Together with
the gains in survival and QoL, the endovascular strategy is likely to be good value for money in the UK
NHS. Given the relative robustness of the results to the different analytical assumptions, this intervention
is also likely to be cost-effective in other health-care settings.
Comparison with other studies
At the time of writing, the Dutch AJAX80 and French ECAR22 trials have published outcomes at 6 months
and 12 months, respectively. The individual participant data meta-analysis of these trials and the IMPROVE
trial indicated that there was no significant survival benefit for the endovascular strategy compared with
open repair, although there was some heterogeneity between studies/countries.82 The ECAR trial did not
report HRQoL or cost-effectiveness but AJAX found (1) no between-group differences in 6-month QoL and
(2) that endovascular repair was not cost-effective.80 These findings contrast with those from the IMPROVE
trial, probably because the IMPROVE trial included a wider range of patients (more representative of total
ruptured AAA caseload). In addition, AJAX used aorto-uni-iliac devices (with subsequent femoro-femoral
crossover grafting) for endovascular repair (resulting in a more expensive procedure) and applied unit costs
from a single centre.
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Limitations
First, this was a pragmatic trial and, among those participants with a ruptured AAA, the endovascular
procedure was started in only 58% of those who were randomised to the endovascular strategy (with
26 endovascular-suitable participants receiving open repair for operational reasons) and 33 participants in
the open repair group receiving endovascular repair (primarily because they were deemed unfit for general
anaesthesia). Second, data completion was very good, including questionnaire responses, but ≈40% of
randomised participants had missing QoL or resource use data (at either 3 or 12 months post randomisation).
Missing data were addressed with multiple imputation, which assumes that any systematic differences in
outcomes can be explained by the variables included in the imputation model. Third, there was no adjustment
for testing of multiple hypotheses (except for subgroup analyses) but all reported outcomes were prespecified.
Fourth, reinterventions and costs following EVAR for rupture may increase after 1 year and all participants
were followed up for 3 years to address this (see Chapter 6).
Summary
We have presented clinical effectiveness and cost-effectiveness evidence from a large randomised trial,
conducted in the challenging setting of emergency patients requiring an immediate operation to avoid
death. It was based on the randomisation of unselected patients, including appropriate representation of
women, to optimise the generalisability of the findings, and all centres were accredited for providing EVAR
in routine and emergency practice. In the IMPROVE trial, and in meta-analysis with the other two European
trials, there is no evidence that an endovascular strategy or endovascular repair offers a survival benefit at
1 year. Although, in the IMPROVE trial, the endovascular strategy offers no overall survival benefit for
participants with ruptured AAAs compared with open repair at 1 year after randomisation, this chapter
outlines the evidence that suggests that a wider provision of emergency endovascular services is likely to
be a cost-effective use of health-care resources.
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Chapter 6 Three-year outcomes, survival,
reinterventions and health economics
Overview
There are very few studies that have followed up patients with a ruptured AAA in the medium or longer
term (> 12 months after rupture) and these, including one from the Vascular Study Group of New
England79 and one from the Amsterdam cohort with ruptured aneurysms,87 are non-randomised and
mainly retrospective. Such studies are subject to confounding by baseline aortic morphology83 and
other factors.
After full recruitment and analysis of 30-day results, longer-term projections of the mortality data from the
IMPROVE trial suggested that ≈50% of the randomised participants remained alive at 3 years. Therefore,
it was considered to be very important to incorporate accurate estimates of longer-term survival, QoL,
reinterventions, cost and, hence, cost-effectiveness for future policy recommendations and, thus, the trial
was extended to include 3 years of follow-up for all participants. Even at 1 year, the endovascular strategy
was cost-effective, driven by better QoL scores than in the open repair group. Health-care costs were
non-significantly lower in the endovascular strategy group than in the open repair group and there was
no significant mortality difference between the groups.83
In randomised trials of the repair of intact aneurysms, the early survival benefit of endovascular repair
compared with open repair is eroded within the first 2 or 3 years after aneurysm repair and, in the longer
term, the rate of reinterventions after endovascular repair is double the rate after open repair.79,88,89 Would
similar trends following the repair of ruptured aneurysms erode the benefits of the more rapid recovery
and early QoL gains after endovascular repair, and hence cost-effectiveness, in the medium or longer
term? Data from the Vascular Study Group of New England suggested that, after 3–5 years, survival was
similar for those participants who had endovascular repair and those who had open repair (although many
participants had been lost to follow-up) and that patient comorbidities and shock on admission were the
main determinants of longer-term survival.79 The Amsterdam cohort study (the total population of ruptures
admitted to Amsterdam hospitals from which AJAX participants were selected) was dominated by open
repair participants but showed that any early survival benefit of endovascular repair had been eroded by
2 years; thereafter, survival was similar in participants treated by open repair or endovascular repair, with
≈50% of participants remaining alive at 3 years.90 This Amsterdam cohort study also showed that, after
2 years, reinterventions were slightly, but not significantly, more common after endovascular repair than
open repair but, for those discharged alive, reinterventions were twice as common after endovascular repair.
In this chapter, we report the follow-up of all participants from the IMPROVE trial for mortality for ≥ 3 years,
to the end of July 2016, and the complete follow-up of the subgroup of greatest clinical interest, the
502 participants in whom repair of a ruptured aneurysm was commenced (for mortality, aneurysm-related
reinterventions and QoL), to the 3-year time point, analysed by the group to which these participants were
randomised. This, in turn, enables 3-year cost-effectiveness evaluations. The analysis plan prespecified
the reporting for both the entire cohort of 613 participants and the principal sensitivity analysis for the
502 participants in whom repair of a ruptured aneurysm had started. The analysis plan paralleled that of the
1-year outcomes reported in Chapter 5, except for the classification of the severity of the reinterventions,
an assessment of how baseline aortic morphology influenced reinterventions, the inclusion of two additional
subgroups for analyses (by aneurysm neck length and lowest systolic blood pressure on admission) and the
specification of mortality and reinterventions by time: acute (0–90 days), mid-term (3 months to 3 years) and
beyond 3 years. To enable comprehensive reporting of all aneurysm-related reinterventions, including those
at non-trial hospitals, the participants who were randomised in Scotland were audited carefully, including
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the correspondence section of the notes and participant contact, as relevant. All reinterventions that took
place in England were cross-validated by data from HES, which also provided details of aneurysm-related
admissions and reinterventions at non-trial hospitals. However, because these data were available only
for readmissions or reinterventions within 3 years of primary admission discharge, full reporting of
aneurysm-related reinterventions beyond 3 years of follow-up was not possible. The cost-effectiveness
analysis was therefore limited to the reporting of 3-year, rather than lifetime, outcomes, using the same
methods as described in detail in Chapters 2 and 5.
Results
Study population and treatments
The CONSORT diagram (see Figure 8) shows the follow-up of participants to 3 years after randomisation.
In the endovascular strategy group, 310 participants had an aortoiliac aneurysm, 27 had an asymptomatic
AAA and another acute diagnosis, 14 had an acute symptomatic aneurysm, 275 had an AAA rupture and
six did not have an aortic aneurysm. In the open repair group, 294 participants had an aortoiliac aneurysm,
19 had an asymptomatic AAA and another acute diagnosis, eight had an acute symptomatic aneurysm,
261 had an AAA rupture and three did not have an aortic aneurysm. In total, in 536 participants (259 in
the endovascular strategy group and and 243 in the open repair groups) blood was found to breach the
aneurysm sac (rupture): 34 participants died before repair and repair was started in 502 participants
(the critical subgroup for this analysis). In the endovascular strategy group, 300 out of 316 participants
underwent CT, of whom 186 (62%) were considered anatomically suitable for EVAR; EVAR was commenced
in 154 participants, and a further 26 participants underwent open repair against protocol (mainly because
a staffed endovascular suite was not immediately available). In the open repair group, 33 participants
underwent EVAR (mainly because they were poor candidates for general anaesthesia). Between 30 days and
3 years, two participants in each randomised group emigrated and were lost to follow-up. At randomisation,
the mean age was 77 years, 22% of the participants were women and the mean AAA diameter was 8.3 cm
(baseline characteristics by randomised group are given in Table 1).
Mortality in all 613 participants
Overall follow-up for mortality was 4.9 years (median 4.7 years; range 0.1–7.1 years), with a mean of 2.5
person-years of observation (to death or censoring). There were 179 deaths (22.0 per 100 person-years)
in the endovascular strategy group and 183 deaths (25.2 per 100 person-years) in the open repair group
(Table 12) (HR 0.92, 95% CI 0.75 to 1.13; p = 0.41), with similar findings for aneurysm-related mortality
(HR 0.89, 95% CI 0.69 to 1.16; p = 0.41) and after adjustment (see Appendix 2, Figure 27 and Table 33a
and b). Kaplan–Meier survival curves (Figure 9) show a slight divergence after the acute phase (0–90 days),
with lower mortality in the endovascular strategy group between 3 months and 3 years (HR 0.57, 95% CI
0.36 to 0.90), before the curves converge again by 6 years. At 3 years, mortality was 48% and 56%
in the endovascular strategy group and open repair group, respectively (OR 0.73, 95% CI 0.53 to 1.00;
p = 0.053). The increased number of deaths in the open repair group between 3 months and 3 years was
not aneurysm-related (see Table 12; this table also gives more detailed causes of death). Subgroup analysis
suggested that the endovascular strategy might be more effective in reducing mortality in women than in
men, but there were no differences associated with age or Hardman index (see Appendix 2, Figure 28).
By 3 years, 48% and 56% of participants had died and the mean numbers of life-years were 1.72 and
1.61 in the endovascular strategy group and open repair group, respectively (p = 0.32).
Principal subgroup analysis: mortality in 502 participants with a confirmed rupture and
repair started
The baseline characteristics of these participants are shown in Table 13. Kaplan–Meier curves for the 502
participants with a confirmed rupture and in whom repair had started follow a similar pattern to those for
the full trial cohort (see Figure 9b) (overall HR 0.86, 95% CI 0.68 to 1.08; p = 0.19). By 3 years, 109 out of
259 participants in the endovascular strategy group (42%) and 131 out of 243 participants in the open
repair group (54%) had died. The OR for 3-year mortality was 0.62 (95% CI 0.43 to 0.89; p = 0.009).
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Because ≈12% of these 502 participants (26 in the endovascular strategy group and 33 in the open repair
group) had not complied with their randomised treatment, a causal analysis was conducted for treatment
compliers only; the OR for 3-year mortality was slightly lower (OR 0.54, 95% CI 0.34 to 0.85; p = 0.008).
Over the entire period of follow-up that compared the groups as randomised, the unadjusted HR for
aneurysm-related mortality was 0.89 (95% CI 0.67 to 1.18; p = 0.41) and the adjusted HR was similar,
at 0.92 (95% CI 0.69 to 1.23). A post hoc analysis showed that the effect of sex was stronger in this
subgroup of 502 participants, particularly for aneurysm-related deaths (HR in women 0.44, 95% CI 0.24 to
0.81, and HR in men 1.09, 95% CI 0.79 to 1.52; interaction p = 0.010).
Reinterventions in 502 participants with confirmed rupture and repair started
There were 230 aneurysm-related reinterventions recorded within 3 years of randomisation: 121 in the
group assigned to an endovascular strategy and 109 in the group assigned to open repair (rate of
TABLE 12 Causes of death, by randomised group and time period, in 613 participants
Time period Cause of death
Trial group, n (%)
HR (95% CI) p-valueEndovascular strategy Open repair
All follow-up AAA-related 112 (63) 120 (66)
Cardiovascular 26 (14) 23 (13)
Pulmonary 13 (7) 15 (8)
Cancer 19 (11) 13 (7)
Other 9 (5) 12 (7)
Total 179 183 0.92 (0.75 to 1.13) 0.41
Baseline to 3 months AAA-related 104 (87) 112 (95)
Cardiovascular 8 (7) 3 (3)
Pulmonary 5 (4) 0 (0)
Cancer 1 (1) 0 (0)
Other 2 (2) 3 (3)
Total 120 118 0.98 (0.76 to 1.26) 0.88
3 months to 3 years AAA-relateda 5 (16) 5 (11)
Cardiovascular 12 (38) 16 (34)
Pulmonary 5 (16) 10 (21)
Cancer 7 (23) 10 (21)
Other 2 (6) 6 (13)
Total 31 47 0.57 (0.36 to 0.90) 0.015
> 3 years AAA-related 3 (11) 3 (17)
Cardiovascular 6 (21) 4 (23)
Pulmonary 3 (11) 5 (28)
Cancer 11 (39) 3 (17)
Other 5 (18) 3 (17)
Total 28 18 1.44 (0.80 to 2.62) 0.23
a Including two deaths from later elective repair of the asymptomatic AAA identified at primary admission, one in each
randomised group.
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reintervention HR 1.02, 95% CI 0.79 to 1.32; p = 0.88). (In the entire cohort of 613 participants, there were
two further aneurysm-related reinterventions, after repair of symptomatic, non-ruptured aneurysms, before
3 years.) The reinterventions, categorised by severity (details at www.journalslibrary.nihr.ac.uk/programmes/
hta/073764/#/; accessed 16 November 2017) and whether they were arterial, laparotomy related or
other, are shown in Table 14. Overall, and by time period (acute 0–90 days or 3 months to 3 years),
the reintervention rates in the 502 participants in whom repair of a ruptured aneurysm had started were
not significantly different between the randomised groups, with ≈28% of each group needing at least one
reintervention. The cumulative incidence of participants with at least one intervention to 3 years is shown
in Figure 10a and the cumulative incidence of participants with at least one arterial or laparotomy-related
reintervention (4* and 5*; see www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/, accessed
16 November 2017, for categorisation) for a life-threatening condition is shown in Figure 10b.
0
20
40
60
80
100
Pe
rc
en
ta
g
e 
su
rv
iv
in
g
316
297
186
163
176
150
163
130
116
97
53
63
22
25
Number at risk
Endovascular strategy
Open repair
0 1 2 3 4 5 6
Years since randomisation
Trial arm
Endovascular strategy
Open repair
(a)
0
20
40
60
80
100
Pe
rc
en
ta
g
e 
su
rv
iv
in
g
259
243
161
139
154
127
148
110
108
84
50
56
21
23
Number at risk
Endovascular strategy
Open repair
0 1 2 3 4 5 6
Years since randomisation
Endovascular strategy
Open repair
(b)
Trial arm
FIGURE 9 Kaplan–Meier estimates for overall survival, by randomised group. For (a) all 613 participants who were
randomised (log-rank test p= 0.40); and (b) the 502 participants with a confirmed rupture for whom repair had
started (log-rank test p= 0.186).
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New reinterventions for life-threatening conditions continued to occur at a much slower, but steady, rate
between 3 months and 3 years in both of the randomised groups (see Appendix 2, Table 34). The HRs
for risk of reintervention, both overall and by time, remained similar after adjustment (see Appendix 2,
Table 35).
The aneurysm-related reinterventions were also assessed by indication for treatment received in the 502
ruptures in which repair was started (see Appendix 2, Table 36), both by intention to treat and by treatment
received, although this latter comparison is subject to bias. It shows that the burden of reinterventions in the
first 90 days is much higher after open repair (see Appendix 2, Table 36a). Nine of these reinterventions were
carried out at readmission in the endovascular strategy group, compared with only one at a readmission in
the open repair group. Between 3 months and 3 years, there were more reinterventions after EVAR (12.5 per
100 person-years and affecting 21% of participants) than after open repair (5.0 per 100 person-years
affecting 9% of participants; p < 0.001), but the majority of reinterventions after EVAR were minor arterial
reinterventions (see Appendix 2, Table 36b).
TABLE 13 Baseline characteristics of the 502 participants in whom repair of a ruptured aneurysm had started,
by randomised group
Variable
Missing
data, (n)
Trial group, n (%)
Endovascular strategy (N= 316) Open repair (N= 297)
Age (years), mean (SD) 0 76.0 (7.4) 76.2 (7.6)
Sex, n (%) 0
Male 209 (81) 195 (80)
Female 50 (19) 48 (20)
Admission blood pressure (mmHg), n (%) 9
Systolic 108.7 (33.1) 109.0 (31.1)
Diastolic 65.1 (22.0) 65.3 (22.7)
Admission haemoglobin (g/dl), mean (SD) 4 11.2 (2.5) 11.0 (2.3)
Admission creatinine (µmol/l), median (IQR) 11 122 (95–154) 116 (95–151)
Hardman index (0–5), n (%) 57
0 83 (36) 60 (28)
1 103 (44) 97 (46)
2 36 (15) 43 (20)
3 9 (4) 10 (5)
4 2 (1) 2 (1)
5 0 (0) 0 (0)
CT carried out, n (%) 0
Yes 251 (97) 216 (89)
No 8 (3) 27 (11)
Core-laboratory-measured maximum aortic
diameter (cm), mean (SD)
68 8.7 (1.7) 8.4 (1.8)
Neck length (mm), mean (SD) 93 24 (17) 23 (16)
Time to AAA repair, randomisation to
theatre admission (minutes), median (IQR)
5 47 (28–73) 37 (22–62)
IQR, interquartile range.
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TABLE 14 Reinterventions in the 502 participants in whom repair of a ruptured aneurysm had started
AAA-related reintervention
Participants with ruptured AAA in whom
repair started (N= 502)
Endovascular strategy Open repair
Overall
Participants with at least one reintervention, n/N (%) 75/259 (29) 65/243 (27)
Reinterventions/person-years (rate per 100 person-years), (%) 121/463.8 (26.0) 109/387.3 (28.1)
Arterial, n (%) 93 (77) 62 (57)
Laparotomy, n (%) 16 (13) 34 (31)
Other, n (%) 12 (10) 13 (12)
Severity of arterial reintervention, n (%)
1* 0 (0) 1 (2)
2** 24 (26) 10 (16)
3*** 32 (34) 11 (17)
4**** 9 (10) 5 (8)
5***** 28 (30) 35 (56)
Severity of laparotomy reintervention, n (%)
Major 5 (31) 4 (12)
Minor 11 (69) 30 (88)
0–90 days
Participants with at least one reintervention, n/N (%) 57/259 (22) 51/243 (21)
Reinterventions/person-years (rate per 100 person-years), (%) 81/43.6 (185.6) 88/38.9 (226.1)
Arterial, n (%) 60 (74) 49 (56)
Laparotomy, n (%) 11 (14) 27 (31)
Other, n (%) 10 (12) 12 (14)
Severity of arterial reintervention, n (%)
1* 0 (0) 1 (2)
2** 13 (22) 6 (12)
3*** 21 (35) 9 (18)
4**** 5 (8) 3 (6)
5***** 21 (35) 30 (61)
Severity of laparotomy reintervention, n (%)
Major 2 (18) 3 (11)
Minor 9 (82) 24 (89)
3 months to 3 years
Participants with at least one reintervention, n/N (%) 27/167 (16) 15/146 (10)
Reinterventions/person-years (rate per 100 person-years), (%) 40/420.1 (9.5) 21/348.3 (6.0)
Arterial, n (%) 33 (83) 13 (62)
Laparotomy, n (%) 5 (13) 7 (33)
Other, n (%) 2 (5) 1 (5)
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TABLE 14 Reinterventions in the 502 participants in whom repair of a ruptured aneurysm had started (continued )
AAA-related reintervention
Participants with ruptured AAA in whom
repair started (N= 502)
Endovascular strategy Open repair
Severity of arterial reintervention, n (%)
1* 0 (0) 0 (0)
2** 11 (33) 4 (31)
3*** 11 (33) 2 (15)
4**** 4 (12) 2 (15)
5***** 7 (21) 5 (38)
Severity of laparotomy reintervention, n (%)
Major 3 (60) 1 (14)
Minor 2 (40) 6 (86)
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FIGURE 10 Time to first reintervention for the 502 participants in whom repair of a ruptured aneurysm had started.
(a) All reinterventions and (b) reinterventions for life-threatening conditions (arterial or laparotomy related).
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Narrative descriptions of some adverse outcomes requiring reintervention
A small group of patients and members of the public considered amputation to be the most adverse
reintervention, whereas clinicians did not (see www.journalslibrary.nihr.ac.uk/programmes/hta/073764/#/;
accessed 16 November 2017). There were eight amputations within the first 3 years, five in the endovascular
strategy group and three in the open repair group, but seven of these occurred following open repair.
Other reinterventions that were considered to be very serious by the patients and members of the public
included those for graft infection or secondary rupture, complete repetition of the primary operation and a
permanent stoma. Such reinterventions (n = 19) took place in eight participants in the endovascular strategy
group and in 11 participants in the open repair group.
Overall, six cases of graft infection were reported. It is worth noting that, following EVAR, the only cases
of graft infection were after implantation of aorto-uni-iliac endografts, with the infection being in the
femoro-femoral crossover graft (two cases of graft infection in 36 aorto-uni-iliac grafts). It is also worth
reporting that type I endoleak after EVAR was reported in 12 out of 186 participants (seven type Ia and
five type Ib endoleaks), and 11 of these cases were detected > 6 months following repair. In due course,
beyond 3 years, three cases of secondary rupture were reported; two cases following a type 1b endoleak
and one case following a type 1a endoleak. Only one secondary rupture was reported after open repair.
Effect of baseline aortic morphology on reinterventions
We also investigated whether or not baseline aortic morphology was associated with the rate of
reinterventions (either arterial only or all aneurysm-related). These analyses included only participants with a
CT scan measured in the core laboratory and excluded those with common iliac aneurysm (CIA) ruptures.
The analyses were by treatment received and not by randomised group. The results (see Appendix 2, Table 37)
show that both arterial aneurysm-related and all-aneurysm-related reinterventions tended to increase with an
increasing CIA diameter, particularly following EVAR. Following EVAR, for all reinterventions the HR per 9-mm
increase is 1.32 (95% CI 1.01 to 1.72) and for arterial reinterventions the HR is 1.48 (95% CI 1.13 to 1.93).
For open repair, the strongest association was with increasing aneurysm neck diameter. However, given the
multiple comparisons that were conducted, these results should be considered as hypothesis-generating only.
Quality of life, resource use and cost-effectiveness for all 613 participants to 3 years
The response rate for the QoL questionnaires (EQ-5D-3L) at 3 years was very high (> 85%) (see Figure 8).
Although the endovascular strategy group had better QoL in the first year after randomisation, by 3 years
the QoL was similar between the randomised groups (Figure 11) and similar to that of an age- and
sex-matched population. QoL, QALYs and resource use, all following multiple imputations, are shown in
Table 15. Complete case analyses are given in Appendix 2, Table 38. The mean QALY gain at 3 years for
the endovascular strategy group was 0.166 (95% CI 0.002 to 0.311 QALYs), appearing to be slightly
higher for women and those with the highest baseline Hardman index scores but otherwise similar across
subgroups (Table 16).
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FIGURE 11 Quality of life (EQ-5D-3L) gained up to 3 years (shaded area) for 613 participants by randomised group.
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TABLE 15 Quality-of-life (EQ-5D-3L) utility scores, life-years and QALYs up to 3 years. Results are reported after
multiple imputation for the 613 participants who were randomised
EQ-5D-3La for ruptured
AAA survivors
Trial group, n (%)
Mean difference
(95% CI) p-value
Endovascular strategy Open repair
nb Mean (SD) nb Mean (SD)
3 months 168 0.76 (0.23) 150 0.66 (0.31) 0.097 (0.031 to 0.163) 0.004
12 months 161 0.78 (0.19) 140 0.71 (0.33) 0.068 (0.002 to 0.134) 0.045
36 months 150 0.74 (0.25) 112 0.73 (0.31) 0.013 (–0.069 to 0.096) 0.751
Life-years for all
randomised participants
316 1.72 (1.43) 297 1.61 (1.41) 0.115 (–0.110 to 0.341) 0.315
QALYs (3-year) for all
randomised participantsc
316 1.22 (1.11) 297 1.05 (1.10) 0.174 (–0.005 to 0.353) 0.057
a The EQ-5D-3L is a QoL measure anchored on a scale that includes 0 (death) and 1 (perfect health).
b For EQ-5D-3L scores, n corresponds to the total number of participants eligible for follow-up. The 3-month EQ-5D-3L
data are missing for 30 endovascular strategy participants (18%) and 38 open repair participants (27%); 36-month
EQ-5D-3L data are missing for 33 endovascular strategy participants (22%) and 21 open repair participants (19%).
c This includes deceased participants and those without proven rupture, who were assumed to have, on average, the
same QoL as elective participants.
TABLE 16 Incremental net benefit (95% CI) (GBP) within 3 years of randomisation, by subgroup, at the
recommended willingness-to-pay threshold stipulated by NICE (£30,000 per QALY)36
Subgroup
Incremental
INB (95% CI)a p-valueCost (95% CI) QALYs (95% CI)
Sex
Male (n = 480) –4066 (–7573 to –557) 0.092 (–0.099 to 0.283) 6824 (204 to 13,444) 0.440
Female (n= 133) 2817 (–3806 to 9439) 0.358 (0.038 to 0.712) 7914 (–4401 to 20,229)
Hardman index score
0 (n= 164) –4017 (–9758 to 1725) 0.016 (–0.141 to 0.465) 8878 (–1686 to 19,442) 0.279
1 (n= 254) –2448 (–7022 to 2126) 0.005 (–0.244 to 0.254) 2594 (–5943 to 11,131)
≥ 2 (n= 121) –923 (–7306 to 5461) 0.423 (0.092 to 0.755) 13,622 (2025 to 25,219)
Neck length (mm)
< 22 (n= 234) –769 (–5595 to 4057) 0.216 (–0.027 to 0.459) 7243 (–1216 to 15,702) 0.461
≥ 22 (n= 247) –4250 (–8859 to 358) 0.111 (–0.131 to 0.352) 7568 (–959 to 16,095)
Lowest systolic blood pressure (mmHg)
< 90 (n= 263) –3881 (–8604 to 842) 0.067 (–0.185 to 0.319) 5881 (–2949 to 14,711) 0.275
≥ 90 (n= 305) –1540 (–5879 to 2798) 0.213 (–0.013 to 0.439) 7932 (–14 to 15,878)
a Results are following multiple imputation. Estimates were obtained from a regression model (adjusted for age, sex,
Hardman index, neck length and lowest systolic blood pressure) that included a randomised-group-by-subgroup
interaction term. p-values were reported for this interaction coefficient.
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Table 17 summarises the resource use and costs up to 3 years after randomisation, related to primary
admission and aneurysm-related readmissions, including those for reinterventions. This information is
provided for the time periods of 0–1 years and 1–3 years. Between 1 and 3 years, participants were not
asked to complete health resource usage questionnaires, in part because of problems with recall over this
TABLE 17 Resource use and costs (GBP) up to 3 years, reported across all participants randomised. Results are
reported after multiple imputation
Resource and time period
Resource use Cost (£)
Endovascular
strategy (N= 316)
Open repair
(N= 297)
Endovascular
strategy (N= 316)
Open repair
(N= 297)
Between randomisation and 1 year
Primary admission
Days in critical care, mean (SD) 5.3 (12.0) 7.4 (11.9) 6672 (16,430) 9674 (16,446)
Days on routine ward, mean (SD) 7.0 (11.9) 7.8 (12.0) 1835 (3107) 2031 (3158)
Other resource use,a mean (SD) 6563 (3779) 4757 (2896)
Transfer to secondary hospital,
n (%)
10 (3) 36 (12)
Number of inpatient days,
mean (SD)
0.7 (4.5) 4.8 (21.1) 175 (1159) 1245 (5479)
Total days in primary admission,
mean (SD)
13.0 (20.5) 20.0 (31.9) 15,245 (18,356) 17,707 (20,842)
Readmissions
One or more readmission, n (%) 27 (9) 11 (4)
Number of inpatient days, mean (SD) 0.7 (4.6) 0.2 (1.5) 215 (1469) 57 (433)
Reinterventions
One or more reintervention, n (%) 65 (23) 60 (22) 520 (1323) 655 (1711)
Outpatient and community care,b
mean (SD)
525 (739) 829 (5772)
Total days in hospital up to 1 year,
mean (SD)
13.7 (21.3) 20.2 (31.9) 16,505 (19,084) 19,248 (22,365)
Between 1 and 3 years
Readmissions
One or more readmission, n (%) 24 (8) 12 (4)
Number of inpatient days, mean (SD) 0.7 (4.4) 0.3 (2.3) 270 (1667) 137 (981)
Reinterventions
One or more reintervention, n (%) 20 (6) 11 (4) 107 (626) 98 (690)
Total days in hospital up to 3 years,
mean (SD)
14.4 (23.4) 20.5 (32.1) 16,878 (19,624) 19,483 (22,412)
Incremental cost (95% CI) –2605 (–5966 to 702)
INMBc (95% CI) 7637 (1820 to 13,454)
a Includes costs related to the emergency room, CT scan, devices, consumables and theatre.
b Includes costs related to outpatient, general practitioner and district nurse visits.
c The INB for endovascular repair compared with open repair is calculated by multiplying the mean difference in QALYs
using the NICE-recommended willingness-to-pay threshold (£30,000 per QALY gain)36 and subtracting from this the
incremental cost.
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follow-up period. Therefore, the cost of any outpatient care and community care during this period is not
included. Between 1 and 3 years, the proportion of participants being readmitted for aneurysm-related
reasons was higher in the endovascular strategy group, but the proportion who received aneurysm-related
reinterventions was similar in each group. Hospital stay was, on average, a few days shorter in the
endovascular group than in the open repair group [mean total number of days in hospital 14.4 days
(SD 23.4 days) compared with 20.5 days (SD 32.1 days), with a total incremental cost difference of
–£2607 (95% CI –£5949 to £735)].
When the incremental costs and QALYs are represented on the cost-effectiveness plane, most of the
estimates (88%) are in the quadrant that designates the endovascular strategy as ‘dominant’, with lower
mean costs and higher mean QALYs (Figure 12a). The INMB of the endovascular strategy compared with
open repair is positive, at £7367 (95% CI £1829 to £13,454), remains similar across subgroups (see
Appendix 2, Table 39) and is robust to a range of assumptions (see Appendix 2, Figure 29). The probability
that the endovascular strategy was more cost-effective was > 0.90 at all realistic thresholds of willingness
to pay for a QALY gain (Figure 12b). Similarly, there was no significant evidence that the INMBs differed by
participant subgroups.
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FIGURE 12 (a) Uncertainty in the mean cost (GBP) and QALY differences and their joint distribution for the
endovascular strategy compared with open repair for 613 participants; and (b) cost-effectiveness acceptability
curve at 3 years, reporting the probability that the endovascular strategy is cost-effective at a range of alternative
thresholds of willingness to pay for a QALY gain.
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Discussion
This is the only randomised comparison of treatments for ruptured AAA with comprehensive mid-term
(3-year) reporting. The IMPROVE trial was designed to test the hypothesis that an endovascular strategy
(the availability of endovascular repair for those deemed morphologically suitable for EVAR) would offer a
30-day survival advantage compared with open repair for participants presenting with a clinical diagnosis
of ruptured AAA. The early 30-day results did not support this hypothesis,21 despite showing amore rapid
patient recovery in the endovascular strategy group and later, at 1 year, evidence of better QoL and
cost-effectiveness in this group.23 However, at 3 years, the time point at which half of the participants
remained alive, all of the evidence points in the same direction. There is far more convincing evidence for
the benefits of being in the endovascular strategy group: interim survival is better and both QALYs gained
and the INMB (cost-effectiveness) are much higher than the values at 12 months, without a significantly
higher burden of aneurysm-related reinterventions, especially serious reinterventions.
Although all 613 randomised participants were followed up for mortality, more comprehensive follow-up
(QoL, aneurysm-related hospital readmissions and aneurysm-related reinterventions) was limited to the
subgroup of 502 participants in whom repair of a confirmed rupture was started and postoperative
consent was obtained. The baseline characteristics of these 502 participants, including aortic morphology,
were very similar between those assigned to the endovascular strategy group and those assigned to the
open repair group. Although 34 out of 536 participants with a proven AAA rupture (blood outside the
aneurysm sac) died before AAA repair was started, the number of participants who died was similar in
each group (see the CONSORT diagram in Figure 8). Therefore, there should be little bias when comparing
the outcomes between the groups as randomised for the principal sensitivity analysis with 502 participants.
If anything, the longer time taken to start the repair in the endovascular strategy group would act as a bias
against those assigned to an endovascular strategy (see Tables 1 and 13).
Over the entire period of follow-up to 7 years, there was no difference in survival between the two
randomised groups, although the separation between the Kaplan–Meier curves was maximal at 3 years
and of borderline significance in favour of the endovascular strategy group. At 3 years, the relative
advantage of the endovascular strategy for women compared with men, first observed at 30 days
(due mainly to the high perioperative mortality following open repair in women), had been attenuated,
although the QALY gain at 3 years was higher in women than in men.
For the principal sensitivity analysis of 502 participants in whom repair of a confirmed rupture was started,
the survival benefit of the endovascular strategy between 3 months and 3 years, and at 3 years, was more
marked. This was supported by a causal analysis that suggested that mortality for treatment compliers
randomised to an endovascular strategy was half of the mortality of treatment compliers in the open
repair group. However, by 6 years of follow-up, the survival curves had, again, reconverged, although the
number of data at this time point was limited.
In the 502 participants for whom repair of a ruptured AAA had started, overall aneurysm-related
reinterventions were more severe and more often laparotomy related, rather than arterial, in the open
repair group and hence were more likely to be conducted under general, rather than local, anaesthesia,
and such factors might have contributed to the interim survival benefit for the endovascular strategy group
at 3 years. The reconvergence of the survival curves beyond 3 years is also unexplained but, as in the situation
of elective AAA repair, secondary ruptures and increased cancer deaths may have been contributory.89
Observational series using administrative or registry data, which cannot fully account for selection bias, have
also noted the reconvergence of survival curves at 4/5 years, following a strong survival benefit for EVAR
during the acute period, but without discussion of underlying reasons for this.47,79
The burden of reinterventions reflects the number of reinterventions, their severity and the associated
bed-days in hospital, and probably also the type of anaesthesia used (although type of anaesthesia was
not recorded, local anaesthesia would probably be used more often than general anaesthesia for arterial
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reinterventions, especially the less severe reinterventions). The recategorisation of reinterventions as
arterial, laparotomy related or other, and by the severity of the procedure, has been useful. Particularly
during the early part of follow-up, reinterventions were more severe in the open repair group (and more
often laparotomy related rather than arterial). More surprisingly, new and serious reinterventions continued
at a low but steady rate after the acute period (0–90 days) in both the open repair group and the
endovascular group. Therefore, there was no significant excess of reinterventions in the endovascular
strategy group in the later phase of follow-up, as has been indicated in other studies.47,87
The earlier advantage of better QoL in the endovascular strategy group was no longer evident at 3 years but,
importantly, the mid-term survivors had a QoL similar to, or slightly better than, that of an age–sex matched
population, supporting aneurysm repair in this older population (the mean age at rupture was 77 years). The
earlier gains in QoL, coupled with the survival advantage between 3 months and 3 years of the endovascular
strategy group, resulted in a significant, although modest, gain in QALYs at 3 years for this group. Apart
from QoL, at 3 years all other health outcomes and costs indicated that the endovascular strategy was more
favourable than open repair in this population. The cost differences observed at 30 days (non-significantly
in favour of the endovascular strategy group) were not eroded by an increased burden of reinterventions
in later follow-up. In contrast, elective endovascular repair has been associated with higher costs and is
probably not cost-effective.91 The longer-term follow-up strengthens the positive cost-effectiveness profile of
the endovascular strategy group reported at 1 year and, by 3 years, the between-group differences in both
QALYs and INMB were almost double those at 1 year. This cost-effectiveness of the endovascular strategy
dominates open repair, irrespective of the decision-maker’s willingness to pay for a QALY gain.
This study has several limitations. First and foremost, this was a pragmatic trial in a life-or-death emergency
setting. This meant that not all randomised participants had a ruptured aneurysm, although 99% had an
aortic aneurysm, and that there was significant non-compliance with allocated treatment in both randomised
groups (≈10% of each group). Second, some of the participants with a ruptured aneurysm died before their
aneurysm could be repaired, but the number of participants in this category was similar in each randomised
group. Third, after 30-days, follow-up was focused on the subgroup of 502 participants in whom repair of a
ruptured aneurysm was started. However, this subgroup of 502 participants in whom repair of a ruptured
AAA had started is the most clinically relevant group and was analysed by intention to treat; thus, there
should be minimal bias. Fourth, after the acute period, only aneurysm-related reinterventions were reported,
but these data were complete, including procedures at non-trial hospitals collected through data linkage
with routine hospital statistics, and more than half of the reinterventions were audited. Fifth, although this is
by far the largest randomised trial for the management of ruptured aneurysm, with hindsight, the sample
size may have been insufficient, with the CIs for mortality often being relatively wide.
There are also several strengths to this study. First, recruitment was non-selective and over half of the
potentially eligible patients at the trial centres were randomised, adding to the generalisability of the
results. Second, it is the first randomised study with full prospective mid-term follow-up. Third, very few
participants were lost to follow-up and the response rate to QoL questionnaires was excellent.
Summary
The endovascular strategy (emergency EVAR if anatomically feasible) provides a better option for patients
presenting with a ruptured AAA (especially women) with early gains in QoL, a QALY gain at 3 years and
probably an interim survival advantage at 3 years without excessive aneurysm-related reinterventions, all of
which combine to result in an endovascular strategy being highly likely to be cost-effective. Therefore, a
strong case can be made for an endovascular strategy being more widely adopted within the NHS, and in
our opinion all vascular centres should be able to offer emergency EVAR, as well as emergency open
repair, at all times.
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Chapter 7 Developing and validating a 48-hour
mortality risk score following emergency admission
for a ruptured abdominal aortic aneurysm
Overview
The purpose of this work was to develop a novel, point-of-care risk score to identify patients with a
ruptured AAA in whom either immediate aneurysm repair or transfer to a specialist centre for repair would
be potentially worthwhile and those in whom aneurysm repair may be futile. Important features of the risk
score are that it is based on both physiological and imaging data that are immediately available in the
emergency department and that it focuses on 48-hour mortality as the primary outcome measure, rather
than in-hospital or 30-day mortality. The highest attrition rate following repair is in the first 48 hours
(see Figure 4). The developed risk score would help to address the question of whether or not more
patients in the UK should be offered the chance of aneurysm repair because there currently appears to be
undertreatment in England compared with the USA.92
The outcome considered was death within 48 hours of presentation to the emergency department where
an operation, if commenced, used either open repair or EVAR. Previous risk scores have been derived but
are generally based on in-hospital mortality as an outcome and are therefore sensitive to changes and
improvement in critical care.93 Furthermore, few of these risk scores have been validated externally.
We therefore used the opportunity presented by the collection of individual patient data from the three
largest ruptured AAA trials undertaken worldwide and two observational cohorts [the wider Amsterdam
cohort87 and the STAR (STockholm Aneurysm Ruptures) cohort74] to (1) develop a 48-hour risk score
in the IMPROVE trial, (2) externally validate the risk score in the AJAX, ECAR trials and the Amsterdam and
STAR observational cohorts and (3) additionally assess the predictive capabilities of previously published risk
scores, namely the Vascular Study Group of New England,93 the Hardman index30 and the Vancouver94
ruptured AAA risk scores, within all RCTs and observational cohorts.
Modelling
Participants for the development and validation of the risk score
Participants from the IMPROVE RCT were used to develop the score; participants with a final diagnosis
other than ruptured AAA (i.e. excluding incidental or symptomatic AAA) were excluded but those with
aortoiliac ruptures were included. All participants with ruptured AAA or aortoiliac ruptures are considered
in the risk score regardless of whether or not aneurysm repair was commenced.
External validation of the risk score was conducted in participants from the AJAX19 and ECAR22 RCTs. The
inclusion criteria for randomisation in these two RCTs, and hence the participant population, were slightly
different to those in the IMPROVE trial. The IMPROVE trial randomised patients with a clinical diagnosis of
ruptured AAA, before confirmation of either rupture or suitability for EVAR, and participants did not have
to be haemodynamically stable. The AJAX and ECAR trials required participants to undergo CT before
randomisation to confirm the presence of an aneurysm with acute haemorrhage outside the aortic wall
and that patients be suitable for both EVAR and open repair and be haemodynamically stable on arrival.19,22
Therefore, we also undertook external validation using the wider Amsterdam cohort,87 which included
those participants who were unsuitable for randomisation in AJAX, as well as a large observational cohort
of all patients presenting with ruptured AAAs in the Stockholm area (the STAR cohort74).
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Outcome measure
The principal outcome measure that is predicted is mortality within 48 hours of randomisation. The developed
48-hour risk score was also assessed to investigate whether or not it could reliably predict 30-day mortality.
Candidate predictors
We predefined a set of variables for potential inclusion in the risk score based on the data available from
the three trials of ruptured AAA (IMPROVE, AJAX and ECAR).
These variables included age, sex, admission systolic blood pressure, additional admission variables for the
assessment of the Hardman index [haemoglobin, creatinine, acute myocardial ischaemia on electrocardiography
and loss of consciousness] and four basic morphological features of the aneurysm that were measured using
CT, which were chosen because they are required to assess the feasibility of EVAR and are relatively easy to
measure in a time-critical situation (maximum aortic diameter, aortic neck diameter, aortic neck length and
proximal neck angle). The AJAX and ECAR trials did not provide data regarding the volume of intravenous
fluids administered or whether or not the participant suffered a preoperative cardiac arrest. Nevertheless,
these variables were assessed for their predictive ability when developing the model in the IMPROVE trial data.
For the nine continuous candidate predictors (age, haemoglobin, creatinine, admission systolic blood
pressure, volume of intravenous fluids administered, maximum aortic diameter, aortic neck diameter, aortic
neck length and proximal aortic neck angle), non-linear relationships with the log-odds of mortality were
investigated using fractional polynomials (FPs) based on complete data.95 The powers of each predictor that
were considered in the FP were –2, –1, –0.5, 0, 0.5, 1, 2 and 3, where, by convention in FP terminology,
χ(0) was defined as log (χ). A FP of degree –2 was first considered with the best-fitting degree –2 FP compared
with the best-fitting degree –1 FP using a chi-squared test of the difference in deviance (a p-value of > 0.1
rejected the use of the more complex degree –2 FP). Similarly, a degree –1 FP was compared with just a linear
relationship. Shapes of association were plotted for each final chosen FP for a predictor to assess biological
plausibility.
Missing data
To deal with missing data in the predictors, multiple imputation was carried out. The imputation model
included all variables considered in the risk score plus the outcome measure (48-hour mortality), 30-day
mortality, lowest systolic blood pressure, randomised group, preoperative cardiac arrest, operation received
(EVAR, open repair or no operation) and hospital. Predictive mean matching was used for continuous
variables and a chained equation strategy was used. Passive imputation was conducted for any non-linear
relationships that were found in the prior FP exercise. Forty imputed data sets were generated. Systolic
blood pressures, observed or imputed, that were < 33 mmHg were set to the lowest presumed recordable
value of 33 mmHg.
Variable selection
A multivariable model was chosen using backwards selection, whereby all candidate predictors using their
chosen FP transformation were initially included in the model. Estimates and standard errors (SEs) were
obtained from pooling multiply imputed data sets using Rubin’s rules to give (pooled) Wald p-values.
The variable with the highest Wald p-value of ≥ 0.157 was then removed from the model (note that this
p-value threshold approximately corresponds to a change in deviance of 2, and is akin to using the Akaike
information criterion to carry out variable selection). This process was repeated until all remaining variables
had a p-value of < 0.157.
The pooled coefficients of the selected variables across the multiply imputed data sets were used to define
the risk score. The predicted probability (of mortality within 48 hours) for each person was obtained using the
pooled coefficients applied to data from each imputed data set separately. The resultingM= 40 linear
predictors were then pooled using Rubin’s rules before being transformed back to the probability scale to
obtain a single risk prediction for each person.32
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Developing a bedside predictive model
For ease of use, it was also important to develop a simplified bedside prediction model, in which continuous
covariates were dichotomised and coefficients from a fitted logistic model were converted to integers, to allow
a simple summation of risks associated with an individual’s risk factors. For each predictor, dichotomisation
was implemented at a clinically relevant cut-off point or at a level close to the observed median.
Predictive performance
The predicted probabilities of 48-hour mortality that were obtained from the continuous model and the
bedside model were assessed in terms of calibration and discrimination. Calibration was assessed by plotting
observed risks compared with predicted risks within deciles of predicted risk and reporting the estimated
calibration slope from a Cox proportional hazards model with the risk score as the predictor.96 Discrimination
was assessed using the area under receiver operating characteristic (AUROC) curve, which assesses the
ability of the prediction model to differentiate between those who do and do not experience the outcome.
The AUROC gives an estimate of the probability of correctly identifying the case in a randomly chosen
case–control pair of individuals, with a value of 1 indicating perfect discrimination and a value of 0.5
indicating that discrimination is no better than chance.
Internal validation (within the IMPROVE trial data set) was conducted using 10-fold cross-validation to avoid
overoptimistic estimates of predictive performance caused by overfitting. Within each cross-validation, the
FP and variable selection processes were re-derived using nine-tenths of the data to obtain a new prediction
model, which was then validated on the remaining one-tenth of the data. This procedure was repeated
10 times for each nine-tenths split of the data and the average AUROC over these cross-validations was
calculated to give an optimism-corrected estimate.
External validation was conducted using data from the AJAX and ECAR trials to give an assessment of how
well the derived risk score applies in other populations. A further assessment of the model was carried out
in the wider Amsterdam cohort87 and the STAR cohort.74
Comparison with other published ruptured-abdominal aortic aneurysm risk scores
For a comparison of the utility of the new ruptured AAA risk score for 48-hour mortality, we compared its
predictive performance with the performance of other published risk scores using data from all three RCTs.
Preoperative cardiac arrest was not comprehensively recorded in the three randomised trials and so was
omitted from scores that used this variable. Furthermore, the use of a suprarenal clamp was not specifically
recorded in these data sets and so a proxy (aortic neck length of < 10 mm) was used instead. This proxy
was chosen based on a consensus arising from a questionnaire that asked ‘What is the minimal length of
aortic neck required to utilise an infrarenal clamp for AAA repair?’, which was circulated at the June 2015
annual meeting of the British Society of Endovascular Therapy.
Results
Participant characteristics
A total of 536 IMPROVE trial participants with a final diagnosis of ruptured AAA met the inclusion criteria,
of whom 135 (25%) died within 48 hours of randomisation. A total of 319 participants commenced
open repair, 182 participants commenced EVAR and a further 35 participants did not receive an operation
(were palliated or died before reaching theatre). There were 113 and 107 participants in the AJAX and
ECAR trials, respectively, who met the inclusion criteria, of whom 17 (15%) and 15 (14%), respectively,
died within 48 hours of randomisation. In the IMPROVE trial, participants were, on average, 2 years older
and had larger aneurysms and a greater proportion of women were included (Table 18). In the Amsterdam
cohort, 131 out of 514 patients (25%) died within 48 hours; the mortality rate was much higher in the
STAR cohort, in which 107 out of 284 patients (38%) died, which was attributable, in part, to participants
being an average of 4 years older. Patients in the STAR cohort also had, on average, lower admission
systolic blood pressures and shorter aneurysm neck lengths, and a higher proportion had lost
consciousness before arrival in the operating theatre.
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Risk score development
Unadjusted ORs for each candidate variable are given in Table 19, after multiple imputation. Most
candidate predictors were correlated with the outcome. FP modelling indicated a cubic effect of age, an
inverse squared effect of admission systolic blood pressure and a log-transformed effect of neck length on
the log-odds of mortality (see Appendix 2, Figure 30). Following backwards variable selection, the final
variables retained in the prediction model were (1) age, (2) sex, (3) admission haemoglobin, (4) admission
creatinine, (5) admission systolic blood pressure, (6) aortic neck length, (7) aortic neck angle and (8) acute
cardiac ischaemia. Coefficients based on transformations of these variables are shown in Appendix 2,
Table 40. A simplified ‘IMPROVE bedside score’ also was derived using an integer points system (see
Appendix 2, Table 40).
Calibration and discrimination
Calibration plots are shown in Appendix 2, Figure 31, for both the IMPROVE score and the IMPROVE
bedside score applied to the IMPROVE trial data. Both scores are generally well calibrated, particularly for
individuals at a lower risk. The calibration slope was estimated as 1.07 (95% CI 0.83 to 1.32; p = 0.55) and
1.08 (95% CI 0.81 to 1.35; p = 0.54) for the IMPROVE score and IMPROVE bedside score, respectively,
indicating that both low and high predictions are well calibrated.
TABLE 18 Descriptive statistics of the candidate predictors for the three RCTs and two cohorts
Candidate predictor
Trial Cohort
IMPROVE
(N= 536);
135 48-hour
deaths (25%)
AJAX
(N= 113);
17 48-hour
deaths (15%)
ECAR
(N= 107);
15 48-hour
deaths (14%)
Amsterdam
(N= 525);
131 48-hour
deaths (25%)
STAR
(N= 284);
107 48-hour
deaths (38%)
Age (years), mean (SD) [N] 76 (8) [536] 74 (9) [113] 74 (11) [107] 75 (9) [515] 79 (9) [284]
Sex (male), n (%) [N] 424 (79) [536] 97 (86) [113] 97 (91) [107] 398 (77) [517] 215 (76) [284]
Admission haemoglobin (g/dl),
mean (SD) [N]
11.1 (2.4)
[530]
11.5 (2.3)
[113]
10.6 (2.3)
[107]
11.1 (2.5)
[499]
11.1 (2.3)
[273]
Admission creatinine (µmol/l),
median (IQR) [N]
118 (95–153)
[524]
106 (91–142)
[107]
114 (91–136)
[105]
110 (89–139)
[478]
117 (90–140)
[268]
Admission systolic blood pressure
(mmHg), mean (SD) [N]
108 (32) [526] 120 (40) [110] 108 (30) [104] 113 (37) [440] 104 (39) [283]
Volume of i.v. fluids given before
arrival in theatre (l), mean (SD) [N]
1.06 (1.13)
[391]
– – – –
Maximum aneurysm diameter
(mm), mean (SD) [N]
86 (17) [460] 76 (16) [92] 77 (20) [106] – 81 (19) [192]
Aneurysm neck diameter (mm),
mean (SD) [N]
25 (4.3) [390] 26 (4.0) [92] 24 (4.5) [106] – 29 (11) [192]
Neck length (mm), mean (SD) [N] 23 (17) [435] 27 (13) [92] 25 (14) [101] 21 (14) [271] 18 (18) [192]
Neck angle; proximal (degrees),
mean (SD) [N]
33 (20) [432] 39 (21) [92] 34 (26) [96] 37 (22) [271] 23 (16) [192]
Acute ischaemia detected on
ECG (yes), n (%) [N]
38 (7.7) [495] 12 (18.5) [65] 4 (3.7) [107] 42 (21.7) [194] 60 (43.2) [139]
Participant lost consciousness
(yes), n (%) [N]
47 (9.2)
[512]
13 (11.5)
[113]
12 (11.2)
[107]
– 68 (23.9)
[284]
Cardiac arrest (yes), n (%) [N] 8 (1.5) [536] – – – –
–, not available; ECG, electrocardiogram; IQR, interquartile range; i.v., intravenous.
Reproduced from Sweeting et al.97 © 2018 The Authors. BJS published by John Wiley & Sons, Inc., on behalf of BJS Society
Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which
permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for
commercial purposes.
DEVELOPING AND VALIDATING A 48-HOUR MORTALITY RISK SCORE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
The AUROCs of the model applied to the IMPROVE trial are provided in Table 20. The AUROC for this
internal validation is derived using 10-fold cross-validation. The discriminative ability of the model is
reasonable, but not exceptional, with an IMPROVE score AUROC of 0.720 (SE 0.025); this provides a slightly
better predictive ability than the IMPROVE bedside score, which has an AUROC of 0.688 (SE 0.026).
External validation
The IMPROVE score and IMPROVE bedside score were validated on the four external data sets (the AJAX
and ECAR trials and the Amsterdam and Stockholm area cohorts).
TABLE 19 Univariate analysis of candidate predictors using multiply imputed data
Variable
Univariate
ORa (95% CI) p-value
Age (years) per 8-year increase 1.49 (1.18 to 1.80) < 0.001
Admission haemoglobin (g/dl) per 2.4-g/dl increase 0.63 (0.50 to 0.76) < 0.001
Admission creatinine (µmol/l) per 66-µmol/l increase 1.37 (1.11 to 1.62) 0.001
Admission systolic blood pressure (mmHg) per 32-mmHg increase 0.71 (0.56 to 0.86) 0.002
Volume of i.v. fluids given before arrival in theatre (l) per 1.13-l increase 1.28 (1.03 to 1.53) 0.014
Maximum aneurysm diameter (mm) per 17-mm increase 0.85 (0.67 to 1.03) 0.13
Aneurysm neck diameter (mm) per 4.3-mm increase 0.95 (0.74 to 1.16) 0.63
Neck length (mm) per 17-mm increase 0.64 (0.49 to 0.79) < 0.001
Neck angle; proximal (degrees) per 20° increase 0.92 (0.72 to 1.12) 0.45
Sex (male) 0.44 (0.28 to 0.69) < 0.001
Acute ischaemia detected on ECG (yes) 2.79 (1.46 to 5.34) 0.002
Participant lost consciousness (yes) 1.54 (0.80 to 2.94) 0.19
ECG, electrocardiogram; i.v., intravenous.
a Per SD increase for continuous variables and compared with the reference level for categorical variables.
TABLE 20 Discriminative performance of the developed IMPROVE risk score for predicting 48-hour mortality,
validated both internally (using IMPROVE trial data) and externally (using data from the AJAX and ECAR RCTs and
the Amsterdam and STAR cohorts). Comparisons with other published risk scores are also shown
Model
Data set, AUROC (SE)
Development Validation
IMPROVE
(n= 536)
AJAX
(n= 113)
ECAR
(n= 107)
Amsterdam
cohort (n= 514)
STAR cohort
(n= 284)
IMPROVE score 0.720 (0.025)a 0.665 (0.062) 0.722 (0.073) 0.737 (0.024) 0.650 (0.034)
IMPROVE bedside score 0.688 (0.026)a 0.682 (0.055) 0.688 (0.079) 0.662 (0.025) 0.594 (0.035)
VSGNE93 0.638 (0.027) 0.628 (0.065)b 0.672 (0.068)b 0.655 (0.026)c 0.655 (0.033)b
Hardman index30 0.648 (0.026) 0.749 (0.050) 0.730 (0.068) 0.690 (0.026) 0.606 (0.035)
Vancouver94 0.635 (0.028) 0.609 (0.079)b 0.725 (0.069)b 0.642 (0.029)c 0.702 (0.033)b
VSGNE, Vascular Study Group of New England.
a Cross-validated AUROC (optimism corrected).
b Excluding cardiac arrest.
c Excluding preoperative cardiac arrest and loss of consciousness.
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In AJAX, both AUROCs were < 0.70, whereas, in the ECAR trial, only the IMPROVE score gave an AUROC
of > 0.70 (AUROC, 0.722; SE 0.073). In the two cohort studies, the Amsterdam cohort had a similar
predictive performance to the ECAR trial, with a relatively high C-index for the IMPROVE score (0.737) but
a low one for the IMPROVE bedside score (0.662), whereas the performance of both IMPROVE scores in
the STAR cohort was relatively poor (AUROCs were < 0.650).
Comparison with other published risk scores
We compared the developed IMPROVE risk scores with previously published risk scores, namely the
Vascular Study Group of New England risk score,93 the Hardman index30 and the Vancouver risk score.94
The derivation of each score is given in Appendix 2, Table 41.
In terms of discrimination, the developed IMPROVE risk score outperformed other published risk scores in
the IMPROVE trial data, whereas the Hardman index score outperformed the new developed (IMPROVE)
scores in the AJAX and ECAR trial data for 48-hour mortality (see Table 20). There is some heterogeneity
in the performance of each risk score when applied to different populations. For example, the Hardman
index score performed well in the AJAX and ECAR trials but less well in the Amsterdam and STAR cohorts,
perhaps attributable to the fact that the randomised trials AJAX and ECAR recruited a selected population
of participants with ruptured AAA (only patients with relative haemodynamic stability and morphologically
suitable for EVAR). The overall performance of each risk score in comparison with the predictive ability
(discrimination) using age alone is presented in Figure 13. The average C-index increase is pooled across
cohorts, weighted by the study-specific number of events. The change in C-index is highest when using
the IMPROVE score, although the increase is still rather modest: ΔC = 0.08 (95% CI 0.05 to 0.11).
Performance of the risk scores in predicting 30-day mortality
The five different risk scores also were assessed for their ability to predict 30-day mortality, the results of
which are given in Appendix 2, Table 42. The performance of two IMPROVE scores in the prediction of
48-hour mortality was similar; the difference in the C-index for 30-day mortality and for 48-hour mortality
varied by study and risk score. For the three previously published risk scores (Vascular Study Group of New
England, Hardman index and Vancouver) the 30-day C-indices were higher than the 48-hour C-indices in
all studies except for the ECAR randomised trial, underlining the fact that these scores were developed
using 30-day or in-hospital mortality as the outcome measure.
Decision curve analysis
The clinical usefulness of any particular ruptured AAA risk score depends on the ability to make better
decisions with a model than without it.98 If the risk score was to be used to decide whom to operate on,
or whom to transfer to a specialist centre, then a cut-off point is required to classify patients either as low
risk (operate) or high risk (palliate).96 The cut-off threshold should balance the benefit against the harms
and, in an emergency setting, this threshold would naturally be very high because the harms of not
treating ruptured AAA patients are dire. Nevertheless, there may be a range of very high-risk individuals
in whom surgeons feel that it is futile to attempt an operation and that palliation is the best course of
action. Following methodology developed by Vickers and Elkin,99 the net benefit of treating patients at
different risk cut-off points compared with treating none can be quantified and the value of a ruptured
AAA risk score can be assessed. The cut-off value naturally defines the benefit-to-harm ratio that a
surgeon is willing to accept. For example, supposing harms and benefits can be simply expressed in
terms of quality-adjusted remaining life expectancy, a surgeon treating patients with a 48-hour mortality
probability of ≤ 98% quantifies the consequence of not operating when it would have been of benefit to
be 98 : 2 (49 times worse than the consequence of operating unnecessarily).96
Figure 14 shows the net benefit decision curve for the full range of possible threshold probabilities.
The green horizontal line denotes the decision to treat no one (the net benefit being zero for all possible
probability cut-off points). The blue line denotes the net benefit of treating everyone in relation to a chosen
benefit–harm trade-off (the threshold probability) and the black line denotes the net benefit of treating only
those with a mortality risk below the chosen threshold. The net benefit is higher than treating no one for
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FIGURE 13 Change in C-index for five ruptured AAA risk scores compared with the reference score using age alone. VSGNE, Vascular Study Group of New England.
Reproduced from Sweeting et al.97 © 2018 The Authors. BJS published by John Wiley & Sons, Inc., on behalf of BJS Society Ltd. This is an open access article under the terms of
the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and
is not used for commercial purposes.
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higher cut-off points in which the benefit-to-harm ratio is high. At a threshold probability of 1.0 (right hand
side of the figure) surgeons would value an operation as infinitely better than no operation and hence the
‘treat all’ scenario gives the highest net benefit.
In Figure 14, the black line shows the net benefit if treatment decisions are based on the IMPROVE
ruptured AAA risk score. The net benefit is almost identical to that of treating everyone for thresholds of
> 50%. The benefit of a ruptured AAA risk score only becomes apparent for surgeons who would treat
only low-risk individuals (i.e. with 48-hour mortality risk of ≤ 40%). At a higher threshold of 90%, the
ruptured AAA risk score would correctly identify all 401 survivors in the IMPROVE trial but it also correctly
identifies only 2 out of 135 participants (1.5%) who died within 48 hours. This lack of sensitivity highlights
why a ruptured AAA risk score is no better than a treat-all solution for most sensible thresholds.
Conclusions
The developed ruptured AAA risk score has shown that there are some important predictors of survival
to 48 hours after emergency admission, including two morphological variables (neck length and angle)
that complicate emergency surgical repair by influencing the feasibility of endografting. Some of these
predictors were found to have a non-linear relationship with the log-odds of mortality. The derived
IMPROVE score performed adequately in the IMPROVE participants and outperformed other published risk
scores in validation on some, but not all, external patient populations. In general, the published ruptured
AAA risk scores to date do not have sufficient predictive accuracy to enable surgeons to make life or death
decisions regarding providing an operation, as highlighted in the decision curve analyses. This conclusion is
in agreement with the recent study100 evaluating five different scoring systems for 30-day mortality in a
cohort of Dutch patients (from outside the Amsterdam area) with a ruptured AAA. This study100 evaluated
the Vancouver score and Hardman index scores, together with the Glasgow101 and Edinburgh102 scores
and the newly developed Dutch Aneurysm Score,103 with areas under the curve ranging from 0.59 to 0.72.
Vos et al.100 also concluded that an almost perfect prediction is needed to withhold an intervention, and
no current scoring system is capable of that.
The unconvincing performance of risk scores, when applied to data sets from which they were not derived,
is disappointing. The IMPROVE risk score was novel in that it is the only risk score to focus on 48-hour
mortality and to include morphological parameters. However, it does not really perform better than older
– 4
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1
N
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Treat if ruptured AAA risk score 
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FIGURE 14 Decision curve showing the benefit of the IMPROVE ruptured AAA risk score in helping to make treatment
decisions. The graph shows the expected net benefit per patient relative to no treatment in any patient. Reproduced
from Sweeting et al.97 © 2018 The Authors. BJS published by John Wiley & Sons, Inc., on behalf of BJS Society Ltd. This
is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits
use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for
commercial purposes.
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scores focusing on 30-day mortality when applied to other data sets, including population-based data sets
such as those from the Stockholm area of Sweden and the Amsterdam area of the Netherlands. This
would suggest that further research to assess the role of risk scores in the transfer of patients, from
centres without emergency vascular cover to specialist vascular centres, would not be fruitful. The inability
of risk scores to predict outcomes following emergency surgical repair with sufficient accuracy indicates
that any risk score should be used only for comparing different populations or adjusting population data,
as the Hardman index was used in the IMPROVE trial. If the mortality risk of ruptured AAA repair cannot
be predicted with sufficient accuracy, we urge that the focus should shift to offering repair to more
patients and to reducing non-intervention rates for emergency ruptured AAA repair, which are currently
too high in England92 and some other countries. In this context, it is of interest that, when we used a
Delphi consensus approach to formulate guidelines for the transfer of patients to specialist vascular
centres, cardiac arrest in the same admission was the only condition with complete agreement that the
patients should not be transferred.62 Nevertheless, there is some evidence that few patients (14%) may
survive emergency repair of a ruptured AAA even after a preoperative cardiac arrest.104 In such life or
death situations, perhaps it is just not ethical to consider using risk scores to withhold treatment and
we suggest that the focus should shift to ensuring that the wishes of the patient and their family
are respected.
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Chapter 8 Collaborative research projects
emanating directly from the IMPROVE trial
The collaborative individual patient data meta-analysis, which draws data from the three recentEuropean randomised trials for the management of ruptured AAAs, has been discussed in the chapters
focusing on the 30-day and 1-year outcomes of the IMPROVE trial (Chapters 3 and 5, respectively). The
IMPROVE trial achieved its target recruitment because of the enthusiasm of the many local trial investigators
and has provided detailed information about the morphology of ruptured AAAs from the core laboratory
at St George’s Hospital, London (under the supervision of grant applicants Matthew M Thompson and
Robert J Hinchliffe). These factors have enabled the following four collaborative research projects, all of
which had the approval of the IMPROVE Trial Management Committee and appropriate ethics approvals at
collaborating centres as necessary:
1. The development of a practical approach to expert elicitation for RCTs with missing health outcomes,
in collaboration with colleagues Alexina Mason, Manuel Gomes, Richard J Grieve and James Carpenter
from the London School of Hygiene & Tropical Medicine.
2. The comparative morphology of intact and ruptured AAAs, in collaboration with colleagues at
St George’s Hospital CT core laboratory (including Alan Karthikesalingam, Matthew Grima and staff)
and statisticians Mohammed Hudda and Michael J Sweeting.
3. Computational fluid dynamics of ruptured AAAs, in collaboration with Barry Doyle, Karol Miller and
their students at the University of Western Australia.
4. Computational flow dynamics of CIAs, again in collaboration with Barry Doyle, Karol Miller and their
students at the University of Western Australia as well as Maarit Venermo (University of Helsinki) and
Igor Koncar (University of Belgrade).
The development of a practical approach to expert elicitation for
randomised controlled trials with missing health outcomes
The IMPROVE trial, like most RCTs, assessed participant HRQoL. In the IMPROVE trial, it was not possible
to collect baseline data, but data were collected at three time points: 3 months, 12 months and 3 years
after randomisation. Like most randomised trials with missing data, it was assumed that, after conditioning
on the observed data, the probability of missing data does not depend on the participant’s outcome
and so the data are ‘missing at random’.16,23 This assumption is usually implausible, for example because
participants in relatively poor health may be more likely to be non-responders to questionnaires or demit
from routine clinical follow-up. Methodological guidelines recommend that trials undertake sensitivity
analysis, which is best informed by elicited expert opinion, to assess whether or not conclusions are robust
to alternative assumptions about the missing data. A major barrier to implementing these methods in
practice is the lack of relevant practical tools for eliciting expert opinion.
We developed a new practical tool for eliciting expert opinion within the IMPROVE trial and demonstrate
its use for the IMPROVE trial and its applicability to other randomised trials with missing QoL data. In the
IMPROVE trial at 3 months post randomisation, 21% of participants did not complete HRQoL questionnaires
(assessed using the EQ-5D-3L). We addressed this problem by developing a web-based tool that provides a
practical approach to eliciting expert opinion about EQ-5D-3L differences between participants with missing
data and those with complete data.
We developed an easy-to-use web-based elicitation tool using Shiny (RStudio Inc., Boston, MA, USA),
a web application framework within the widely used statistical software, R (The R Foundation for Statistical
Computing, Vienna, Austria),105 which could be administered by e-mail or in conference breaks. We
adopted a graphical approach, using three cartoon characters who had undergone either open repair or
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endovascular repair of their ruptured AAA, minimised the administrative burden by collecting informed
consent electronically and offered a £20 Amazon (www.amazon.co.uk; Amazon.com, Inc., Bellevue, WA,
USA) gift card as a token of appreciation for completed surveys. ‘Good practice’ recommendations for
eliciting expert opinion were followed, in particular by including a feedback question and allowing the
experts to revise their answers.106
The scale of scores for the elicitation exercise is the same as the original scale for the EQ-5D-3L utility
score, multiplied by 100 for ease of completion. The expert is provided with possible scores for typical
patients, with six exemplar diagnoses on the scale between –20 and 100 (based on published literature),
which were chosen as they were anticipated to be familiar to our experts and because they spanned the
EQ-5D-3L scale.
A total of 26 experts participated in the elicitation exercise, the majority at the Annual Meeting of the
Vascular Society of Great Britain and Ireland in Bournemouth in November 2015, because the Shiny tool
was not compatible with all NHS interfaces. The elicited EQ-5D-3L scores were lower on average for the
participants with missing data than for those with complete data, but there was considerable uncertainty
in these elicited values.
We show how this expert opinion can define informative priors within a fully Bayesian framework to carry
out sensitivity analyses that allow the missing data to depend on unobserved participant characteristics.
The ‘missing-at-random’ analysis found that participants randomised to the endovascular strategy,
compared with those randomised to open repair, had a higher average EQ-5D score, of 0.062 (95% CI
–0.005 to 0.130). Our sensitivity analysis, which used the elicited expert information as pooled priors,
found that the gain in average EQ-5D-3L score for the endovascular strategy, compared with open repair
groups, was 0.076 (95% CI –0.054 to 0.198).
The estimated effect of randomised group on average EQ-5D-3L score was similar across the alternative
approaches to the missing data, but the sensitivity analysis resulted in greater uncertainty about this mean
difference; the credible intervals from allowing the data to be non-randomly missing were wider than
following the missing-at-random assumptions and the complete case analyses. These wider credible
intervals recognise the variation within and across the experts in the likely differences in outcomes
between those with missing data and those with observed EQ-5D-3L data.
In conclusion, we have designed and exemplified a practical tool for eliciting the expert opinion required by
recommended approaches to the sensitivity analyses of RCTs. We show how this approach allows the trial
analysis to fully recognise the uncertainty that arises from making alternative plausible assumptions about
the reasons for missing data. This tool can be widely used in the design, analysis and interpretation of future
trials. This research project has now been published in Clinical Trials,107 and to facilitate the use of this
practical tool for other trials, materials have now been made available for download.107
The comparative aortic morphology of intact and ruptured abdominal
aortic aneurysms
Most AAAs are broadly fusiform in shape and, to date, the AAA diameter provides the best guide to the
risk of aneurysm rupture. Some small studies have suggested that other factors, such as wall stress and the
volume of luminal thrombus, might be just as important,108 but none of these factors has been subject to a
prospective investigation. Because automated or semi-automated three-dimensional reconstruction of aortic
CT scans is now widely available and essential to the planning of endovascular repair, we wished to test the
hypothesis that morphological features (other than maximum aortic diameter) might be associated with a
ruptured AAA rather than an intact AAA and hence could be useful in assessing the risk of AAA rupture.
COLLABORATIVE RESEARCH PROJECTS EMANATING DIRECTLY FROM THE IMPROVE TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
64
Using a standard methodology,26 we measured the aortic morphology of 907 patients who had undergone
elective repair of an intact AAA at St George’s Hospital between 2009 and 2013 and 294 cases of
ruptured AAA (blood outside the AAA sac and adequate-quality CT scan) from the IMPROVE trial. All CT
scans were anonymised and held only trial numbers or St George’s Hospital database identifying numbers.
The following parameters were measured: proximal aneurysm neck (suprarenal aortic diameter, diameter
of 1 mm below the distal renal artery, neck length, α neck angle and neck conicality), maximum AAA
diameter and thrombus volume, iliac bifurcation middle angle, and common iliac artery diameter and iliac
tortuosity index.
Analysis was conducted in accordance with a prespecified analysis plan using a logistic regression
approach in which analyses were stratified by sex. Regression models were adjusted for two prespecified
confounders: maximum aneurysm diameter and age. In order to adjust for maximum aneurysm diameter,
we formed narrow categories of the diameter and adjusted for the categorised variable in the models.
These narrow categories were formed after careful examinations of the overlap of the AAA diameters in
both populations.
The distribution of the morphological variables by ruptured or intact AAA and by sex is shown in Table 21. The
association between aneurysm morphology and rupture of an AAA, when adjusting for all eight morphology
variables and the prespecified confounders, is shown in Table 22. Neck diameter was associated with rupture
in women, in whom an increase of 4.1 mm led to an adjusted OR of 2.06 (95% CI 1.10 to 3.86; p= 0.02).
Furthermore, aneurysm neck angle α was also associated with rupture, but only in males. The adjusted OR was
1.53 (95% CI 1.22 to 1.92; p< 0.01) per 18.3° increase.
The maximum iliac tortuosity index and iliac bifurcation middle angle both showed strong evidence of
an inverse association with rupture in both sexes. An increase of 0.3 in the tortuosity index led to an
adjusted OR of 0.27 (95% CI 0.20 to 0.37; p < 0.01) in men and of 0.28 (95% CI 0.13 to 0.63; p < 0.01)
in women. For a 22.6° increase in the iliac bifurcation middle angle, there was an adjusted OR of 0.36
(95% CI 0.27 to 0.49; p < 0.01) in men and of 0.49 (95% CI 0.29 to 0.83; p = 0.01) in women.
TABLE 21 Mean (SD) of key morphological variables (based on analysis sample)
Measurement
Sex, mean (SD)
Males (N= 1046) Females (N= 151)
Elective repair
(n= 800)
Rupture repair
(n= 246)
Elective repair
(n= 103)
Rupture repair
(n= 48)
Aneurysm neck diameter at 1 mm (mm) 24.2 (4) 25.4 (3.8) 22 (4) 23.9 (5.2)
Aneurysm neck length (mm)a 31.5 (14.1) 30.9 (13.8) 29 (13.2) 29.8 (13.9)
Aneurysm neck angle α (degrees)a 20.9 (16.9) 31.5 (19) 26.6 (20.2) 32.9 (19.7)
Maximum common iliac artery diameter (mm)a 20.2 (7.3) 21 (8.7) 17.8 (6.8) 18 (5.3)
Neck conicality (mm) 0.5 (0.9) 0.6 (1.2) 0.6 (1.3) 0.6 (0.9)
Aortic aneurysm thrombus volume (mm3)a 97.1 (85.8) 190.8 (125) 80 (63.5) 109.1 (82.5)
Maximum iliac tortuosity indexa 1.5 (0.2) 1.3 (0.3) 1.5 (0.3) 1.2 (0.3)
Maximum aortic aneurysm diameter (mm) 65.9 (11.2) 84.3 (14.5) 62.9 (8.6) 70.9 (9.9)
Iliac bifurcation middle angle (degrees) 60.5 (22.8) 46.7 (15.9) 67.0 (22.9) 48.1 (26.5)
Age (years) 80.5 (8.3) 79.2 (7.4) 81.8 (8.2) 83.6 (6.8)
Suprarenal aortic diameter (mm) 27.4 (3.4) 26.1 (3.1) 26.1 (3.9) 24.7 (3.8)
a Non-normally distributed variables.
DOI: 10.3310/hta22310 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 31
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Ulug et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
65
TABLE 22 Comparison of morphological parameters in intact and ruptured aneurysms, given separately for men and women
Morphological variables
Sex
Males (n= 1044)a Females (n= 151)
Univariate OR
(95% CI) p-value
Multivariable OR
(95% CI) p-value
Univariate OR
(95% CI) p-value
Multivariable OR
(95% CI) p-value
Aneurysm neck diameter at 1 mm per
4.1-mm increase
1.15 (0.96 to1.37) 0.134 1.17 (0.92 to 1.49) 0.209 1.55 (1.04 to 2.31) 0.033 2.06 (1.10 to 3.86) 0.024
Aneurysm neck length per 14.0-mm increase 1.13 (0.94 to 1.36) 0.191 1.24 (0.99 to 1.55) 0.060 0.97 (0.62 to 1.53) 0.910 1.14 (0.63 to 2.08) 0.668
Aneurysm neck α angle per 18.3° increase 1.34 (1.12 to 1.61) 0.001 1.53 (1.22 to 1.92) < 0.001 1.20 (0.81 to 1.78) 0.373 1.10 (0.66 to 1.84) 0.707
Maximum common iliac artery diameter per
7.5-mm increase
0.96 (0.81 to 1.15) 0.663 1.22 (0.97 to 1.53) 0.088 0.86 (0.53 to 1.40) 0.549 0.70 (0.30 to 1.61) 0.399
Conicality per 1.0% per 1-mm increase 0.99 (0.84 to 1.17) 0.895 1.11 (0.90 to 1.37) 0.327 1.04 (0.71 to 1.53) 0.838 1.20 (0.70 to 2.05) 0.502
Aneurysm thrombus volume per 100.2-mm3
increase
1.05 (0.87 to 1.28) 0.86 1.08 (0.83 to 1.41) 0.548 1.01 (0.56 to 1.83) 0.974 0.82 (0.36 to 1.88) 0.642
Maximum iliac tortuosity index per
0.3 increase
0.28 (0.21 to 0.37) < 0.001 0.27 (0.20 to 0.37) < 0.001 0.31 (0.15 to 0.63) 0.001 0.28 (0.13 to 0.63) 0.002
Iliac bifurcation angle per 22.6° increase 0.36 (0.28 to 0.47) < 0.001 0.36 (0.27 to 0.49) < 0.001 0.45 (0.27 to 0.76) 0.003 0.49 (0.29 to 0.83) 0.009
a Two men whose age was missing do not appear in the adjusted models.
Note
Odds ratios per SD change for key morphological variables from the multivariable imputed analysis, adjusted for all other key morphological variables.
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The results for patients, by quintiles of those morphological variables with significant associations with
rupture, were also examined. Neck diameter demonstrates a positive linear trend among men across
quintiles and a similar but less defined relationship in women. Neck angle, α, showed an increasing
positive linear association with rupture across the quintiles, but this relationship was unclear in women.
The negative linear association between quintiles of tortuosity index and rupture among men was replicated
in women, except for the fourth quintile, in which the adjusted OR increased slightly. The adjusted ORs for
the quintiles of iliac bifurcation middle angle showed an extremely similar relationship to that of tortuosity
index, in which a linear negatively associated relationship was visible in both sexes. The discrepancies and
wide 95% CIs were likely to be attributable to the small group numbers in the analysis of women.
These data suggest that iliac artery parameters, including the aortic bifurcation angle and iliac tortuosity
index, in addition to aortic diameter, might be helpful in assessing the risk of rupture. The cases of
ruptured aneurysms from the IMPROVE trial had (after adjustment for aortic diameter and the other
morphological variables), on average, narrower aortic bifurcation angles and less iliac artery tortuosity than
cases of intact aneurysms. It may also be important to note that, after adjustment for aortic diameter and
other morphological characteristics, thrombus volume was not associated with ruptured aneurysms
compared with intact aneurysms.
These data and analyses have several limitations, particularly the relatively poor repeatability of the
measurement of proximal neck angle and iliac bifurcation angle. For these reasons, newer software has
been obtained, which allows for more repeatable measurement of angles. This measurement is ongoing
and, therefore, the above analyses are regarded as preliminary. They have been reported and discussed at
the International Meeting for Aortic Diseases in Liège, Belgium, in September 2016. The novel findings
concerning iliac bifurcation angles and tortuosity also have been considered in our ongoing collaborations
with the computation flow dynamics laboratory in Western Australia (reported in the next two sections).
Computational fluid dynamics of ruptured abdominal aortic aneurysm
Knowledge of how aortic morphology influences AAA biomechanics is still developing. In a single case
from the IMPROVE trial, we have considered whether or not regions of high wall stress in the aneurysm
sac can predict the site of aneurysm rupture,109 with further work in progress. The effects of proximal neck
angle and iliac bifurcation angle on both wall shear stress (WSS) and wall stress have been previously
reported. Previously, it has been indicated that AAA wall stress increased with both iliac bifurcation angle
and aortic neck angle, whereas AAA WSS remained almost constant.110 This might suggest that AAAs with
higher proximal neck angles and iliac bifurcation angles are at a higher risk of rupture. However, the recent
comparisons of the morphology of ruptured AAAs and intact AAAs (see The comparative aortic morphology
of intact and ruptured abdominal aortic aneurysms) have questioned these suggestions and hinted that AAAs
with wider iliac bifurcations might be less prone to rupture, despite other morphological factors.
Therefore, fluid–structure interaction simulations were carried out on a range of idealised AAA geometries
to conclusively determine the influence of both proximal neck angle and iliac bifurcation angle on AAA
wall stress and WSS.
We found a positive linear relationship between peak AAA WSS (i.e. the peak WSS observed in the AAA sac
region) and iliac bifurcation angle (see Appendix 2, Figure 32). The mean peak WSS across all geometries
was 4.52 Pa with maximum and minimum values of 2.91 Pa and 6.19 Pa, respectively. Therefore, peak WSS
increased more than twofold when the iliac bifurcation angle increased from 30° to 150°. Peak WSS in the
AAA increased only when the proximal neck angle was > 30° and when the velocity field also changed to
> 30°. In contrast, peak wall stress (but not von Mises stress) increased linearly with iliac bifurcation angle,
but there was no clear association with time-averaged WSS (TAWSS) (see Appendix 2, Figure 32).
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These observations from fluid–structure interaction simulations may be important to support our findings of
an apparent association between bifurcation angle and likelihood of rupture, with ruptured AAAs tending
to have a smaller iliac bifurcation angle than an intact AAA (see The comparative aortic morphology of
intact and ruptured abdominal aortic aneurysms). The simulation data have been submitted for publication.
Morphological and computational flow dynamic characteristics of
common iliac aneurysms
Common iliac aneurysms are rare (compared with AAAs); much less is known about their natural history111
and the evidence base for their management is scant, although both open repair and endovascular repair
are clinically effective.112 In the IMPROVE trial, there were seven cases of rupture of an isolated common
iliac aneurysm (in the absence of a significant AAA). In scientific studies such as computational flow
dynamics, CIAs have the advantage of often having a normal or nearly normal contralateral common iliac
artery for comparison. Initially, our interest was focused on whether the distribution of WSS or intraluminal
thrombus predicted the site of CIA rupture. Common iliac aneurysms sometimes have one or more patent
distribution arteries. So, using a single case study with several branches of the internal iliac artery, we
undertook a simulation study to evaluate the effect of these outflow arteries on haemodynamics in the
iliac aneurysm. We concluded that accounting for small downstream arteries may not be vital to accurate
computations of upstream flow.113 Other preliminary investigations included the residence time of platelets
and monocytes, velocity fields, TAWSS, oscillatory shear index and endothelial cell activation potential. We
found that high cell residence times, low TAWSS, high oscillatory shear index and high endothelial cell
activation potential all correlate with regions of intraluminal thrombus development.114 Initial investigations
showed that the point of CIA rupture was usually in a region of low TAWSS (Figure 15).
After the indication that the iliac bifurcation angle and iliac artery tortuosity might be influential in
discriminating the morphology of ruptured AAAs compared with intact AAAs, investigations were
expanded to include a more comprehensive assessment of the morphology and computational flow
dynamics of both ruptured CIAs and intact CIAs and their contralateral common iliac arteries. In particular,
the underlying hypothesis was that the wider the iliac artery bifurcation was, the lower the WSS in the
distal aneurysm would be, leading to an enhanced risk of rupture.
Through a network of collaborations, a total of 23 good-quality CT scans of CIAs, suitable for both
morphological assessment and computational flow dynamics, were identified (10 cases of rupture and
13 cases of elective repair of an intact CIA; in 2/23 cases the aneurysms were bilateral). Visual inspection
of the three-dimensional reconstructions of the CT scans suggested that the gross anatomy could be
categorised as one of four types (Table 23), with most of the ruptures being of the saccular or forward-
projecting type. The ruptures had a larger average CIA diameter than the intact CIAs (82.1 mm compared
with 50.3 mm, respectively) and contained larger thrombus and calcium volumes than the intact CIAs. On
average, the ruptured cases had wider bifurcation angles (91° compared with 67° for intact CIA cases) and
more tortuous abdominal aortas than the intact CIA cases. For fusiform aneurysms, five out of eight cases
had a right CIA but the other forms had predominantly left CIAs.
Although wider bifurcation angles were associated with intact AAAs compared with ruptured AAAs,
the converse would appear to hold for an isolated CIA, in which rupture is associated with wide iliac
bifurcation angles. These relationships provide novel mechanistic insights into the role of haemodynamics
(and cellular activation) in precipitating the catastrophic event of aneurysm rupture and are subject to
ongoing computational flow dynamic investigations.
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FIGURE 15 Rupture (marked by an x) usually occurs in regions of low TAWSS.
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Added value from collaborations and future use of IMPROVE trial data
This chapter provides a flavour of the added value emanating from a cohort of carefully phenotyped
participants in a randomised trial. Some of the projects have been completed, whereas others will
continue. In addition, we hope that data from the IMPROVE trial will be used in future high-quality
collaborative studies, particularly to progress the management of patients with intact and ruptured AAAs.
TABLE 23 Categories of gross anatomy of common iliac aneurysms
CIA type Gross anatomy Image
Saccular Large round aneurysm
Forward-projecting The aneurysm protrudes forward with a large area
in the sagittal plane, maintaining a comparatively
small area in the axial and coronal views
Fusiform A less severe dilatation that extends over a section
of the artery in the direction of flow
Kinked There is a tight bend in the CIA, with the aneurysm
immediately distal to this feature; in our data, all
occurred on the left side
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Chapter 9 Concluding remarks and suggestions
for further research
There are few randomised trials carried out in contexts in which emergency surgery is required tosave a patient’s life. As such, this trial presented important challenges in design, implementation
and interpretation.
Trial design
An understanding of the trial design is pivotal to understanding and interpreting the findings of the
IMPROVE trial. The pragmatic design (randomisation of patients at the point of clinical diagnosis by a
senior clinician rather than after rupture had been proved on diagnostic imaging) has been criticised
because it allowed the randomisation of patients without a rupture. In contrast, the design had the
real advantage of reflecting the real-life situation in the emergency room, allowing for non-selective
randomisation and randomisation of the most severely ill and unstable patients and stimulating rapid
recruitment. Originally, another reason for the trial design was that it was feared that delays in CT and
transfer to theatre in the endovascular strategy group might offset any benefits from EVAR; by the time
the trial started, emergency CT scans were more accessible and CT was ubiquitous in both randomised
groups. However, randomisation before CT to assess both rupture and the suitability for EVAR meant that
we were comparing an endovascular strategy (EVAR with the default of open repair when either aortic
morphology or operational reasons precluded EVAR) with open repair. Patients also were randomised
before anaesthetic opinion about their suitability for general anaesthesia and whether or not the necessary
endovascular facilities were available (such as theatre and staffing, including a CT radiographer). The
IMPROVE trial was comparing different strategies for managing patients with suspected aneurysm rupture
and, for this reason, was bound to have a higher rate of treatment non-compliance than most randomised
trials, but it also allowed for a high external validity. The IMPROVE trial design contrasts with the ‘cleaner’
but highly selective designs of the Dutch19 and French22 randomised trials, in which patients were not
randomised until after CT had indicated the presence of a rupture and when the patients were sufficiently
stable to give informed consent. In the IMPROVE trial, the consent process included consent from relatives
and, under the Mental Capacity Act 2005,25 if approved by a senior non-treating clinician. Overall, the
IMPROVE trial was designed to inform service provisions that would result in better outcomes for patients
with ruptured AAAs and to collect data on health economic outcomes as well as the primary outcome of
mortality and the clinical outcome of reinterventions.
Implementation
The early phases of recruitment were slow because of regulatory difficulties and the need for sites to fulfil
the credential criterion of having completed at least five cases of emergency EVAR with reasonable outcomes,
a criterion approved by the Trial Steering Committee. However, in the last 18 months, recruitment was at
the rate of ≈20 participants per month, with more than half of eligible (non-moribund) participants being
randomised. This differs from the very selective randomisation in the Dutch19 and French22 trials, each of
which took ≈7 years to recruit just over 100 participants. There has been criticism that the credential criteria
did not allow for adequate experience in emergency EVAR. However, the timing of the trial was important.
Recruitment took place between 2009 and 2013, before the National Abdominal Aortic Aneurysm Screening
Programme was fully rolled out, which had an impact on the number of ruptures in men. The falling numbers
of ruptures that have been operated on in England after this time emphasises the relevance of these
considerations (Table 24).
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Interpretation
The early results from the IMPROVE trial showed few advantages for an endovascular strategy. By 30 days,
mortality and reinterventions were similar in the two groups; only women (22% of the cohort) seemed to
benefit from the endovascular strategy, in part because of their very high mortality after open repair.
However, on average, participants in the endovascular strategy group (in which 64% were morphologically
suitable for EVAR) spent less time in intensive care and went home sooner than those in the open repair
group, and more often directly to home, leading to lower average costs. Similarly, despite their more
selective designs, the Dutch and French trials also found no difference in 30-day mortality between their
EVAR and open repair groups.
After 1 year, again none of the three trials showed a significantly higher mortality for open repair,
although there was good evidence that the absolute mortality rate, particularly at 30 days, was influenced
by aortic morphology and that those participants who were suitable for EVAR had lower mortality than
those who were not suitable for EVAR, irrespective of the type of repair. This was a real advantage for the
non-selective design of the IMPROVE trial. More importantly for participants in the IMPROVE trial, average
QoL at both 3 and 12 months was better in the endovascular strategy than in the open repair group, with
a QALY gain of borderline significance. Because the majority of costs were related to the primary
admission and, at 1 year, average costs remained lower for the endovascular strategy group, the
endovascular strategy was cost-effective at 1 year.
The IMPROVE trial is the only one of the three recent European trials to report comprehensive 3-year outcomes.
Over time, there was a consistent trend for survival, for QoL to be slightly better and for costs to be lower,
although not always significantly so, in the endovascular strategy group. These trends are amplified by 3 years.
At 3 years, the survival curves had diverged. Compared with the open repair group, the endovascular
strategy had lower mortality, a finding that was particularly evident in the 502 participants for whom repair
of a ruptured aneurysm had started. The reasons for the mid-term difference in survival are possibly related
to the severity and invasiveness of the initial intervention and the subsequent need for intensive care.
Participants in the open repair group had, on average, longer critical care stays than the endovascular
strategy group (6.3 days compared with 4.2 days, respectively), and 46 participants in the open repair group
required renal replacement therapy postoperatively, compared with 32 in the endovascular strategy group.
Because both prolonged stay in critical care and acute kidney injury115,116 are known to be associated with
higher long-term mortality, it may be the differences in critical care that result in the mid-term divergence of
the survival curves.
TABLE 24 The proportion of EVAR procedures compared with open repair procedures used for ruptured AAA
repair in England, since the start of the IMPROVE trial
Year n
Percentage of procedures
EVAR Open repair
2009/10 1888 20.2 79.8
2010/11 1861 26.3 73.7
2011/12 1898 24.9 75.1
2012/13 1893 30.0 70.0
2013/14 1717 33.3 66.7
2014/15 1438 35.6 64.4
2015/16 1545 39.7 60.3
Note
Data are from HES.
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By 3 years, there was no significant difference in QoL between the groups, but the earlier gains in QoL,
together with the survival gain, led to QALYs being significantly greater for the endovascular strategy
group. The reintervention rate was similar between the randomised groups, but the endovascular strategy
group had less severe reinterventions, leading to the overall costs still being lower for the endovascular
strategy group. These factors then combine to give a very high probability (90%) of dominance for the
endovascular strategy on the cost-effectiveness plane.
Contrasting results of the randomised trials in the elective setting and
emergency setting
After aneurysm rupture, an endovascular strategy offers no reduction in operative mortality at 30 or 90 days
but offers an interim survival advantage at 3 years, which, together with the early gains in QoL, leads to a
QALY gain after 3 years. Aneurysm-related reinterventions, particularly the more severe reinterventions, took
place at a similar rate in both groups. For ruptures, the cost differences observed at 30 days (non-significantly
in favour of the endovascular strategy group)21 were not eroded by an increased burden of reinterventions in
later follow-up; therefore, the endovascular strategy was deemed cost-effective. All of these results are in
sharp contrast to those of earlier trials of elective EVAR compared with open repair of AAAs (Table 25).
The earlier trials of elective EVAR compared with open repair enrolled only selected participants who were
known to be suitable for either treatment and mostly adhered strictly to the IFU of the likely endovascular
device. In these trials in the elective setting, participants were younger, on average, by ≈3 years, and the
proportion of women was smaller than in the IMPROVE trial. The trials found that 30-day mortality was
2.5 times lower for the EVAR groups than for the open repair groups but that, after 3 years, there was no
difference in mortality between the groups. The reintervention rate to 5 years and beyond, was always
much higher in the EVAR groups and, if anything, by 1 year, the open repair group had a higher average
QoL and lower average health-care costs. Therefore, there was no evidence that EVAR was cost-effective.
The reasons for these differences in the comparative effectiveness of the endovascular strategy and open
repair in the emergency and elective settings remain speculative. The shock associated with rupture,
especially in those with pre-existing cardiac disease, probably kills many patients irrespective of the type
of repair, but EVAR is less invasive and can be conducted under local anaesthesia, so that patients recover
more rapidly than after open repair. The proportion of women in the IMPROVE trial (22%) was much
higher than in the trials of elective aneurysm repair, and the advantages of the endovascular strategy were
greater in women than in men. The continuing burden of major laparotomy-related reinterventions after
open repair for ruptures (which are not seen after elective open repair) might contribute to both mid-term
TABLE 25 Comparison of mid-term health outcomes from randomised trials for endovascular vs. open repair for
elective and ruptured AAA repair
Parameter
Repair
Elective Rupture
30-day mortality 2.5-fold higher for open repair88 No difference51
3-year mortality No difference88 Endovascular strategy better
Length of primary hospital stay No difference41,117 Shorter for endovascular strategy23
Reintervention rate Twofold to threefold higher after EVAR88 No difference
Major or severe reinterventions Twofold to threefold higher after EVAR89 No difference
QoL Better after open repair or no difference
at 1 year41,118,119
Better at 3 months and 1 year for
endovascular strategy
Costs EVAR higher41,120 Endovascular strategy slightly lower
Cost-effectiveness EVAR not cost-effective91,119–121 Endovascular strategy is cost-effective
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mortality and costs in the open repair group, whereas endovascular devices and the technical skills to
deploy them may have improved since the trials of elective repair were conducted. The reconvergence of
the survival curves beyond 3 years is unexplained too, but this phenomenon has also been observed in the
analysis of Medicare47 and registry data.79 Possible explanations include excess cancer deaths and late
failure of EVAR.
Metrics for reporting reinterventions after emergency aneurysm repair and
patient perspectives
The categorisation of reinterventions for the mid-term follow-up in the IMPROVE trial was based on
clinician opinion of the severity of the intervention and whether or not the life of the patient was
threatened if the reintervention was not successful. The scoring system used was based on the one
developed for the very long-term follow-up of the EVAR 1 trial,89 with additional reinterventions that were
more specific to rupture and laparotomy-related complications scored by consensus of the IMPROVE trial
investigators. The acceptance of scoring reinterventions on a scale from 1 to 5 would argue that similar
scoring systems, with specific reporting metrics for events such as secondary rupture and late conversions
to open repair, should be incorporated into the National Vascular Registry and similar data sets. Perhaps
more importantly, the low number of patients and members of the public who were consulted had very
different opinions to clinicians about the severity of reinterventions. They were unanimous in ranking
amputation as the most feared complication or reintervention. These observations argue for the need for
further work to incorporate patients’ opinions into the metrics used for reporting the outcomes of
ruptured AAA repair.
Implications for future health care
The findings from the IMPROVE trial suggest that an endovascular strategy is better than open repair for a
ruptured AAA. Therefore, a strong case can be made that all providers of emergency vascular services
should be able to offer both emergency EVAR and open repair at all times (24 hours a day, 7 days a week).
This requires considerable logistics with respect to the availability of appropriate personnel, facilities and
consumables. Not all IMPROVE trial centres could offer randomisation every day of the week because
specialist endovascular teams and/or facilities were not available. As a result, 26 out of 259 participants with
a confirmed rupture and morphological suitability for EVAR and who were randomised to the endovascular
strategy subsequently underwent open repair because the endovascular team and/or facility was not
immediately available. The evidence from other centres across the world suggests that the use of standard,
well-rehearsed protocols for ruptured aneurysm repair can reduce operative mortality, particularly for
EVAR.54,122 The development of optimal protocols and training is being addressed by the relevant
professional bodies in the UK. The IMPROVE trial has shown that about one-third of patients are not
morphologically suitable for standard EVAR, and using EVAR in morphologically unsuitable patients is
associated with a high 30-day mortality. Therefore, the real challenges in the future may be associated with:
l providing sufficient capacity for emergency endovascular services
l the potential further restructuring of services for emergency vascular care to allow patients to be
treated in centres that also have expertise in either emergency open surgery or complex endovascular
surgery (e.g. using fenestrated or branched endografts), for the treatment of patients who are not
morphologically suitable for standard EVAR
l ensuring the equitable availability and continuing cost-effectiveness of emergency vascular services.
Data from HES indicate that the proportion of emergency AAA repairs being carried out by EVAR is
increasing year on year (see Table 24). The conduct and results of the IMPROVE trial may have contributed
to these changes and further emphasises the need to provide sufficient capacity for emergency endovascular
services. Given the findings of the IMPROVE trial, it would seem important for the health service to have
sufficient capacity to ensure that the proportion of emergency AAA repairs that are undertaken by EVAR
rather than open repair increases further.
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Suggestions for further research
These arise both from the trial itself and the associated studies described in Chapters 4, 7 and 8. Two very
crucial pieces of further research are suggested:
1. Formal assessment of whether or not avoidance of general anaesthesia improves the survival of patients
undergoing EVAR for ruptured AAA repair.
2. Improving resuscitation techniques for older persons with circulatory collapse, including the identification
of evidence-based blood pressure targets, which can be incorporated into guidelines. This research
should include but not be limited to ruptured aneurysms.
Other significant recommendations for further research include:
l To consider whether or not emergency paramedical staff and general practitioners could diagnose
ruptured AAA with sufficient accuracy to allow the direct transfer of patients from home to a specialist
vascular centre.
l To assess metrics, other than mortality, for reporting the outcomes of emergency surgery, which
include the viewpoints of patients, timelines to treatment and avoidance of secondary transfers.
l To assess whether or not further centralisation of emergency vascular services may be required to
allow provision of sufficient expertise in emergency complex endovascular repair (using fenestrated or
branched endografts) and open repair of juxtarenal aneurysms and other aortoiliac aneurysms that are
unsuitable for standard EVAR, as well as to increase the availability of emergency standard EVAR and
open repair at all times (24 hours a day, 7 days a week).
l With the introduction of AAA screening for men, an increasing proportion of ruptures is likely to be in
women and there is a need for the acquisition and analysis of more sex-specific data that might lead to
further suggestions for improving outcomes for women.
In addition, and not specifically related to ruptured AAAs:
l to consider the practice of consent waivers and post-randomisation consent for trials of emergency
medical treatment that is required to save a patient’s life.
Final words
This trial would not have been possible without the real commitment and enthusiasm of the vascular
surgical community in the UK, as part of their enthusiasm to provide better-quality care for their patients.
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Trial progress and recruitment
The IMPROVE trial organisation and committees
Grant applicants: Professor Janet T Powell (Chief Investigator), Mr Bruce Braithwaite, Professor
Nicholas J Cheshire, Professor Roger M Greenhalgh, Professor Richard J Grieve, Dr Tajek B Hassan,
Professor Robert J Hinchliffe, Dr Simon Howell, Dr Fionna Moore, Dr Anthony A Nicholson, Professor
Chee V Soong (deceased), Professor Matthew T Thompson and Professor Simon G Thompson.
Data and trial management: Dr Pinar Ulug (Trial Manager) and Ms Francine Heatley (Trial Manager,
maternity cover, 2012–13), Ms Aisha Anjum (Trial Monitor, 2012–14) and Ms Gosia Kalinowska
(Trial Administrator, 2014).
Statistical analyses: Dr Michael J Sweeting and Professor Simon G Thompson.
Health economics costs analyses: Dr Manuel Gomes and Professor Richard J Grieve.
Trial Management Committee: Professor Janet T Powell (Chairperson), Dr Raymond Ashleigh, Dr Manuel Gomes,
Professor Roger M Greenhalgh, Professor Richard J Grieve, Professor Robert J Hinchliffe, Dr Michael J Sweeting,
Professor Matthew T Thompson, Professor Simon G Thompson and Dr Pinar Ulug.
Trial Steering Committee: Professor Ian Roberts (Chairperson), Professor Sir Peter RF Bell, Mrs Anne Cheetham,
Ms Jenny Stephany (2009–2012) and Professor Alison Halliday.
Data Monitoring and Ethics Committee: Professor Charles Warlow (Chairperson), Mr Peter Lamont,
Professor Jonathan Moss and Professor Jan Tijssen.
Credentialing committee: Mr Bruce Braithwaite and Dr Anthony A Nicholson.
Core laboratory: Professor Matthew T Thompson, Dr Raymond Ashleigh and Luke Thompson.
The IMPROVE trial local investigators by participating NHS trust (in order of site start date from the earliest
(September 2009) to the most recent (February 2013); numbers in parentheses indicate the number of
participants entered into the trial:
l UK – Colin D Bicknell and Nicholas J Cheshire (to October 2014), Imperial College Healthcare NHS Trust,
London (20); Jonathan R Boyle, Addenbrooke’s Hospital, Cambridge (40); Ferdinand Serracino-Inglott
and J Vince Smyth (December 2012 to November 2013), Manchester Royal Infirmary, Manchester
(69); Matthew T Thompson and Robert J Hinchliffe, St George’s Hospital, London (75); Rachel Bell,
St Thomas’ Hospital, London (81); Noel Wilson, Kent and Canterbury Hospital, Canterbury (23);
Matt Bown and Martin Dennis (to December 2010), Leicester Royal Infirmary, Leicester (18); Meryl Davis,
Royal Free Hospital, London (1); Raymond Ashleigh, Wythenshawe Hospital, Manchester University NHS
Foundation Trust, Manchester (21); Simon Howell, Leeds General Infirmary, Leeds (23); Michael G Wyatt,
Freeman Hospital, Newcastle (23); Domenico Valenti, King’s College Hospital NHS Foundation Trust,
London (2); Paul Bachoo, Aberdeen Royal Infirmary, Aberdeen (4); Paul Walker, The James Cook
University Hospital, Middlesbrough (5); Shane MacSweeney, Queen’s Medical Centre, Nottingham
(34); Jonathan N Davies, Royal Cornwall Hospital, Truro (5); Dynesh Rittoo and Simon D Parvin (to
December 2011), Royal Bournemouth Hospital, Bournemouth (22); Syed Waquar Yusuf, Royal Sussex
County Hospital, Brighton (5); Colin Nice, Queen Elizabeth Hospital, Gateshead (5); Ian Chetter,
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Hull Royal Infirmary, Hull (32); Adam Howard, Colchester General Hospital, Colchester (24); Patrick Chong,
Frimley Park Hospital, Surrey (14); Raj Bhat, Ninewells Hospital, Dundee (8); David McLain, Royal Gwent
Hospital, Newport; Andrew Gordon and Ian Lane (to June 2012), University Hospital of Wales, Cardiff
(4); Simon Hobbs, New Cross Hospital, Wolverhampton (3); Woolagasen Pillay, Doncaster Royal Infirmary,
Doncaster (8); Timothy Rowlands and Amin El-Tahir (to November 2012), Royal Derby Hospital, Derby
(13); John Asquith, Royal Stoke University Hospital, Stoke-on-Trent (15); and Stephen P Cavanagh,
The York Hospital, York (3).
l Canada – Luc Dubois and Thomas L Forbes (to August 2014), London Health Sciences Centre and
Western University, London, Ontario (13).
Trial co-ordinators: Emily Ashworth, Ayoola Awopetu, Sara Baker, Hashem Barakat, Patricia Bourke,
Claire Brady, Joanne Brown, Jennie Bryce, Christine Bufton, Debbie Campbell, Tina Chance,
Angela Chrisopoulou, Marie Cockell, Andrea Croucher, Gail Curran, Leela Dabee, Nikki Dewhirst,
Jo Evans, Christopher Fenner, Andy Gibson, Siobhan Gorst, Moira Gough, Norma Gourlay, Lynne Graves,
Michelle Griffin, Josie Hatfield, Florence Hogg, Susannah Howard, Cían Hughes, Thomas Hughes,
Alex James, Elizabeth Keene, Michelle Lapworth, Ian Massey, David Metcalfe, Awad Mohalhal,
Teresa Novick, Daré Oladokun, Gareth Owen, Noala Parr, David Pintar, Joanna Smee, Tom Smith,
Sarah Spencer, Helen Thompson, Claire Thomson, Orla Thunder, Tom Wallace, Sue Ward, Vera Wealleans,
Lesley Wilson, Janet Woods, Manu Zachariah and Ting Zheng.
Writing committee for reporting of 30-day outcomes: Janet T Powell (Chairperson), Michael J Sweeting,
Matthew T Thompson, Raymond Ashleigh, Rachel Bell, Manuel Gomes, Roger M Greenhalgh,
Richard J Grieve, Francine Heatley, Robert J Hinchliffe, Simon G Thompson and Pinar Ulug.
Writing committee for reporting of 1-year and 3-year outcomes: Raymond Ashleigh, Manuel Gomes,
Roger M Greenhalgh, Richard J Grieve, Robert J Hinchliffe, Janet T Powell (Chairperson), Michael J Sweeting,
Matthew T Thompson, Simon G Thompson and Pinar Ulug.
Referral of patients with ruptured aneurysms, trial recruitment,
participant flow and completeness of participant follow-up
The trial started in April 2009, with the recruitment of 600 participants initially planned to take place
between October 2009 and December 2011 in 20–24 centres across the UK. Obtaining all of the relevant
permissions for the trial to start in these centres was much slower than anticipated (Figure 16). The
availability of centres to start recruiting is shown in Figure 17 and recruitment to December 2011 is shown
in Figure 18. The slow recruitment led us to investigate whether or not patients were being appropriately
referred into the trial centres.
The referral of patients with ruptured abdominal aortic aneurysm and
the development of guidelines for patient transfer
The aims of these studies were to explore areas of consensus and disagreement concerning the interhospital
transfer of patients with a clinical diagnosis of ruptured AAA. A three-round Delphi questionnaire approach
was used among vascular and endovascular surgery from the IMPROVE trial and emergency medicine
specialists, from IMPROVE trial centres and the NHS Wessex Clinical Strategic Network, to explore patient
characteristics and clinical management issues for emergency interhospital transfer. Agreement was reported
when 70% of respondents were in agreement. Initially, there was agreement that transfer patients should
be: < 85 years of age, either alert or with fluctuating consciousness, with moderate or minimal systemic
disease and needing no or some help with daily living. Round 3 clarified that patients requiring inotropes and
those who were institutionalised for mental infirmity should be transferred. Those with cardiac arrest in a
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FIGURE 16 Time from NHS Site-Specific Information Form submission to NHS approval by December 2010. The
vertical axis shows the site number. The average time to approval for 22 centres was 7 months. Site-Specific
Information Forms initiate the permission process in the Integrated Research Application System.
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FIGURE 17 Progress with centres that were able to recruit. The target number of centres had opened by
October 2010, > 12 months behind schedule.
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current episode should not be transferred. There was no agreement regarding whether or not those who
were institutionalised with physical infirmities, unconscious and/or intubated patients or those with severe
systemic disease should be transferred. Speed was accepted as important, with agreement for specialty
trainees to arrange transfer, if consultants were not on-site. Consultant–consultant discussion was
recommended for patients with severe systemic disease. CT confirmation of diagnosis was considered
unnecessary before transfer (but ultrasound assessment was desirable) and transfers should not be delayed
by waiting for specific tests. There was no agreement about blood tests and electrocardiography before
transfer or whether or not blood should accompany the patient being transferred. There was no agreement
regarding whether or not specific staff and/or facilities needed to be in place at the specialist hospital. A
systolic blood pressure of ≥ 70mmHg was sufficient for transfer without the need for intravenous fluids,
unless deterioration occurred. Overall, broad agreement about the type of patient who should be eligible for
transfer was achieved but disagreements about patient management issues, before and during transfer,
remained. These findings were reported by Hinchliffe et al.62 and led to the development of guidelines for
patient referral, which have been adopted by the Royal College of Emergency Medicine, The Vascular Society
of Great Britain and Ireland and the Royal Society of Radiologists.24
Trial extensions and final trial recruitment
Owing to the slow start to recruitment, the trial was awarded a 15-month extension, with the new target of
recruiting 600 participants by the end of June 2013 and with follow-up and reporting to be completed by
July 2014 (which meant that many of the participants who were recruited in 2013 would have been followed
up for < 1 year). Additional centres were opened to achieve this. However, the ongoing reorganisation of
vascular surgical services resulted in some centres, such as King’s College Hospital NHS Foundation Trust
(London), Queen Elizabeth Hospital (Gateshead) and New Cross Hospital (Wolverhampton), being closed.
The recruitment target of 600 participants was achieved during the revised recruitment period and additional
participants were randomised during early July 2013, during the period when sites were being notified of the
close to recruitment (Figure 19).
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FIGURE 18 Recruitment to December 2011.
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All centres also maintained a log of non-recruited patients, providing reasons (Table 26). Both the recruited and
non-recruited participants are shown in the trial CONSORT diagram (Figure 20). In summary, 1275 patients
were identified with a diagnosis of ruptured AAA, 623 were randomised and 652 were not randomised.
The Data Monitoring Committee approved the post-randomisation exclusion of 10 patients (three in the
endovascular strategy group and seven in the open repair group) deemed ineligible because of violation
of the inclusion. Two patients had a secondary rupture with previous aneurysm repair, one patient was
admitted electively for aneurysm repair, three patients were randomised without consent before reaching
the trial centre and the in-hospital clinical diagnosis was not ruptured aneurysm and four patients could
not be identified in any hospital records. It is assumed that these four patients were randomised before
reaching hospital and did not arrive alive.
The 30-day outcomes that were reported included mortality (the primary outcome measure),
reinterventions, length of hospital stay, place of discharge and aneurysm morphology.
The new outcome measures that were included at the 1-year time point were QoL and use of health resources,
both obtained from questionnaires, and cost-effectiveness. The Health Economist for the trial, Richard J Grieve,
was spearheading methodological developments that would add to the robustness of the cost-effectiveness
evaluations and we realised that half of the participants remained alive at 3 years after randomisation; a
further extension request was submitted and granted. This second extension provided for cost-effectiveness
reporting over a longer and more relevant time horizon and the follow-up of all participants for 3 years after
randomisation, with closure and final reporting in December 2016. For the 1- to 3-year time period, the
responsibility for collecting reintervention data was transferred from the local trial co-ordinators to the trial
manager and audit team. Because the large majority of participants were from English sites, we planned to
use HES to supplement the audit, particularly to collect information about aneurysm-related reinterventions
at non-trial hospitals. Our final sources of data concerning first reinterventions are shown in Table 27.
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TABLE 26 Non-randomised patients, with reasons
Participating centrea
Reason (n)
Total
excluded (n)
Within
inclusion
criteriab
Patient
preferencec Operationald
Clinician
preference Unknown
Imperial College London
(St Mary’s Hospital and
Charing Cross Hospital)
13 1 0 3 1 18
Addenbrooke’s Hospital 29 0 2 7 13 51
Manchester Royal Infirmary 3 1 0 0 0 4
St George’s Hospital 11 1 0 1 5 18
St Thomas’ Hospital 24 6 0 0 0 30
Kent and Canterbury
Hospital
4 1 1 0 0 6
Leicester Royal Infirmary 49 7 31 3 4 94
Wythenshawe Hospital 8 0 1 5 34 48
Leeds General Infirmary 22 4 4 3 6 39
Freeman Hospital 40 2 24 1 11 78
King’s College Hospital 0 0 0 0 2 2
James Cook University
Hospital
9 1 2 1 0 13
Queen’s Medical Centre 44 2 1 13 0 60
Royal Cornwall Hospital 7 0 6 0 1 14
Royal Bournemouth Hospital 0 2 0 0 0 2
Royal Sussex County
Hospital
1 0 15 0 0 16
Queen Elizabeth Hospital 5 0 3 0 0 8
Hull Royal Infirmary 5 1 0 8 0 14
Colchester General Hospital 19 3 0 0 15 37
Frimley Park Hospital 4 1 4 0 0 9
Royal Gwent Hospital and
University Hospital of Wales
13 1 12 0 0 26
New Cross Hospital 3 0 2 1 0 6
Doncaster Royal Infirmary 4 0 1 0 1 6
Royal Derby Hospital 8 6 0 1 4 19
Royal Stoke University
Hospital
6 0 0 0 0 6
London Health Sciences
Centre and Western
University
23 2 2 1 0 28
Total 354 42 111 48 97 652
a Four participating centres did not provide data for non-randomised patients.
b Includes participants who were unfit for CT and/or intervention; EVAR suitability was pre-established.
c Refusal of trial, preference for a specific treatment or preference for no treatment.
d No radiology cover, EVAR suite not available, etc.
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Other
discharge
diagnosis
[n = 22;
3 (14%) died]
Randomised
(n = 623)
Excluded after Data
Monitoring Committee review
(n = 10a)
Endovascular
strategy
(n = 316)
Open repair
(n = 297)
Other
discharge
diagnosis
[n = 33;
11 (33%) died]
EVAR
[n = 150;
38 (25%) died]
Open repair
[n = 112 (28b); 
43 (38%) died]
Open repair
[n = 220;
81 (37%) died]
EVAR
[n = 36;
8 (22%) died]
No repair
[n = 17;
16 (94%) died]
No repair
[n = 19;
19 (100%) died]
• Ruptured AAA, n = 275
• Symptomatic, n = 8
• Ruptured AAA, n = 261
• Symptomatic, n = 14
Patients with admission
clinical diagnosis of 
ruptured AAA
(n = 1275)
Excluded
(n = 652)
Eligible for
analysis
(n = 613)
Overall 112/316 (35%) died Overall 111/297 (37%) died
EVAR converted
to open repair
[n = 4; 4 (100%) died]
• Within exclusion criteria, n = 354
• Patient preference, n = 42
• Clinician preference, n = 48
• Operational reasons, n = 111
• Unknown reason, n = 97
 
FIGURE 20 A CONSORT diagram for outcomes to 30 days. a, Breach of protocol; numbers include two and three symptomatics in the endovascular strategy group and the
open repair group, respectively. b, 28 morphologically suitable for EVAR.
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Owing to delays in obtaining data from HES to report aneurysm-related admissions and reinterventions at
non-trial hospitals (received 16 December 2016), a further extension of 3 months, to 31 March 2017, was
obtained. CONSORT diagrams show the completeness of follow-up at 1 year and 3 years (Figures 20 and 8,
respectively). At these stages, information from HES and similar sources was used to check for hospital
admissions and procedures during the first 1 and 3 years after randomisation.
The trial, its extensions and its reporting deadlines are summarised in Figure 21.
TABLE 27 Source of aneurysm-related reintervention data in 502 participants in whom repair of a rupture
had started
Time period
for first
reintervention
(years)
Primary source
according to the
protocol
Participants per data source (n)
Participants
identified with
reinterventions (n)
Trial
co-ordinator HESa
Participant
questionnaires Audit
0–1 Trial co-ordinator 162 5 2 22 191, with 0 at non-trial
hospitals
1–3 Audit, supported
by HES
20 10 1 17 48, with 2 at non-trial
hospitals
a Health Episode Statistics for England only, providing data for trial and non-trial hospitals to 3 years after participant
discharge from primary admission. During the first year, all data from HES or questionnaires were subsequently verified
by the trial co-ordinators; there were an additional six participants with other surgery not related to the AAA. Between
1 and 3 years, all data from HES or questionnaires were verified by audit. Data from the trial co-ordinators were verified
by audit.
Audit also identified participants with first and subsequent reinterventions beyond 3 years.
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April
2009
2010 2011 2012 2013 2014 2015 2016 2017
Initial
contract
Recruitment and reporting of 30-day and
1-year outcomes
Recruitment 330 patients
Plus first
extension
To allow for recruitment of 600 patients by June 2013 (accomplished)
Recruitment 613 patients
Outputs 30-day
mortality
BMJ/BJS
(1) Morphology
and 30-day
outcomes
(2) 1-year
clinical
effectiveness 
and cost-
effectiveness
outcome
(3) Individual 
patient data 
meta-analysis 
of three trials
Interim
3-year
results to
Vascular
Society
3-year
results
at Charing
Cross
Symposium
and Society 
for Vascular
Surgery
Plus second
extension
To allow for 3-year follow-up of all patients by July 2016 and individual patient meta-analyses of all European
trials
No cost
extension
for HES
data
Future
outputs
(1) 3-year
clinical 
effectiveness 
and cost-
effectiveness
(2) Risk
scoring
(3) Further
morphology
data
(4) Video
overview
FIGURE 21 Overview of the trial. BJS, British Journal of Surgery; BMJ, British Medical Journal; HES, Hospital Episode Statistics.
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Appendix 2 Additional tables and figures
TABLE 28 Unit costs (GBP) for 1-year analyses
Description Unit
Cost (£)
Source
Open
repair
Endovascular
strategy
Medical devices and parts
Endovascular stent and parts Patient 5700 Medtronic (Minneapolis, MN, USA) and
Cook Medical (Bloomington, IN, USA)a
Vascular graft (straight) Patient 623 Maquet (Rastatt, Germany)
Vascular graft (bifurcated) Patient 901 Maquet
Consumables
Endovascular package Patient 600 Maquet and Cook Medical
Mechanical retractor Patient 90 Health-Care Equipment (Surrey, UK)
Cell salvage Patient 74 Davies et al. 2006123
Surgical instrument set Patient 51 51 Health-Care Equipment
Anaesthetics and other drugs Patient 184 41 British National Formulary 2012b
Contrast agent ml 0.10 0.10 IMPROVE trial centresb
Blood Unit 132 132 NHS Blood and Transplant 2012
Platelets Unit 205 205 NHS Blood and Transplant 2012
Fresh-frozen plasma Unit 25 25 NHS Blood and Transplant 2012
CT scan Unit 105 105 NHS Reference Costs 201229
Emergency room Minute 0.40 0.40 Dixon et al. 2009124
Overheads
Theatre Minute 2.65 2.65 IMPROVE trial centres
Staffc
Surgeon (consultant) Minute 2.20 2.20 PSSRU 201228
Surgeon (registrar) Minute 1.16 1.16 PSSRU 201228
Anaesthetist (consultant) Minute 2.20 2.20 PSSRU 201228
Anaesthetist (registrar) Minute 1.16 1.16 PSSRU 201228
ODA Minute 0.58 0.58 PSSRU 201228
Scrub nurse Minute 0.72 0.72 PSSRU 201228
Runner Minute 0.58 0.58 PSSRU 201228
Senior house officer Minute 0.83 PSSRU 201228
Radiologist (consultant) Minute 2.20 PSSRU 201228
Radiologist (registrar) Minute 1.16 PSSRU 201228
Radiographer Minute 0.58 PSSRU 201228
Radiologist nurse Minute 0.72 PSSRU 201228
continued
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TABLE 28 Unit costs (GBP) for 1-year analyses (continued )
Description Unit
Cost (£)
Source
Open
repair
Endovascular
strategy
Critical care
ITU/HDU: one organ supported Bed-day 630 630 NHS Reference Costs 201229
ITU/HDU: two organs supported Bed-day 870 870 NHS Reference Costs 201229
ITU/HDU: three organs supported Bed-day 1214 1214 NHS Reference Costs 201229
ITU/HDU: four organs supported Bed-day 1410 1410 NHS Reference Costs 201229
ITU/HDU: five organs supported Bed-day 1587 1587 NHS Reference Costs 201229
ITU/HDU: six organs supported Bed-day 1759 1759 NHS Reference Costs 201229
ITU/HDU: seven organs supported Bed-day 2000 2000 NHS Reference Costs 201229
Other hospital care
Inpatient coronary care unit Bed-day 436 436 NHS Reference Costs 201229
Inpatient stroke unit Bed-day 309 309 NHS Reference Costs 201229
Inpatient routine wardd Bed-day 260 260 NHS Reference Costs 201229
Outpatient doctor visit Visit 139 139 PSSRU 201228
Outpatient nurse visit Visit 85 85 PSSRU 201228
Outpatient haemodialysis Session 65 65 NHS Blood and Transplant, Price list
2011/12
Community care
Nursing home Bed-day 105 105 PSSRU 201228
Family doctor visite Visit 55 55 PSSRU 201228
Nurse at home visite Visit 18 18 PSSRU 201228
HDU, high-dependency unit; ITU, intensive therapy unit; ODA, operating department assistant; PSSRU, Personal Social
Services Research Unit.
a Average (range from £5400 to £6500) list price of the EVAR stents and parts that are most supplied to NHS hospitals for
ruptured AAAs [Endurant™ (Medtronic, Minneapolis, MN, USA) and Zenith Flex® (Cook Medical, Bloomington,
IN, USA)].
b Local and general anaesthesia components were taken from one IMPROVE trial centre.
c Typical levels of staff use in theatre were recorded in 10 IMPROVE trial centres.
d The same tariff was applied to routine wards in both primary and secondary hospitals.
e Assuming 15-minute appointments.
Note
Reproduced from the IMPROVE Trial Investigators.23 © The Authors 2015. Published by Oxford University Press on behalf of
the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use,
distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please
contact journals.permissions@oup.com.
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TABLE 29 Survey of staff (who were present in the operating suite for endovascular repair and open repair);
from 10 IMPROVE trial centres in November 2012
Staff use by type of operation
Trial centre number (n)
Total (n) Base case
Sensitivity
analysis1 2 3 4 5 6 7 8 9 10
Open repair
Anaesthetist (consultant) 0 0 1 1 1 1 1 0 1 1 10 ✓ ✓
Anaesthetist (registrar) 1 1 1 1 1 1 1 1 1 1 7 ✓ ✓
Vascular surgeon (consultant) 1 1 1 1 1 1 1 1 1 1 10 ✓ ✓
Vascular surgeon (registrar) 1 1 1 1 1 1 1 1 1 1 10 ✓ ✓
ODA (grade 5) 1 1 1 1 1 1 1 1 1 1 10 ✓ ✓
Scrub nurse (grade 6) 1 1 1 1 1 1 1 1 1 1 10 ✓ ✓
Runner (grade 5) 1 1 1 1 1 1 1 1 1 1 10 ✓ ✓
House officer (level 2) 0 1 0 1 0 0 0 0 0 1 3 ? ✓
Second nurse (grade 5) 0 1 0 0 0 0 0 0 0 0 1 ? ✓
Second runner (grade 5) 1 0 1 0 0 0 0 1 0 0 3 ? ✓
Second surgeon (consultant) 0 0 0 1 0 0 0 0 0 0 1 ? ✓
Second surgeon (registrar) 0 0 0 1 0 0 0 0 0 1 2 ? ✓
EVAR
Anaesthetist (consultant) 1 1 1 1 1 1 1 1 1 1 10 ✓ ✓
Anaesthetist (registrar) 0 0 1 0 0 1 1 0 1 1 5 ✓ ✓
Vascular surgeon (consultant) 1 1 1 1 1 1 1 1 1 1 9 ✓ ✓
Vascular surgeon (registrar) 0 1 1 1 1 1 1 1 1 1 10 ✓ ✓
ODA (grade 5) 1 1 1 1 1 1 1 1 1 1 10 ✓ ✓
Scrub nurse (grade 6) 1 1 1 1 1 1 1 1 1 1 10 ✓ ✓
Runner (grade 5) 1 1 1 1 1 1 1 1 1 1 10 ✓ ✓
Radiographer 1 1 1 1 1 1 1 1 1 1 10 ✓ ✓
Radiologist (consultant) 1 1 1 0 1 1 1 1 1 1 9 ✓ ✓
Radiology nurse (grade 6) 1 1 0 0 0 1 0 1 1 1 6 ✓ ✓
Second runner (grade 5) 0 0 1 0 0 0 0 1 0 0 2 ? ✓
Radiologist (registrar) 0 0 0 0 1 0 1 0 1 0 3 ? ✓
ODA, operating department assistant.
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TABLE 30 Resource use and costs (GBP) to 30 days, by randomised group
Cost component
Treatment group
Endovascular strategy (N= 316) Open repair (N= 297)
Primary admissions
Time in emergency room (minutes), mean (SD)a 93 (370) 73 (157)
Cost (£) 136 (138) 119 (51)
Devices and consumables (£), mean (SD) 4337 (2915) 2523 (2036)
Time in theatre (minutes), mean (SD)b 156 (100) 180 (107)
Cost (£) 2050 (1290) 2101 (1264)
Days in critical care, mean (SD) 4.2 (5.9) 6.3 (7.7)
Cost (£) 5249 (8779) 8100 (11,020)
Days on routine ward, mean (SD)c 5.2 (5.0) 5.7 (6.7)
Cost (£) 1425 (1591) 1518 (1814)
Reinterventions, n (%) 44 (14) 48 (16)
Cost (£), mean (SD) 172 (581) 224 (1042)
Readmissions
Number of readmissions, n (%) 6 (1.7) 5 (1.9)
Cost (£), mean (SD) 64 (554) 34 (290)
Total hospital stay (days), mean (SD) 9.8 (9.0) 12.2 (10.2)
Total cost (£), mean (SD) 13,433 (10,354) 14,619 (12,353)
Incremental cost (£) (95% CI) –1186 (–2997 to 625)
a Includes costs of CT and contrast agent.
b The unit cost of theatre time for those who actually received the EVAR procedure was £885 per hour and, for those
who actually received open repair, was £675 per hour; reflecting the additional staff required for the EVAR procedure.
c Participants who did not undergo aneurysm repair (8.9%) were assumed to stay on a routine ward throughout
the hospitalisation.
Note
For ≈8% of participants, resource use data were missing; results reported are following multiple imputations. Unit costs are
reported Table 28.
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TABLE 31 Variables considered for multiple imputations and imputation models considered
Variable Missing values, n (%)a Imputation model
Baseline variables and vital status
Randomised group (endovascular strategy vs. open repair) 0 (0) None required
Age 0 (0) None required
Sex 0 (0) None required
Loss of consciousness during care episode 27 (4) Logistic regression
Admission haemoglobin 6 (1) Predictive mean matching
Admission creatinine 13 (2) Predictive mean matching
Acute myocardial ischaemia 52 (8) Logistic regression
Maximum aortic diameter 95 (15) Predictive mean matching
Aneurysm neck diameterb 230 (38) Predictive mean matching
Aneurysm proximal neck angleb 132 (22) Predictive mean matching
Aneurysm neck lengthb 132 (22) Predictive mean matching
Death within 1 year 2 (0) None done
Resource use variables
Primary admission: time in theatre 22 (4) Predictive mean matching
Primary admission: days in critical care 13 (2) Predictive mean matching
Primary admission: days in routine ward 48 (8) Predictive mean matching
Primary admission: reintervention time in theatre 22 (4) Predictive mean matching
Readmissions at 3 months: days in critical care 20 (6) Predictive mean matching
Readmissions at 12 months: days in critical care 32 (11) Predictive mean matching
Readmission at 3 months: days in routine ward 19 (6) Predictive mean matching
Readmission at 12 months: days in routine ward 31 (10) Predictive mean matching
Outpatient visits at 3 months 37 (12) Predictive mean matching
Outpatient visits at 12 months 47 (16) Predictive mean matching
Family doctor visits at 3 months 75 (24) Predictive mean matching
Family doctor visits at 12 months 83 (28) Predictive mean matching
Nurse at-home visits at 3 months 62 (19) Predictive mean matching
Nurse at-home visits at 12 months 68 (23) Predictive mean matching
QoL variables
EQ-5D at 3 months 66 (21) Predictive mean matching
EQ-5D at 12 months 72 (24) Predictive mean matching
a For baseline variables, vital status and primary admissions, the overall sample size was the total number of randomised
participants (n= 613). For other resource use and QoL variables, the relevant sample sizes were the total numbers of
participants who were eligible for the 3-month and 12-month follow-ups (n= 318 and n= 301, respectively).
b Measurements from the core laboratory.
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TABLE 32 Quality-of-life (EQ-5D) health state profiles for participants with a proven rupture, who commenced an
operation and who were alive and fully completed the questionnaire at 3 months and 12 months post randomisation
EQ-5D component
Time point, n (%)
3 monthsa 12 monthsb
Endovascular strategy
(N= 138)
Open repair
(N= 114)
Endovascular strategy
(N= 127)
Open repair
(N= 102)
Mobility
1 74 (54) 51 (45) 63 (50) 55 (54)
2 64 (46) 60 (53) 65 (51) 48 (47)
3 1 (1) 3 (3) 0 (0) 2 (2)
Self-care
1 116 (84) 76 (67) 112 (88) 82 (80)
2 21 (15) 34 (30) 15 (12) 20 (20)
3 1 (1) 5 (4) 1 (1) 4 (4)
Usual activities
1 60 (43) 49 (43) 59 (46) 61 (60)
2 71 (51) 51 (45) 63 (50) 36 (35)
3 8 (6) 15 (13) 5 (4) 9 (9)
Pain/discomfort
1 82 (59) 58 (51) 76 (60) 62 (61)
2 53 (38) 52 (46) 51 (40) 36 (35)
3 4 (3) 4 (4) 1 (1) 7 (7)
Anxiety/depression
1 101 (73) 83 (73) 93 (73) 74 (73)
2 37 (29) 27 (24) 33 (26) 27 (26)
3 1 (1) 4 (4) 2 (2) 2 (2)
a Thirty (18%) and 36 (24%) participants had incomplete 3-month questionnaires in the endovascular strategy and open
repair groups, respectively.
b Thirty-four (21%) and 38 (27%) participants had incomplete 12-month questionnaires in the endovascular strategy and
open repair groups, respectively.
Notes
Key: 1= no problems, 2= some problems and 3= severe problems.
Results are presented for the samples with complete information. The numbers of complete responses/eligible participants
are as follows: at 3-months, 138/168 (82%) (endovascular strategy) and 114/150 (76%) (open repair); at 12-months,
127/161 (79%) (endovascular strategy) and 102/140 (73%) (open repair).
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TABLE 33a Unadjusted and adjusted HRs for the endovascular strategy compared with open repair, for both
all-cause mortality and aneurysm-related mortality for all available follow-up data: overall
n HR (95% CI) p-value
All-cause mortality
Unadjusted 613 0.92 (0.75 to 1.13) 0.41
Adjusteda (complete cases) 397 0.89 (0.69 to 1.16) 0.39
Adjusteda (multiply imputed) 613 0.91 (0.74 to 1.12) 0.38
Aneurysm-related mortality
Unadjusted 613 0.89 (0.69 to 1.16) 0.41
Adjusteda (complete cases) 397 0.88 (0.64 to 1.22) 0.45
Adjusteda (multiply imputed) 613 0.90 (0.69 to 1.16) 0.42
a Adjusted for age, sex, Hardman index, lowest systolic blood pressure and neck length.
TABLE 33b Unadjusted and adjusteda HRs for the endovascular strategy compared with open repair, for both
all-cause mortality and aneurysm-related mortality for all available follow-up data: by time period
n (remaining under follow-up) HR (95% CI) p-value
All-cause mortality
0–3 months 613 0.98 (0.76 to 1.26) 0.88
> 3 months 373 0.80 (0.57 to 1.15) 0.23
Aneurysm-related mortality
0–3 months 613 0.90 (0.69 to 1.17) 0.43
> 3 months 373 0.91 (0.34 to 2.43) 0.85
a Adjusted for age, sex, Hardman index, lowest systolic blood pressure and neck length.
TABLE 34 Reinterventions in the first 3 years of follow-up, by operation commenced, for participants with a final
diagnosis of ruptured AAA
AAA-related reintervention
Participants with ruptured AAA in whom repair
started (N= 502)
Endovascular strategy
commenceda (N= 182)
Open repair
commencedb
(N= 320) p-value
Participants with at least one reintervention, n/N (%) 52/182 (29) 88/320 (28) 0.80
Reinterventions/person-years (rate per 100 person-years),
(%)
77/338.1 (22.8) 153/513.0 (29.8) 0.054
Arterial, n (%) 66 (86) 89 (58) < 0.001
Laparotomy, n (%) 2 (3) 48 (31)
Other, n (%) 9 (12) 16 (10)
continued
DOI: 10.3310/hta22310 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 31
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Ulug et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
TABLE 34 Reinterventions in the first 3 years of follow-up, by operation commenced, for participants with a final
diagnosis of ruptured AAA (continued )
AAA-related reintervention
Participants with ruptured AAA in whom repair
started (N= 502)
Endovascular strategy
commenceda (N= 182)
Open repair
commencedb
(N= 320) p-value
Severity of arterial reinterventions, n (%)
1* 1 (2) 0 (0) < 0.001
2** 23 (35) 11 (12)
3*** 17 (26) 26 (29)
4**** 10 (15) 4 (4)
5***** 15 (23) 48 (54)
Severity of laparotomy reinterventions, n (%)
Major 1 (50) 7 (15) 0.41
Minor 1 (50) 40 (83)
Unknown (scored 4) 1
Randomisation to 3 months
Participants with at least one reintervention, n/N (%) 29/182 (16) 79/320 (25) 0.022
Reinterventions/person-years (rate per 100 person-years),
(%)
39/33.0 (118.3) 130/49.6 (262.0) < 0.001
Arterial, n (%) 30 (77) 79 (61) 0.011
Laparotomy, n (%) 2 (5) 36 (28)
Other, n (%) 7 (18) 15 (12)
Severity of arterial reinterventions, n (%)
1* 1 (3) 0 (0) 0.017
2** 9 (30) 10 (13)
3*** 8 (27) 22 (28)
4**** 4 (13) 4 (5)
5***** 8 (27) 43 (54)
Severity of laparotomy reinterventions, n (%)
Major 1 (50) 3 (8) 0.17
Minor 1 (50) 32 (89)
Unknown (scored 4) 1
3 months to 3 years
Participants with at least one reintervention, n/N (%) 26/125 (21) 16/188 (9) 0.002
Reinterventions/person-years (rate per 100 person-years),
(%)
38/305.1 (12.5) 23/463.4 (5.0) < 0.001
Arterial, n (%) 36 (95) 10 (43) < 0.001
Laparotomy, n (%) 0 (0) 12 (52)
Other, n (%) 2 (5) 1 (4)
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TABLE 34 Reinterventions in the first 3 years of follow-up, by operation commenced, for participants with a final
diagnosis of ruptured AAA (continued )
AAA-related reintervention
Participants with ruptured AAA in whom repair
started (N= 502)
Endovascular strategy
commenceda (N= 182)
Open repair
commencedb
(N= 320) p-value
Severity of arterial reinterventions, n (%)
1* 0 (0) 0 (0) 0.07
2** 14 (39) 1 (10)
3*** 9 (25) 4 (40)
4**** 6 (17) 0 (0)
5***** 7 (19) 5 (50)
Severity of laparotomy reinterventions, n (%)
Major 4 (33)
Minor 8 (67)
a Includes five individuals who converted to open repair (four died within 30-days and one survived).
b Includes one participant with laparotomy who was palliated (open and close).
TABLE 35 Unadjusted and adjusted HRs for the endovascular strategy compared with open repair, for time to first
AAA reintervention and time to any reintervention within the first 3 years of follow-up
Rate per 100 person-years (n/person-years)
Model N HR (95% CI) p-valueEndovascular strategy Open repair
Time to first AAA-related reintervention
22.6 (75/332.2) 21.0 (66/314.2) Unadjusted 613 1.10 (0.79 to 1.54) 0.59
Adjusteda (complete cases) 397 1.09 (0.73 to 1.62) 0.67
Adjusteda (multiply imputed) 613 1.10 (0.79 to 1.54) 0.57
Time to any AAA-related reintervention (Andersen–Gill model)
26.0 (121/464.5) 28.3 (110/388.3) Unadjusted 613 1.02 (0.79 to 1.32) 0.89
Adjusteda (complete cases) 397 0.93 (0.68 to 1.27) 0.64
Adjusteda (multiply imputed) 613 1.02 (0.79 to 1.33) 0.87
Randomisation to 3 months
182.5 (81/44.4) 222.7 (89/40.0) Unadjusted 613 0.88 (0.65 to 1.19) 0.40
Adjusteda (complete cases) 397 0.78 (0.55 to 1.11) 0.17
Adjusteda (multiply imputed) 613 0.87 (0.64 to 1.18) 0.37
3 months to 3 years
9.5 (40/420.1) 6.0 (21/348.3) Unadjusted 313 1.57 (0.93 to 2.67) 0.09
Adjusteda (complete cases) 217 1.67 (0.82 to 3.43) 0.16
Adjusteda (multiply imputed) 313 1.54 (0.90 to 2.62) 0.12
a Adjusted for age, sex, Hardman index, lowest systolic blood pressure and neck length.
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TABLE 36a Indications for re-interventions within 90 days of randomisation
Aneurysm-related indication for
502 repairs with rupture started
Randomised to
EVAR strategy
(n= 259)
Randomised to
open repair
(n= 243)
Treated with
EVAR (n= 182)
Treated with
open repair
(n= 320)
Access site 4 1 3 2
Abdominal compartment syndrome 7 10 2 15
Bowel ischaemiaa 14 16 5 25
Closure open abdomen 5 5 1 9
Distal aneurysm 1 1 2 0
Endograft kinkingb 2 0 2 0
Endoleakc 3 1 4 0
False aneurysm 1 0 1 0
Graft thrombosis/occlusion 3 0 1 2
Graft infection: aorta 0 2 0 2
Graft infection: femoro-femoral 2 0 2 0
Limb ischaemia 22 13 8 27
Ostomy (stoma) 1 1 1 1
Re-bleeding 3 7 1 9
Other indications
Coronary or brain ischaemia 3 2 2 3
Miscellaneousd 0 3 1 2
Nutritional support 0 1 0 1
Pulmonary embolism 0 2 1 1
Renal failure 0 1 0 1
Tracheostomy for ventilator weaning 5 7 2 10
Upper GI bleed 1 5 1 5
Total re-interventions 77 in 55 patients 78 in 53 patients 40 in 29 patients 115 in 79 patients
Note
There were 27 re-interventions for life threatening indications which occurred in patients randomised to the endovascular
aneurysm repair (EVAR) strategy vs. 41 in those randomised to open repair. Fifteen of these re-interventions for life
threatening indications occurred in patients who received EVAR vs. 53 in those who received open repair. There were two
patients in whom two indications were treated simultaneously, one treated for re-bleeding and bowel ischaemia, and one
treated for type 1A endoleak and bowel ischaemia. GI = gastrointestinal.
a Without abdominal compartment syndrome being diagnosed.
b Prophylactic re-intervention to avoid graft thrombosis or occlusion.
c Two type 1A, two type 2.
d Two perforation sigmoid colon, one pleural effusion.
© 2018 The Authors.125 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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TABLE 36b Indications for re-interventions from 3 months to 3 years
Aneurysm-related indication for
313 repairs with rupture started
who survived beyond 90 days
Randomised to
EVAR strategy
(n= 167)
Randomised to
open repair
(n= 146)
Treated with
EVAR
(n= 125)
Treated with
open repair
(n= 188)
Access site 3 1 2 2
Bowel ischaemia 2 1 0 3
Distal aneurysm 3 4 3 4
Endograft kinkinga 2 2 4 0
Endograft migration 1 0 1 0
Endoleakb 14 2 16 0
False aneurysm 1 0 1 0
Graft thrombosis/occlusion 6 1 4 3
Graft infection: aorta 0 2 0 2
Graft infection: femoro-femoral 0 0 0 0
Incisional hernia 0 3 0 3
Limb ischaemia 2 2 3 1
Ostomy (stoma) 0 1 0 1
Proximal aneurysm 1 0 1 0
Secondary rupturec 2 0 2 0
Symptomatic adhesions 1 1 0 2
Other indications
Nutritional support 0 1 0 1
Renal failure 1 0 1 0
Total re-interventions 39 in 27 patients 21 in 15 patients 38 in 26 patients 22 in 16 patients
Note
In those randomised to the endovascular aneurysm repair (EVAR) strategy, 17/39 of the re-interventions were for a life
threatening condition vs. 7/21 in those randomised to open repair. In those having undergone EVAR 14/38 of the
re-interventions were for life threatening conditions vs. 10/22 in those having undergone open repair. There were three
patients in whom two indications were treated simultaneously, one for type 1A endoleak and arteriovenous fistula
formation for renal failure, one for bowel ischaemia and incisional hernia, and one for type 1B endoleak and common
iliac aneurysm.
a Prophylactic re-intervention to avoid graft thrombosis or occlusion.
b Four type 1A (one also had type 2), two type 1B (one also had type 2), nine type 2 only, and one type 3.
c One patient with a type IA endoleak and renal failure requiring dialysis and one with a type 1B endoleak.
© 2018 The Authors.125 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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TABLE 37 The effect of aortic morphology on re-interventions in the first 3 years of follow up
Morphological variable Re-interventions
Treated with EVAR
(n= 182)
Treated with
open repair
(n= 320)
Combined
(n= 502)
Time to any AAA related re-intervention
Maximum AAA diameter
(per 17 mm increase)
All 0.97 (0.72–1.32)
p = .86
0.95 (0.77–1.18)
p= .65
0.95 (0.80–1.12)
p= .52
Arterial 1.02 (0.74–1.39)
p = .94
0.85 (0.66–1.09)
p= .21
0.90 (0.74–1.09)
p= .28
Aneurysm neck diameter at
distal renal artery (per 4 mm
increase)
All 1.00 (0.77–1.30)
p = .98
1.21 (0.99–1.49)
p= .06
1.15 (0.98–1.35)
p= .09
Arterial 0.98 (0.74–1.29)
p = .88
0.94 (0.72–1.24)
p= .67
0.95 (0.78–1.16)
p= .63
Aneurysm neck length
(per 16 mm increase)
All 0.80 (0.58–1.10)
p = .16
0.89 (0.72–1.10)
p= .28
0.87 (0.73–1.03)
p= .12
Arterial 0.74 (0.53–1.04)
p = .08
0.89 (0.69–1.16)
p= .40
0.84 (0.69–1.03)
p= .09
Neck conicality (per 1.6%
per mm length, change
increase)
All 0.72 (0.45–1.15)
p = .17
0.91 (0.74–1.11)
p= .36
0.87 (0.72–1.06)
p= .16
Arterial 0.65 (0.39–1.10)
p = .11
1.07 (0.87–1.31)
p= .52
0.97 (0.77–1.22)
p= .80
Proximal aneurysm neck (α)
angle (per 20° increase)
All 1.01 (0.77–1.31)
p = .96
1.05 (0.89–1.24)
p= .56
1.04 (0.90–1.19)
p= .62
Arterial 0.96 (0.72–1.29)
p = .79
0.90 (0.70–1.16)
p= .42
0.93 (0.77–1.12)
p= .42
Maximum common iliac
diameter (per 9 mm increase)a
All 1.32 (1.01–1.72)
p = .041
1.06 (0.91–1.24)
p= .45
1.11 (0.98–1.26)
p= .11
Arterial 1.48 (1.13–1.93)
p = .004
1.11 (0.92–1.35)
p= .28
1.20 (1.04–1.39)
p= .013
Note
Data are hazard ratio (95% CI). Aortic morphology and the risk of experiencing any re-intervention within 3 years (with
multiple imputation for missing variables). Multivariate model adjusted for all six morphological variables in addition to age,
sex, Hardman index, lowest recorded systolic blood pressure, and randomised group. Hazard ratios are presented per SD
increase of morphological parameter. These analyses are restricted to 502 patients with confirmed rupture who received an
operation by treatment received (endovascular aneurysm repair [EVAR], open or EVAR converted to open). All aneurysm
related re-interventions (and only arterial re-interventions) are considered separately.
a Excluding eight patients with a ruptured common iliac aneurysm.
© 2018 The Authors.125 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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TABLE 38 Quality-of-life (EQ-5D-3L) utility scores, QALYs and life-years up to 3 years for participants with fully
observed outcomes (complete cases)
Treatment group
Mean difference (95% CI) p-value
Endovascular strategy Open repair
n Mean (SD) n Mean (SD)
EQ-5D-3La for ruptured AAA survivors
3 months 138 0.76 (0.23) 114 0.69 (0.30) 0.073 (0.007 to 0.138) 0.030
12 months 127 0.78 (0.19) 102 0.74 (0.32) 0.043 (–0.024 to 0.110) 0.211
36 months 117 0.75 (0.24) 91 0.74 (0.31) 0.012 (–0.063 to 0.088) 0.746
Life-years (up to 3 years)b 313 1.71 (1.43) 295 1.60 (1.41) 0.113 (–0.114 to 0.339) 0.329
QALYs (3-year)
Ruptured AAA
survivors
91 2.22 (0.50) 68 2.16 (0.64) 0.052 (–0.126 to 0.230) 0.563
Ruptured AAA
survivors and
deceased
193 1.08 (1.14) 183 0.88 (1.10) 0.207 (–0.021 to 0.435) 0.074
All randomised
participantsc
250 1.01 (1.10) 237 0.88 (1.08) 0.131 (–0.063 to 0.325) 0.187
a The EQ-5D-3L is a QoL measure anchored on a scale that includes 0 (death) and 1 (perfect health).
b For all randomised participants.
c This includes participants without a proven rupture, who were assumed to have, on average, the same QoL as
elective patients.
TABLE 39 Incremental net benefit (GBP) (95% CI) within 3 years of randomisation, by subgroup, at the
recommended willingness-to-pay threshold stipulated by NICE (£30,000 per QALY)
Subgroup
Incremental (95% CI)
INB (95% CI) p-valueCost (£) QALYs
Sex
Male (n = 480) –4066 (–7573 to –557) 0.092 (–0.099 to 0.283) 6824 (204 to 13,444) 0.440
Female (n= 133) 2817 (–3806 to 9439) 0.358 (0.038 to 0.712) 7914 (–4401 to 20,229)
Hardman index score
0 (n= 164) –4017 (–9758 to 1725) 0.016 (–0.141 to 0.465) 8878 (–1686 to 19,442) 0.279
1 (n= 254) –2448 (–7022 to 2126) 0.005 (–0.244 to 0.254) 2594 (–5943 to 11,131)
≥ 2 (n= 121) –923 (–7306 to 5461) 0.423 (0.092 to 0.755) 13,622 (2025 to 25,219)
Neck length
< 22mm (n= 234) –769 (–5595 to 4057) 0.216 (–0.027 to 0.459) 7243 (–1216 to 15,702) 0.461
≥ 22mm (n= 247) –4250 (–8859 to 358) 0.111 (–0.131 to 0.352) 7568 (–959 to 16,095)
Lowest systolic blood pressure
< 90mmHg (n= 263) –3881 (–8604 to 842) 0.067 (–0.185 to 0.319) 5881 (–2949 to 14,711) 0.275
≥ 90mmHg (n= 305) –1540 (–5879 to 2798) 0.213 (–0.013 to 0.439) 7932 (–14.2 to 15,878)
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TABLE 41 Derivation of previously published ruptured AAA risk scores
Variable VSGNE Hardman index Vancouver
Aged > 76 years +2 +1 +0.062 for each 1-year increase in age
Cardiac arrest +2 +1 +0.60
Loss of consciousness +1 +1 +1.14
Suprarenal clamp +1 – –
ECG ischaemia – +1 –
Creatinine concentration of > 190 µmol/l – +1 –
Haemoglobin level of < 9 g/dl – +1 –
–, not used; ECG, electrocardiography; VSGNE, Vascular Study Group of New England.
TABLE 40 Coefficients for the best-fitting model (backwards selection) and the clinically simplified (bedside) model
Best-fitting model Bedside model
Variable β (SE) p-value Rule OR
Score
allocateda
Intercept –0.3040 (0.8024)
age−50
5
 3 0.0028 (0.0008) 0.001 Aged ≥ 76 years 1.40 2
Haemoglobin –0.0897 (0.0524) 0.087 Haemoglobin level of < 11 g/dl 2.10 4
creatinine
5
  0.4522 (0.1613) 0.005 Creatinine concentration of ≥ 120 µmol/l 1.63 3
sbp + 1
100
 −2 0.4665 (0.1339) < 0.001 Systolic blood pressure of < 100mmHg 1.71 3
log
necklength + 1
10
  –0.7070 (0.1954) < 0.001 Neck length of < 15mm 1.92 4
neckangle + 1
10
  –0.0989 (0.0614) 0.107 Neck angle of < 45° 1.94 4
Male –0.4919 (0.2651) 0.063 Female 2.11 4
Acute ischaemia 1.0363 (0.3659) 0.005 Acute ischaemia 2.78 6
a Integer points based on rounding 6.6*log-odds ratio.
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TABLE 42 Discriminative performance of the developed IMPROVE risk score for predicting 30-day mortality,
validated both internally (using IMPROVE trial data) and externally (using data from the AJAX and ECAR RCTs and
the Amsterdam and STAR cohorts)
Model
Data set, c-statistic (SD)
Development Validation
IMPROVE RCT
(n= 536)
AJAX RCT
(n= 113)
ECAR RCT
(n= 105)
Amsterdam
cohort (n= 513)
STAR cohort
(n= 284)
IMPROVE score 0.715a (0.023) 0.677 (0.052) 0.619 (0.069) 0.724 (0.022) 0.693 (0.031)
IMPROVE bedside score 0.691a (0.023) 0.662 (0.054) 0.631 (0.070) 0.664 (0.024) 0.632 (0.033)
VSGNE 0.667 (0.023) 0.691b (0.053) 0.632b (0.063) 0.682c (0.024) 0.683b (0.031)
Hardman index 0.658 (0.023) 0.784 (0.043) 0.694 (0.062) 0.697 (0.023) 0.669 (0.032)
Vancouver 0.653 (0.024) 0.700b (0.059) 0.657b (0.064) 0.685c (0.024) 0.745b (0.029)
VSGNE, Vascular Study Group of New England.
a Cross-validated c-statistic (optimism corrected).
b Excluding preoperative cardiac arrest.
c Excluding preoperative cardiac arrest and loss of consciousness.
Note
Comparison with other published risk scores also shown.
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compared with open repair) by randomised group. Copyright © 2015 The Authors. BJS published by John Wiley &
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FIGURE 24 Survival to 1 year in the AJAX, ECAR and IMPROVE trials. (a) AJAX; (b) ECAR; (c) IMPROVE (all
participants); (d) IMPROVE (data for the 308 IMPROVE participants with a ruptured aneurysm who were suitable
for EVAR); and (e) individual patient meta-analysis of 1-year mortality for participants as randomised in AJAX,
ECAR and IMPROVE. Reprinted from Eur J Vasc Endovasc Surg, 50, Sweeting MJ, Ulug P, Powell JT, Desgranges P,
Balm R, Ruptured Aneurysm Trialists, Ruptured aneurysm trials: the importance of longer-term outcomes and
meta-analysis for 1-year mortality, 297–302, Copyright (2015) with permission from Elsevier. (continued )
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FIGURE 26 Sensitivity analysis that considers the effect on the INMB at 1 year (at £30,000 per QALY) of alternative
assumptions, compared with the base case for 613 participants.
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behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is
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FIGURE 31 Calibration plots for the best-fitting model and the bedside model in the IMPROVE trial data set.
(a) Best-fitting model; and (b) bedside model.
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